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Summary 




West Nile virus (WNV) represents a rapidly emerging infectious disease today and 
causes symptoms ranging from febrile illness to fatal encephalitis. The strain WNV 
(Sarafend) having been passaged through cell culture repeatedly, has lost its ability to 
infect and cause mortality in mice. This study seeks to revive the virus’ murine 
infectability by repeatedly passaging it through mice brains and a mosquito cell line, 
mimicking normal infectious cycles. We found that passaged WNV became more 
persistent in adult BALB/c mice and caused more severe pathogenesis in various 
organs. Unpassaged viruses could only be detected on day 1 post inoculation in the 
serum at 101 PFU/ml whereas mice inoculated with passaged viruses had viremia of 
104 PFU/g tissue in brains and spleens at day 3 post inoculation. Suckling mice 
inoculated with the passaged viruses had an overall lower mean survival time of up to 
48 hours when compared to suckling mice inoculated with unpassaged viruses. 
Additionally, the passaged virus gave higher titres for longer periods when infected 
onto primary neural cultures. An additional passaging regime where WNV was 
passaged repeatedly only in mouse brains was performed and this strain when 
compared to the first passaging regime was found less adapted to infecting adult mice, 
killed suckling mice slower, and gave lower titres in primary cultures. Sequencing the 
genes C, E, NS2, and NS4 found mutations in two hot spots in the C protein at amino 
acid residue 24 and 26. The region encompassing the first six amino acids for the 
NS2a gene was also found variable in the passaged viruses. These mutations are 
speculated to be important for virulence and adaptation of the virus to murine hosts.  
 
 
List of Tables 
x | P a g e  
 
LIST OF TABLES 
  PAGE NUMBER 
Table 1 Confirmed WNV case numbers from 2000 to 2008 ...........................9 
Table 2 Summary of different mice and WNV strains tested ........................12 
Table 3 Cell lines and related information .....................................................27 
Table 4 Viruses used in this study .................................................................29 
Table 5 List of RTPCR primers used and its sequences ................................43 
Table 6 Primer sequences for PCR amplification ..........................................44 
Table 7 List of primer sequences for sequencing PCR ..................................47 
Table 8 PFU/ml sera or PFU/g tissue of adult BALB/c mice inoculated with 
WNVS grown on C6/36 cells ...........................................................68 
Table 9 PFU/ml sera or PFU/g tissue of adult BALB/c mice inoculated with 
WNVS grown on Vero cells .............................................................68 
Table 10 Summary of histopathological findings ..........................................104 
Table 11 Mutations found in the C protein region of the passaged viruses ...127 
Table 12 The only amino acid mutation found in the E protein ....................130 




List of Figures 
xi | P a g e  
 
LIST OF FIGURES 
  PAGE NUMBER 
Figure 1 The Flaviviridae classification ............................................................ 1 
Figure 2 The flavivirus genome organisation..................................................... 3 
Figure 3 Spread of flaviviruses worldwide ...................................................... 10 
Figure 4 A photograph of two wells of plaque assay ....................................... 32 
Figure 5 The ‘Find Edges’ function converts the photograph to negative 
colours ................................................................................................ 32 
Figure 6 Log10 virus yield from sera of AG129 mice inoculated with various 
doses of DV2...................................................................................... 57 
Figure 7 Level of virus in sera of adult AG129 mice inoculated with DV2 .... 58 
Figure 8 Virus levels in spleens and livers of adult AG129 mice inoculated 
with DV2 ............................................................................................ 58 
Figure 9 Red pulps of mock – inoculated and DV2 – inoculated AG129 
mice spleens ....................................................................................... 59 
Figure 10 A granular labelling of DV antigens in infiltrating cells in the 
spleen of AG129 mice inoculated with DV2 ..................................... 61 
Figure 11 Nonspecific labelling on blood vessels and meninges in AG129 
mice .................................................................................................... 61 
Figure 12 Clear indication of a compromised blood vessel in the  
brain section ....................................................................................... 62 
Figure 13 Spleens from AG129 mice inoculated with DV ................................ 64 
Figure 14 Areas of T cell proliferation in AG129 mice ..................................... 65 
Figure 15 Perivascular cuffing made up of basophilic cells .............................. 65 
Figure 16 A phagocyte removing cell debris containing virus proteins ............. 66 
List of Figures 
xii | P a g e  
 
Figure 17 WNVS growth curve in BALB/c suckling mice brain ...................... 69 
Figure 18 Survival curve of BALB/c suckling mice intracerebrally inoculated 
with various WNVS loads. ................................................................ 70 
Figure 19 Relative plaque sizes from the mouse – only ‘m’ passaged viruses .. 74 
Figure 20 Relative size of virus plaques from the alternate mouse passage ...... 75 
Figure 21 Relative size of virus plaques from the alternate C6/36 passage ....... 76 
Figure 22 Standard deviation of plaque sizes of the different passage repeats 
for the mouse – only ‘m’ passaged viruses ........................................ 77 
Figure 23 Standard deviation of plaque sizes of the different passage repeats 
from the alternate mouse passage ...................................................... 77 
Figure 24 Standard deviation of plaque sizes of the different passage repeats 
from the alternate C6/36 passage ....................................................... 78 
Figure 25 Log10 PFU/g tissue sample of virus in suckling mice brains from 
different passages of the mouse only passaging series ‘m’ ............... 80 
Figure 26 Average Log10 PFU/g tissue sample of virus in suckling mice 
brains from the 5 repeats of different passages .................................. 80 
Figure 27 Log10 PFU/g tissue sample of virus in suckling mice livers from 
different passages of the mouse ‘m’ only passaging series ............... 81 
Figure 28 Average Log10 PFU/g tissue sample of virus in suckling mice 
livers from the 5 repeats of different passages in the mouse ‘m’ 
only passaging series .......................................................................... 81 
Figure 29 Log10 PFU/g tissue sample of virus in suckling mice spleen from 
different passages of the mouse ‘m’ only passaging series ............... 82 
List of Figures 
xiii | P a g e  
 
Figure 30 Average Log10 PFU/g tissue sample of virus in suckling mice 
spleen from the 5 repeats of different passages in the mouse ‘m’ 
only passaging series .......................................................................... 82 
Figure 31 Log10 PFU/g tissue sample of virus in suckling mice brain from 
different passages in the mouse – C6/36 ‘c’ passaging series ........... 83 
Figure 32 Average Log10 PFU/g tissue sample of virus in suckling mice 
brains from the 5 repeats of different passages in the mouse – 
C6/36 ‘c’ passaging series ................................................................. 83 
Figure 33 Log10 PFU/g tissue sample of virus in suckling mice livers from 
different passages in the mouse – C6/36 ‘c’ passaging series ........... 84 
Figure 34 Average Log10 PFU/g tissue sample of virus in suckling mice 
livers from the 5 repeats of different passages in the mouse – 
C6/36 ‘c’ passaging series ................................................................. 84 
Figure 35 Log10 PFU/g tissue sample of virus in suckling mice spleens from 
different passages in the mouse – C6/36 ‘c’ passaging series ........... 85 
Figure 36 Average Log10 PFU/g tissue sample of virus in suckling mice 
spleens from the 5 repeats of different passages in the mouse – 
C6/36 ‘c’ passaging series ................................................................. 85 
Figure 37 Log10 PFU/ml of virus from C6/36 cells from different passages in 
the mouse – C6/36 ‘c’ passaging series ............................................. 87 
Figure 38 Average Log10 PFU/ml of virus from C6/36 cells from the 5 
repeats during the different passages in the mouse – C6/36 ‘c’ 
passaging series .................................................................................. 87 
Figure 39 Mortality levels of suckling mice inoculated with passaged viruses 
from the ‘c’ regime ............................................................................ 89 
List of Figures 
xiv | P a g e  
 
Figure 40 Mortality levels of suckling mice inoculated with passaged viruses 
from the ‘m’ regime ........................................................................... 90 
Figure 41 Virus titres from adult mice inoculated with the mouse – C6/36 
passaged virus ‘c’ sacrificed on day 1 ............................................... 94 
Figure 42 Virus titre levels from adult mice inoculated with the mouse – 
C6/36 passaged virus ‘c’ sacrificed on day 3 ..................................... 94 
Figure 43 Virus titres from adult mice inoculated with mouse brain passaged 
virus ‘m’ sacrificed on day 1 post inoculation ................................... 95 
Figure 44 Virus titres from adult mice inoculated with mouse brain passaged 
virus ‘m’ sacrificed on day 3 post inoculation ................................... 95 
Figure 45 Mice weights over 20 days as a test for morbidity ............................ 98 
Figure 46 Least square regression lines of mice weights over 20 days ............. 99 
Figure 47 Mice nett weight gained from 20 days ............................................... 99 
Figure 48 A representative spleen from a day 1 post infected – mouse ........... 101 
Figure 49 Kupffer cells and other inflammatory cells in the livers of various 
mice injected with passaged virus.................................................... 102 
Figure 50 Meningoencephalitis in the pair of mice injected with 10m1 
passaged virus .................................................................................. 103 
Figure 51 Positive labelling of primary neural cells ........................................ 106 
Figure 52 Growth curves of the unpassaged and ‘c’ passaged virus series on 
mouse primary neural culture .......................................................... 107 
Figure 53 Growth curves of the unpassaged and ‘m’ passaged virus series on 
mouse primary neural culture .......................................................... 108 
Figure 54 Growth curve for 10m2 virus infection on primary neural cell 
culture over a total period of 12.5 weeks ......................................... 109 
List of Figures 
xv | P a g e  
 
Figure 55 Titres of 10m2 virus from subcultured persistently - infected 
primary neural cells .......................................................................... 110 
Figure 56 Micrographs of neural cells infected with WNVS previously grown 
in Vero cell culture ........................................................................... 111 
Figure 57 Micrographs of neural cells infected with WNVS previously grown 
in C6/36 cell culture ......................................................................... 112 
Figure 58 Micrographs of neural cells mock – infected ................................... 113 
Figure 59 Micrographs of neural cells infected with WNVS 10c1 .................. 115 
Figure 60 Micrographs of neural cells infected with WNVS 10c5 .................. 116 
Figure 61 Micrographs of neural cells infected with WNVS 10m2 ................. 117 
Figure 62 Micrographs of neural cells infected with WNVS 10m4 ................. 118 
Figure 63 A typical oligodendrocyte ................................................................ 120 
Figure 64 A compromised oligodendrocyte cell .............................................. 120 
Figure 65 Growth curves of unpassaged virus on mouse primary neural brain 
culture .............................................................................................. 121 
Figure 66 Growth curves of the ten passaged viruses on primary neuronal 
mouse brain culture .......................................................................... 122 
Figure 67 Micrographs from unpassaged C6/36 cell culture grown WNVS 
infection on primary neuronal cells ................................................. 123 
Figure 68 Micrographs of primary neuronal cells infected with passaged 
virus from the stock 10m2 virus ...................................................... 124 
Figure 69 Multiple sequence alignment of flavivirus C proteins ..................... 127 
Figure 70 Protean automated predictions of C protein secondary structures ... 129 
Figure 71 Multiple sequence alignment of 4 representative flavivirus E 
proteins ............................................................................................. 131 
List of Figures 
xvi | P a g e  
 














< - less than  
: - ratio 
- - negative 
% - Percentage 
˚C - degrees Celsius 
µg - microgram 
µl - microlitre 
µm - micrometer  
x - times magnitude 
x g - centrifugal force 
α - alpha 
β - beta 
BALB/c - Bagg Albino strain c  
BHK - baby hamster kidney 
BSA - bovine serum albumin 
BSL - biosafety level 
cDNA - complementary deoxyribonucleic acid 
cm - centimetre 
CNS - central nervous system 
DNA - deoxyribonucleic acid 
DV - dengue virus 
E16 - embryonic day 16 mice 
FBS - foetal bovine serum 
g - gram(s) 
IGSS - immnogold silver staining 
IHC - immunohistochemistry 
Log - logarithmic scale 
M - molar 
MOI - multiplicity of infection 
min -  minute(s) 
ml - millilitre(s) 
Abbreviations 
xviii | P a g e  
 
mm - millimetre(s) 
NGC - New Guinea C strain 
nm - nanometre(s) 
NS - non structural 
p - probability 
PBS - phosphate buffered saline 
PCR - polymerase chain reaction 
PFU - plaque forming unit 
PI - post infection 
RNA - ribonucleic acid 
RTPCR -  reverse transcription polymerase chain reaction 
SPF - specific pathogen free 
TBS - tris buffered saline 
UV - ultraviolet 
WNV -  West Nile virus 










1 | P a g e  
 
1.0  INTRODUCTION 
1.1  FLAVIVIRIDAE 
The viruses in the Flaviviridae family are the most common causative agent of viral 
encephalitis in humans (Farrar and Newton, 2000). Flaviviruses are mainly transmitted 
via arthropods, mosquitoes, and ticks, to their vertebrate hosts. The three genera found 
under Flaviviridae are Flavivirus, Pestivirus, and Hepacivirus. The genus Flaviviridae 
contains approximately 57 antigenically – related viruses such as dengue, West Nile, 
Japanese encephalitis, and the genus type species yellow fever virus (Latin ‘Flavus’ = 
yellow). The other two genera contain far fewer members with Pestivirus having six 
species and Hepacivirus with two species (International Committee on Taxonomy of 
Viruses, 2000). Figure 1 shows the Flaviviridae classification. 
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1.2  WEST NILE  
West Nile virus (WNV) was first described in Uganda, 1937 when an adult female came 
down with a severe febrile disease (Smithburn et al., 1940). It was later added to the 
Japanese encephalitis serocomplex which includes St. Louis encephalitis virus. This 
group was further expanded to include Murray Valley encephalitis, Kunjin, Usutu, 
Kokobera, Stratford, and Alfuy viruses after serological studies found antibodies against 
WNV could cross – detect antigens from many other viruses (Smithburn, 1942; De 
Madrid and Poterfield, 1974).  
 
West Nile virus gained worldwide attention in 1999 when it was detected in New York, 
United States. The following year, it spread throughout the North American continent and 
later on to Latin America and the Caribbean (Hayes and Gubler, 2006). Before that, it has 
only been known to be the cause of sporadic outbreaks of febrile illness in Africa, 
Europe, and India (Russell and Dwyer, 2000).  
 
1.3  WEST NILE VIRUS GENOME AND MORPHOLOGY 
The WNV genome is a positive, single – strand RNA roughly 11029 bases long. The 
ends are flanked by noncoding untranslated regions (UTR) and contains a single open 
reading fame of 10301 bases that encodes for ten proteins. There are three structural 
proteins at the 5’ end: C, prM, and E; while the remaining portion encodes the non – 
structural proteins: the large highly conserved NS1, NS3, and NS5, and four small 
hydrophobic proteins; NS2a, NS2b, NS4a, and NS4b. 
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 Figure 2 below shows the general genome layout for flaviviruses (International 
Committee on Taxonomy of Viruses, 2000). 
 
 
Figure 2: The flavivirus genome organisation. 
 
The C protein is important for virus genome encapsidation and is highly conserved within 
the WNV strains as well as within the different dengue strains but significantly different 
when comparing the different members of flaviviruses (Ma et al., 2004). The 25 – 30 
nanometers diameter virus internal core containing RNA is encapsulated within C protein 
spherical or isometric neucleocapsid. Absence of this core gene results in infected cells 
releasing subviral particles lacking both neucleocapsid and virus RNA (Ferlenghi et al., 
2001). The core is surrounded by a lipid membrane. Interspersed throughout the 
membrane covering are the E and prM proteins (Mukhopadhyay et al., 2003). The prM 
protein is processed to pr + M protein late in the virus maturation process by a convertase 
enzyme (furin). This results in mature 50 nanometers spherical virions (Mackenzie et al., 
2004). The virus then either buds from the infected cell for WNV Sarafend (WNVS) or 
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through exocytosis for other flaviviruses. The prM protein is an important chaperone for 
proper folding and transport of E protein during virus particle exocytosis (Lorenz et al., 
2002).  
 
The E protein is the largest of structural proteins and is present on the virus surface. It 
possesses projections of 5 – 10 nanometers long with terminal knobs of two nanometers 
in diameter (Schlesinger, 1980). There are three domains within the E protein. Little is 
known of Domain I. Domain II is suggested to be important during virus entry process as 
exposure of this domain to low pH results in epitope destruction allowing virus fusion to 
the endocytic vesicle membrane (Mandl et al., 1989). This is interesting because other 
flavivirus such as hepatitis C virus and bovine viral diarrhoea virus are acid resistant 
(Tscherne et al., 2006). Domain III is strongly postulated to act as the receptor binding 
domain of the virus as it has an Ig – like fold commonly associated with glycoproteins 
with adhesion functions. This domain also extends perpendicularly up from the virus 
surface and is thus the most exposed region (Rey et al., 1995). Moreover, mutations in 
domain III have been reported to cause changes in virus infectability in mice as well as 
cell cultures (Beasley et al., 2002; Bordignon et al., 2007; Ciota et al., 2008).  
 
Most of the non – structural (NS) proteins associate to form the replicase complex, which 
traditionally was thought to function only in RNA accumulation (Murray et al., 2008). 
Recently, unique roles of various NS proteins are beginning to be known and have now 
emerged as integral components in the process of virion morphogenesis. The NS1 protein 
can be detected in both intracellular and extracellular fractions of infected cells at early 
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virus infection time points (Smith and Wright, 1985). It is thus postulated that NS1 
protein has a role to play in early virus replication. It was also found to co – localise to 
double stranded viral RNA, NS4a protein, and intracellular membranes (Lindenbach and 
Rice, 1999). This shows that NS1 protein plays multiple roles during virus infection and 
replication.  
 
The NS2a protein is an essential component of the virus replicase. Mutations in the NS2a 
gene results in uninfectious yellow fever virus production (Kummerer and Rice, 2002). 
The NS3 protein represents the main viral protease with its associated cofactors NS4a 
and NS2b protein (Murray et al., 2008). It shows RNA helicase, serine protease, and 
nucleoside triphosphatase activities that are essential for viral RNA replication (Kramer 
et al., 2007). The NS2b - NS3 protease mediates the cleavage of the virus polypeptide at 
various locations, in particular, the C protein from its membrane anchor C – prM 
precursor which is crucial for the proper maturation of C protein (Chambers et al., 1990). 
NS4a and NS4b are cofactors which maintain proper NS3 structure by anchoring the 
enzyme to the membrane. The presence of NS4a also significantly increases the activity 
of NS3 (Agapov et al., 2004). 
 
NS5 is the largest and most conserved of the NS proteins. It is also known to be the viral 
RNA – dependant RNA polymerase (RdRp). It is important for RNA synthesis and 
genome capping. This region has very highly conserved zinc – binding motifs and is 
phosphorylated by a putative NS5a kinase. The polymerase activity of NS5 protein is of 
importance as replication – imcompetent genomes were not incorporated into WN Kunjin 
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virions (Khromykh et al., 2001; Reed et al., 1998; Yap et al., 2007). NS5 protein also 
contains N-7 and 2’O-methyltransferase which is involved in the methylation of the 5’ 
RNA cap structure (Kramer et al., 2007). 
 
1.4  WEST NILE LINEAGES  
Nucleotide sequencing, serology, and phylogenetic analysis of WNV genomes based on 
the entire or partial viral gene sequences differentiated WNV into two lineages: lineage I 
and lineage II (Berthet et al., 1997). Lineage I and II can only be separated by very 
specific molecular techniques because they are antigenically very similar (Linke et al., 
2007). Lineage I is divided into three clades. The first clade, Ia, is found worldwide 
(Africa, Europe, and North America), Ib is found in Australia as Kunjin virus (Lanciotti 
et al., 1999), while clade Ic were isolates from India (Umrigar and Pavri, 1977).  
 
Lineage II on the other hand defines viruses from sub – Saharan Africa and Madagascar 
(Scherret et al., 2001). Lineage I has been traditionally linked to higher pathogenicity and 
outbreaks in human populations while lineage II is often associated with endemic 
zoonotic infections. Still, it has been shown that lineage II viruses could also cause 
outbreaks in South Africa and the Middle East (Burt et al., 2002; Jia et al., 1999). 
Recently, Rabensburg and Russian isolates were suggested to form lineage III and IV of 
WNV, respectively (Bakonyi et al., 2005; Lvov et al., 2004). Another group has recently 
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1.5 CLINICAL SYMPTOMS OF WEST NILE VIRUS INFECTION 
While the majority of WNV infections are asymptomatic, it can cause disease in humans 
and animals, with symptoms ranging from febrile illness to fatal encephalitis. About 20 
percent of infected patients display a range of symptoms including fever, headache, 
malaise, back pain, myalgias, eye pain, pharyngitis, nausea, vomiting, diarrhoea, and 
abdominal pain. Incubation period is typically between two to fourteen days although in 
immunosuppressed patients it could last for much longer (Pealer et al., 2003). Out of 
these 20 percent, maculopapular rash appears in approximately half the patients. The rash 
spreads to the chest, back, and arms, and generally lasts for less than one week. Other 
acute symptoms generally subside after two weeks but a subset of these patients would 
acquire more serious clinical manifestations, including neurological effects (Petersen and 
Roehrig, 2001; Watson et al., 2004).  
 
More serious manifestations of WNV are categorized as: encephalitis, meningitis, and 
flaccid paralysis, with the former two more common (Nash et al., 2001). Muscle 
weakness and flaccid paralysis are particularly suggestive of WNV infection (Petersen 
and Marfin, 2002). Asymmetric acute flaccid paralysis syndrome could also occur 
independent of encephalitis and has been noted to be a sign of impending respiratory 
failure (Sejvar et al., 2005). Neurological manifestations of WNV are quite similar to 
Japanese encephalitis and St. Louis encephalitis. Tissue damage is seen in the meninges 
contributing to meningitis, in the brain parenchyma contributing to encephalitis, and in 
the spinal cord contributing to myelitis. In the recent outbreak of WNV in North 
America, generalized muscle weakness, later described as poliovirus – like flaccid 
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paralysis was recognized in most of the infected patients (Sejvar et al., 2003). Older 
(Chowers et al., 2001) and immunocompromised individuals (George et al., 1984) have 
an increased risk of developing fatal disease. 
 
Long term studies on patients who recovered from WNV infections with meningitis or 
encephalitis have found that for patients below 65 years of age, only 37 percent achieved 
full recovery after 12 months (Marciniak et al., 2004). Lasting abnormalities after 18 
months for some patients included muscle weakness, loss of concentration, confusion, 
and light – headedness. For patients suffering from WNV poliomyelitis, there is 
incomplete recovery of limb strength resulting from profound residual deficits. In severe 
cases of quadriplegia and respiratory failure where there is a high level of mortality, 
recovery is slow and invariably incomplete (Betensley et al., 2004). For 
nonneuroinvasive WNV infections, 92 patients with a mean age of 50 years were found 
to recover from fatigue, depression, and had full physical and mental function after one 
year (Loeb et al., 2008). Evident latency of virus in humans has not been reported as yet. 
 
1.6  TRANSMISSION 
The WNV is transmitted by Culex mosquitoes primarily between birds, the amplifying 
hosts of the virus. Mosquitoes also function as bridge vectors for transmission to humans, 
and other mammals (Turell et al., 2005). Although wild birds can develop high levels of 
viremia, most remain asymptomatic (Komar et al., 2003). However, significant avian 
mortality has been reported in United States and Israel where both countries share similar 
WNV genetic strains (Swayne et al., 2001). North American Corvids, including ravens, 
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jays, and crows, are susceptible to the virus. Corvids made up approximately sixty 
percent of collected dead birds tested positive for WNV (Tsai et al., 1998). 
 
Humans are considered dead – end hosts because they usually develop viremia at an 
insignificant level to facilitate further transmission of the virus. West Nile virus 
transmission has also been reported resulting from organ transplantation (DeSalvo et al., 
2004; Jain et al., 2007; Murtagh et al., 2005; Wadei et al., 2004), blood transfusion 
(Macedo de Oliveira et al., 2004; Montgomery et al., 2006), pregnancy (Jamieson et al., 
2006; O'Leary et al., 2006; Skupski et al., 2006), and lactation (CDC, 2002a). 
Occupational WNV infections in laboratory workers have also been documented 
(Hamilton and Taylor, 1954). 
 
1.7  EPIDEMIOLOGY 
Following a 1998 European outbreak, WNV came into the spotlight in 1999 when it was 
identified for the first time in the Americas (Lanciotti et al., 1999). The number of cases 
peaked in 2003 following the spread of WNV to the whole of Northern America, México, 
and Canada. Table 1 summarises the case numbers in the United States from year 2000 to 
2008 according to the Centers for Disease Control and Prevention (CDC) while Figure 3 
shows the global reach of various flaviviruses. 
Table 1: Confirmed WNV case numbers from 2000 to 2008. 
Year Case numbers Reference 
2000 21 (CDC, 2002b) 
2001 66 (CDC, 2002b) 
2002 4,156 (O'Leary et al., 2004) 
2003 9,862 (CDC, 2003) 
2005 2,744 (CDC, 2005) 
2006 4,261 (CDC, 2007a) 
2007 3,304 (CDC, 2007b) 
2008 (Jan – Jul) 43 (CDC, 2008) 
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Figure 3: Spread of flaviviruses worldwide (Mackenzie et al., 2004). 
 
Prior to this, WNV outbreaks had been sporadic and limited to febrile reactions until the 
1990’s when patients with more severe neurological disease started to appear in clusters 
of infection in Romania, Russia, and Israel (Chowers et al., 2001; Platonov et al., 2001; 
Tsai et al., 1998). As the circulating strain in the United States is genetically identical 
(99.7 %) to a virus strain found in Israel, epidemiologists suggest that migrating birds 
imported the virus from the Mediterranean into United States (Ceccaldi et al., 2004; 
Lanciotti et al., 1999).  
 
In 2001, a Cayman Islands resident was found to have developed WNV encephalitis 
(Bernard and Kramer, 2001). Later serological testing in birds and horses from 
surrounding regions showed WNV to be present in the Dominican Republic, Jamaica, 
Guadeloupe, El Salvador, Colombia, and Mexico (Cruz et al., 2005; Estrada-Franco et 
al., 2003; Mattar et al., 2005; Quirin et al., 2004). However, virus isolation from human 
or animal cases are infrequent, raising questions as the serological and morbidity reports 
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did not correlate. Another hypothesis could be that the virus had reverted from being 
neuroinvasive with severe morbidity to mild and lacking CNS infection potential. 
 
WNV has not been isolated in Singapore but there is a significant probability that it could 
one day be endemic to this region as out of the 2500 species of mosquitoes found 
worldwide, Singapore has around 100 identified mosquito species including Aedes 
albopictus and 35 species from the Culex genra which are the main carriers of WNV in 
the United States (Walter Reed Biosystematics Unit, 2008). The small island is also 
known as an important site for migratory bird stopovers between north and central Asia 
to Australia. This is of significance as it was migratory birds coming from Israel into the 
United States that was suggested to be the propagator of WNV. 
 
1.8  THE NEED FOR AN IN VIVO MODEL 
Testing of drugs or vaccine candidates against WNV can only be successfully performed 
if there exists a good animal model that mimics the morbidity, symptoms of infection, 
and mortality rates seen in human patients. Consequences of infection and the virus 
pathogenicity needs to be understood in animal models before testing of promising 
therapies is possible. At the moment, only vaccines licensed for veterinary use are 
available.  
 
1.8.1  Mouse Models to Study West Nile Virus 
Mice are the most commonly used model for WNV investigation. There is a plethora of 
different strains to choose from, inbred and outbred, transgenic and knockout. Strains can 
also be divided into immunocompetent and immunoincompetent mice types; all having 
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different roles to play. The former predicts how a normal immune system would respond 
to an infection while displaying full viral pathogenesis; making it a good vaccine efficacy 
test model. Conversely, specific transgenic or knockout mice mimic 
immunocompromised subjects and are used to study particular immunological response 
pathways affected by either virus or host. Table 2 summarizes some major strains of virus 
and mice used in past WNV studies. Note that models work as a pair; the virus and 
mouse strain must be specific. 
 
Table 2: Summary of different mice and WNV strains tested. 
Mouse strain WNV strain Characteristics Reference 
BALB/c 1952 human 
isolate 
Neuroinvasive,  100 % mortality (Ben-Nathan et al., 
2003) 
Swiss SA89, SEN90, 
USA99b 
Neuroinvasive, 100 % mortality 
 




Nonneuroinvasive, LD50 >10000 
 
(Beasley et al., 2002) 
 
NY99 Neuroinvasive, very virulent, 
 LD50 = 17 PFU 
(Borisevich et al., 
2006) 
C57BL/6 NY2000 30 % mortality (Sitati and Diamond, 
2006) 
WNVS At low dose: neuroinvasive but 
mortality approximately 30 % 
(Wang et al., 2003) 
Unnamed 
equine isolate 




Isr98 Resistant to infection (Mashimo et al., 2002) 
CD4-/- NY2000 Persistent infection, low antibody 
response, 100 % death at 102 PFU 
(Sitati and Diamond, 
2006) 
TLR3 -/- NY99 Reduced neuropathology and 
inflammation, 40 % less mortality 
(Wang et al., 2004a) 
Fas Ligand -/- NY99 
 
Eeffector of CD4+ cells, 100 % 
mortality 
(Sitati and Diamond, 
2006) 
WNVS Increased mortality if coupled with 
perforin knockout (29 % to 63 %) 
(Wang, 2004b) 
IFN β -/- NY99 High virulence, increased 
mortality from 90 % to 100 % 
(Samuel and Diamond, 
2005) 
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Mouse strain WNV strain Characteristics Reference 
IFN γ -/- WNVS, KUN IFN γ does not play a significant 
role in WNV infection 
(Wang et al., 2006) 
 
NY99 Higher viremia, mortality 
increased from 30 to 90 %, 
neuroinvasive 
(Shrestha et al., 2006b) 
CD8+ T cell 
depleted 
WNVS Increased mortality from 27 % to 
70 % at 102 PFU 
(Wang et al., 2003) 
CCR5 -/- NY99 Increased mortality from 30 % to 
100 %, reduced leukocyte 
trafficking 
(Glass et al., 2005) 
 
Both the breed of mice and strain of virus play an important role in defining the 
pathogenicity and prognosis of the infection. This is clear from the different virus strains 
used to infect Swiss and BL6 mice as seen in Table 2. One interesting experiment found 
caught wild field mice totally resistant to WNV infection but nonsense point mutations in 
lab breed mice at the 2’ - 5’oligoadenylate synthetase gene increased its susceptibility to 
WNV infection. Mashimo and colleagues (2002) mapped microsatellite markers from 
BALB/c, 129, C3H, C57BL/6, and eleven other lab mouse strains to arrive at this 
conclusion. The gene was later found to be regulated by IFNβ (Scherbik et al., 2006). 
Similar markers if found in specific human populations would have grave implications.  
 
Promising vaccines normally undergo preclinical tests for safety and efficacy on mice 
before clinical trials are conducted. A WNV / DV chimera DNA vaccine was tested on 
outbreed Swiss and SCID mice and the chimera showed greatly reduced 
neuroinvasiveness in mice (Pletnev et al., 2006) while a WNV / Yellow fever chimera 
safety test successfully used ICR mice to ensure the virus showed no infectivity at high 
doses (Arroyo et al., 2004). This mouse strain was also used to test a lentiviral delivery 
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system and the strong humoral response elicited was able to withstand a virus challenge 
later (Iglesias et al., 2006). These vaccines are now in later phases of clinical trials. 
 
Antibody treatment has been noted to be a potential WNV treatment strategy.  Pregnant 
mice infected with WNV and treated with humanized anti – WNV immunoglobulins had 
a higher dam survival rate and could potentially be used to treat foetal WNV infection in 
humans (Julander et al., 2005). This is important as WNV – infected pregnant BALB/c 
mice had an 88 percent higher chance of mortality as compared to uninfected pregnant 
mice (Cordoba et al., 2007). Unfortunately, no parallel observation has been documented 
in humans. 
 
To study the mechanism of neurovirulence and the body’s immunological response, 
C57BL/6 mice were infected with WNV and sacrificed at different time points to 
determine the level of leukocyte infiltration into the central nervous system. It was found 
that the level of CD45+ cells in the CNS was related to the severity of mice hind leg 
paralysis and three stages were recognized: non – infected, infected, and infected with 
paralysis. The three stages could also be differentiated by histopathology and virus 
antigen labelling by immunohistochemistry (Shrestha et al., 2003). Antigens of WNV 
were found specifically in the cortex, hippocampus, and choroid plexus (Hunsperger and 
Roehrig, 2006). This confirms neurons as a target for WNV infection and improves our 
understanding on its specific brain tissue tropism. Macrophages are also an important 
factor for neuroinvasion and encephalitis as macrophage – depleted mice showed higher 
mortality levels compared to the wild type (Ben-Nathan et al., 1996). IFNβ has been 
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found important for restricting the virus growth in both CNS and peripheral tissue. The 
high virus loads in IFNβ-/- mice resulted in neuronal apoptosis, encephalitis, and higher 
mortality (Samuel and Diamond, 2005). 
 
Using knockdown animal models, the once unknown virus effectors and immune 
pathways involved can now be thoroughly studied. CD4+ T cell knockout mice was found 
unable to resolve primary WNV infection as without CD4+ cells, the virus retains very 
high titres in serum and organs, leading to mortality. CD4+ cells were able to prime 
antibody production, activate CD8+ cells, and kill virus – infected cells through the Fas – 
Fas ligand pathway (Sitati and Diamond, 2006). A screening of CD4+ levels in WNV 
patients could potentially serve as a means of prognosis.  
 
CD8+ T cell on the other hand is important for both viral clearance and pathogenesis. At 
low viral loads, CD8+ cells blocked virus entry into the brain but at high viral load, CD8+ 
cells were overwhelmed and caused an inappropriate immune response that reduced 
survivability (Wang et al., 2003). Further studies with perforin – knockout mice, a 
downstream effector of CD8+ cells, found that CD8+ cells alone were incapable of virus 
clearance without perforin (Shrestha et al., 2006a).  
 
Mice experiments are not without its conflicts. Different groups using similar IFNγ 
knockdown mice (another CD8+ effector), but different WNV strains and different route 
of infection published opposing results. One group found IFNγ-/- mice had slightly higher 
survival rate when injected intravenously with 108 units of WNVS while another group 
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using 102 units of WNV NY99 injected through the mouse footpad had shorter mean 
survival times and higher viremia levels (Shrestha et al., 2006b; Wang et al., 2006). 
Clearly, although almost identical in nucleotide sequence, both virus strains utilise unique 
pathogenic pathways. Sarafend is a laboratory strain believed to be a human isolate from 
Israel from the 1950’s (Scherret et al., 2002) while WNV NY is a strain isolated from a 
dead crow during the 1999 outbreak (Komar et al., 2003).  
 
Toll – like receptors (TLR) are key players in the innate immunity as it primes 
downstream immunological cascades. These receptors upregulate CD4+ response and 
interferon levels. It was found that TLR3 knockout mice had higher levels of viremia in 
peripheral tissues but lower levels in the CNS and reduced signs of encephalitis, 
increasing survival rates (Wang et al., 2004a). This suggests that TLR3 activation 
induces a cytokine storm causing the breach of the blood – brain barrier leading to 
encephalitis. CCR5 is a chemokine receptor that recruits NK, macrophages, CD4+, and 
CD8+ cells to the brain and can cause the blood – brain barrier to become porous and 
leaky, allowing viruses in. Intuitively, CCR5 should favour virus survival in the CNS but 
it was found that CCR5-/- mice showed lower virus burden but also had correspondingly 
lower levels of recruited immune cells, leading to increased mice mortality from 40 
percent to 100 percent. Thus, the regulating of immune cells by CCR5 to the brain is vital 
for virus clearance (Glass et al., 2005).  
 
Mutations in the virus genome can also lead to the loss or acquisition of neurovirulence, 
specific organ tropism, or change in mortality levels. Point mutations in the NS4B region 
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of WNV were found to attenuate its neurovirulence (Wicker et al., 2006) while mutations 
in NS2A or NS3 genes slowed down virus growth but led to persistent infection in Swiss 
mice (Rossi et al., 2007). This is important as timely typing of circulating strains could 
predict the virus genetic drift, giving time to initiate health plans. Specific mutations in 
the domain III of the viral envelope protein can also give rise to viruses displaying 
different levels of neuroinvasiveness. (Chambers et al., 1998). 
 
 
1.8.2  Mouse Models to Study Dengue Virus 
Dengue virus (DV) is a very close cousin of WNV from the same genus Flaviviridae. 
Over the years, two different animals were mainly used to model dengue infection; non – 
human primates and mice. Like for WNV, simian models are difficult to work with and 
may transmit the disease to man (Gubler and Kuno, 1997; Lei et al., 2001). Even though 
monkeys are the closest model to mimic human infection, the lack of correlation with 
serious disease in humans makes it an unlikely choice. This is because monkeys can get 
infected with the virus but show little or no signs of infection (Eckels et al., 1994). Since 
the study of dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) relies 
greatly on histopathology and clinical signs, this model has been largely replaced by the 
mouse. There are a few mouse strains that were successfully infected with DV and 
showed high viremia (Charlier et al., 2004). 
 
The best known model is suckling mice inoculated intracerebrally with virus causing 
encephalitis (Despres et al., 1998; Lucia and Kangwanpong, 1994). Encephalitis is 
something rare in human dengue infections (Lum et al., 1996) making this an unrealistic 
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model for DHF since the clinical manifestation seen are not systemic and capillary 
leakage is rare in clinical cases. However, other immunocompetent mouse strains quickly 
clear the virus and have very short infection periods (Hotta et al., 1981).  
 
Severe combined immunodeficient (SCID) mice reconstituted with human 
hepatocarcinoma cells (Marianneau et al., 1996) displays viremia in many organs after 
inoculation. However, there is difficulty in reconstituting graft cells and the low 
frequency of mice infection following virus inoculation makes it an unreliable model (An 
et al., 1999; Wu et al., 1995). Other models include the SCID mouse (An et al., 2003), 
BL6 (Raut et al., 1996), ICR (Boonpucknavig et al., 1981), A/J (Shresta et al., 2004a), 
C57BL (Chen et al., 2004), and BALB/c (Huang et al., 2000). Each model successfully 
duplicates one area of dengue infection but not the entire disease spectrum.  
 
The C57Bl mouse is used to study T cell activation during virus infection, SCID is useful 
for CNS infection studies, ICR mouse model for studies focused on encephalitis while the 
BALB/c model displays thrombocytopenia. None however could replicate the whole 
spectrum of symptoms found in human infection (Huang et al., 2000; Zhang et al., 1988). 
However, in vivo models are still needed to understand viral pathogenesis (Kurane et al., 
1990; Marianneau et al., 1999). 
 
Interferons (IFN) are the first line of host defense against virus attacks as without it the 
virus infection increases in severity (Sen, 2001). This is of interest as immunocompetent 
mice have a low DV infection probability and viremia is almost impossible to establish 
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(Boonpucknavig et al., 1981). Thus, the AG129 mouse with a double knockout of 
interferon α / β and γ receptors is more susceptible to DV infection (van den Broek et al., 
1995).  Interferon alpha and beta share the same receptor while interferon gamma uses a 
unique one. IFNs also play important roles in complex antigen expression, inhibition of 
cell growth, hematopoiesis, and regulation of cellular and humoral immune response. 
However, Yang and colleagues (1995) reported on the importance of IFNs in initiating 
vascular leakage and shock. Also, soluble tumour necrosis factor receptor levels have 
been found to be correlated to disease severity in DHF patients (Bethell et al., 1998). This 
suggests that AG129, lacking IFN receptors could be more susceptible to DV but unable 
to mount cytokine responses to such a magnitude as to cause haemorrhage or shock, 
making it a less useful dengue virus model. 
 
Such fears were dispelled when DV was found able to replicate in and kill AG129 mice 
(Johnson and Roehrig, 1999; Shresta et al., 2004b). These studies used mouse – adapted 
DV strains and found IFN receptor action to be more important in virus clearing 
compared to B or T cells. Mice were unable to survive for more than thirty days post 
inoculation with a 108 PFU virus load. However, no histopathological studies were 
performed.  
 
1.9  TECHNIQUES USED TO STUDY PATHOLOGICAL CHANGES 
To visualize the disease progression in a model, histopathological observation of tissue 
samples is essential. Differences between uninfected and infected samples will show 
virus activity and the tissue reactions. The standard haematoxylin and eosin method is 
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widely used and sections are processed from paraformaldehyde – fixed, paraffin – 
embedded tissue samples. Pathological evidences are usually consistent with disease 
progression (Peyrefitte et al., 2003). 
 
Immunolocalization of virus antigens is also of importance as the cells in which 
flaviviruses replicate in remain undeciphered (Rosen et al., 1989). There are reports of 
flavivirus antigens and RNA being detected in many different cell types in the body. This 
includes the thymus, kidney, lung, skin, perivascular blood monocytes, liver, and spleen. 
Strong evidence also exists for monocytes, fibroblasts, epithelial cells, hepatocytes, and 
endothelial cells supporting DV replication (Jessie et al., 2004; Killen and O’Sullivan, 
1993). It is thus important to observe if the same cell types are involved in virus infection 
in mice and man.  
 
Immunolabelling exploits the specific binding trait between antibodies with its 
corresponding antigen. This binding site is then identified by attaching a probe to the 
complex. Two types of probes are often used, i.e. fluorescent label or gold – silver 
complex. Immunogold staining was first used in electron microscopy (Faulk and Taylor, 
1971) but soon extended to light microscopy (Holgate et al., 1983). This technique has 
been evolving for more than two decades (Danscher and Norgaard, 1983) and is more 
specific than other enzyme markers like immunoperoxidase or immunofluorescence. Just 
two secondary antibodies with gold conjugates binding to the antibody – antigen complex 
are enough to initiate a silver deposit around the tissue area. This leads to the 
development of a silver signal that can be seen by light microscopy.  
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The coloured substrate, diaminobenzidine (DAB), which is a commonly used substrate, is 
known to give nonspecific staining and false positives (Danscher and Norgaard, 1983). 
Gold is not toxic compared to benzene, the parent compound of DAB, a potential 
carcinogen. The sensitivity level of gold – silver enhancement is far higher than that of 
avidin – biotin, another routinely used enhancer in immunoperoxidase methods. In 
addition, silver does not fade while chromogen stains do over time and double – labelling 
is easily performed with gold particles but not with immunoperoxidase. The amount of 
antibodies and reagents saved because of the heightened sensitivity of the gold labelling 
technique has been found to outweigh its costs (Holgate et al., 1983). 
 
The visualization of silver particles on tissue sections requires a technology known as 
reflection contrast microscopy (RCM) or epi – illumination, an established but not widely 
used method (Filler and Peuker, 2000). It is able to produce superior images and has been 
said to bridge the gap between light and electron microscopy (Prins et al., 2006). The 
uniqueness of RCM is in its ability to suppress stray reflections which allows a wider 
useful range of magnification. Particles as small as five micrometers in diameter and 
sections as thin as 200 nanometers can be visualized using this method, allowing 
simultaneous processing destined for both light and electron microscopy. Because gold – 
silver granules strongly reflect light, it will appear as bright spots under RCM and can be 
easily identified (Gao et al., 1995). The reflected light can also be complimented with 
transmitted light to display the regular morphology of the sections for better cell 
orientation (De Waele et al., 1986). Biological markers will stand out much stronger with 
Introduction 
22 | P a g e  
 
RCM as compared to normal illumination, adding colour, quantitative ability, and 
sensitivity to detection methods (Neelissen et al., 1999). 
 
1.10  EFFECTS OF VIRUS PASSAGING 
It is known that RNA viruses easily acquire genetic changes due to mutations or 
reassortment of its genome. These viruses utilize an error – prone RNA – dependent 
RNA polymerase replication system. Coupled with the large population sizes of viruses 
found in some hosts during infection, this would lead to high levels of genetic diversity 
(Moya et al., 2004). A rate of approximately one mutation for every 10000 basepairs 
replicated was suggested for RNA viruses (Drake and Holland, 1999). Such rates of 
mutation could easily change the virus host specificity, possible modes and dose of 
transmission, shift in virulence, and antiviral drug reaction. 
 
The SARS coronavirus can infect the respiratory tract of inbred mice but does not cause 
illness following infection. This virus was passaged through BALB/c mouse lungs for 
fifteen rounds and virus clones isolated from tissue homogenates were found to result in 
up to 100 percent mortality in adult BALB/c mice (Roberts et al., 2007). A mutant tick – 
borne encephalitis virus carrying a deletion mutation that rendered it non – infectious in 
BHK cell culture could be rescued by natural mutation and selection after passaging the 
virus through BHK cells for five consecutive rounds (Elshuber and Mandl, 2005).  
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West Nile virus that was passaged for six rounds through HeLa cells was found 
attenuated 4000 – fold in adult mice when inoculated intraperitoneally or intranasally. 
The virus was also found antigenically different and temperature – sensitive. Another 
strain of WNV from Egypt was passaged through a similar six rounds and found to have 
lost its ability to infect Vero cells and no longer killed adult mice (Dunster et al., 1990). 
The WNV passaged in hamsters for three rounds caused amino acid substitutions in the 
E, NS1, NS2B, and NS5 regions and produced an asymptomatic persistent infection in 
adult hamster kidneys. This was accompanied by a loss of virulence and a change in 
plaque morphology (Ding et al., 2005). 
 
In another study, strains of WNV from different passaging regimes were found to have 
different neuroinvasive properties and this was mapped to point mutations at the viral 
genomic position 68 corresponding to an E protein glycosylation site. Notably, a strain of 
highly mosquito cell – passaged WNV possessing this glycosylated site was found to be 
325 – fold less neuroinvasive than its parental strain (Chambers et al., 1998). However, 
another study using 19 distinct and differently passaged WNV strains found no strong 
correlation between presence or absence of potential glycosylation sites and mouse 
neuroinvasiveness (Beasley et al., 2002) . The same study also showed that neuroinvasive 
virus strains had more variations in sequence as compared to noninvasive species. This 
tells us that viral neuroinvasiveness is controlled by multiple points in the genome and 
may be a result from an interplay between different regions of the virus genome or 
different subpopulations of viruses during a co – infection.  
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Homogeneous WNV from an infectious clone was passaged twenty times serially in 
either Culex mosquitoes or SPF chickens (Jerzak et al., 2007). The mosquito – passaged 
virus showed greater genetic diversity and heterogeneity but killed fewer mice because 
certain acquired mutations resulted in noninvasiveness. The chicken – passaged virus 
however retained its level of virulence. A similar experiment using mosquito and avian 
cell cultures found WNV passaged through insect cell lines having increased relative 
fitness and replicative ability linked to more numerous amino acid changes in the viral 
genome. The opposite effect was found for virus grown in avian cell cultures (Ciota et 
al., 2007c).  
 
These experiments clearly exemplify the fact that viruses are ever evolving. As such, 
carefully planned experiments could in fact engineer the direction of viral evolution. 
Species infectivity and mortality levels are parameters that could be altered to adapt to 
new environments and hosts.     
 
1.11  OBJECTIVES 
West Nile virus and dengue virus infections are important emerging infectious diseases. 
Much effort has gone into the research of antivirals and other possible drugs to reduce or 





25 | P a g e  
 
The objectives of this study can be summarised as: 
a) To adapt the less pathogenic lineage II West Nile virus (Sarafend) from a mouse 
non – neuroinvasive to a neuroinvasive strain in an immunocompetent mouse 
lineage by serially passaging the virus in a manner mimicking its natural 
infectious cycle. This allows for studies on WNV pathogenesis to be performed at 
BSL 2 instead of BSL 3 which is required for WNV lineage I strains. 
b) To document viral growth changes during this adaptive process. 
c) To compare passaged and unpassaged virus characters in immunocompetent mice 
through: 
i. Detecting pathological differences in various organs of adult mice infected 
with passaged and unpassaged viruses. 
ii. Sequencing selected genes of passaged and unpassaged virus genomes to 
detect regions of mutations. 
iii. Testing of passaged and unpassaged virus morbidity and mortality levels 
in suckling and adult mice. 
iv. Infecting primary mouse neural cells with passaged and unpassaged 
viruses to observe for changes in virus growth kinetics. 
 
Such a virus – mouse combination model would contribute greatly to the area of anti – 
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2.0  MATERIALS AND METHODS  
2.1 CELL CULTURE TECHNIQUES  
All solutions and media for cell culture were made with deionised E - Pure™ water 
(Barnstead, New Hampshire, USA). All cell culture and media preparation works was 
performed under aseptic conditions in a Class II Type A2 BSC hood (Esco Pte. Ltd., 
Singapore). 
 
Cells used in this study were grown in sterile 25 cm2 or 75 cm2 plastic tissue culture 
flasks (Iwaki Glass, Tokyo, Japan), and 24 – well or 96 – well tissue culture plates 
(Greiner Bio – One, St. Louis, USA). Cells were either cultured in a humidified 
incubator (Thermo Fisher Scientific, Massachusetts, USA) with carbon dioxide (5 %) 
or a dry incubator (Memmert GmbH, Schwabach, Germany). Only the mosquito cell 
line C6/36 was grown in the dry incubator.  
 
2.1.1 Cell Lines  
Cell lines that were used in this study are listed in Table 3. The media type, passage 
numbers used for experiments in this project, and origin of the cell lines are included. 
All lines used are adherent cell types. 
 
2.1.2 Media and Solution for Cell Culture  
Culture media supplemented with 10 % foetal bovine serum (PAA Laboratories 
GmbH, Austria) was used as the growth medium (Appendix 1a to d) for the respective 
cell lines. The media pH was adjusted to approximately 7.3 with 1 M sodium 
hydroxide and 1 M hydrochloric acid (Appendices 1e and 1f).  
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Table 3: Cell lines and related information.  





Vero, African Green 
Monkey Kidney cells 
Media 199 
(M199) 
90 – 110  Kind gift from Emeritus 
Professor Edwin 
Westaway, Australia 
C6/36, mosquito cell 
derived from Aedes 
albopictus 
L15 70 – 100  Kind gift from Emeritus 
Professor Edwin 
Westaway, Australia 
BHK 21 (clone 13), 
kidney fibroblast, baby 
hamster kidney 
RPMI 95 – 150  American Type Culture 
Collection, USA 
Primary neural mice 
cells, from foetal mice 
Neurobasal 
 or DME 
1  Laboratory produced 
 
2.1.3 Cultivation and Propagation of Cell Lines  
Flasks of cells were sub – cultured from confluent 75cm2 flask monolayers at a ratio 
of 1 : 5 (Vero and BHK 21 cells) or 1 : 4 (for C6/36 cells). The growth medium 
(Appendix 1a to d) was first discarded. The monolayer was then rinsed with 5 
millilitres of phosphate buffered saline (PBS - Appendix 1g). This was followed by 
incubation with 2 millilitres of trypsin (Appendix 1h). The flask was left for two 
minutes at 37 °C to detach the cell monolayer from the flask. The cells were then 
dislodged by gentle tapping. Appropriate amounts of growth media (total of 10 
millilitres for 75cm2 and 5 millilitres for 25 cm2 flasks) were added to the cell 
suspension to inactivate the enzymatic activity of the trypsin. Cell aggregates were 
dispersed by pipetting up and down to give a single cell suspension. The suspended 
cells were then aliquoted into new tissue culture flasks. The cells were then incubated 
at 28 °C for C6/36 cells or 37 °C for all other cell types. The monolayer would reach 
confluency in two weeks for primary astrocytes or three days for other cell lines and 
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used for experiments. The production of the primary cell lines is described in Section 
2.3.7. 
 
2.1.4 Cultivation of Cells in 24 – Well and 96 – Well Tissue Culture Tray  
A confluent cell monolayer of BHK 21 in a 75 cm2
 
tissue culture flask was used to 
seed four 24 – well plates (Greiner Bio – One, St. Louis, USA). The cell monolayer 
was treated as previously described (Section 2.1.3) to produce a single cell 
suspension. The cell suspension was then made up to a final volume of 48 millilitres 
using appropriate cell culture growth medium (Appendix 1a to d). Aliquots of half a 
millilitre was transferred into each well of the 24 - well plates. The trays were then 
incubated at 37 °C in a humidified incubator (Thermo Fisher Scientific, 
Massachusetts, USA) with 5 % carbon dioxide. The monolayers were confluent in 24 
hours and ready for use.  
 
2.2 INFECTION OF CELLS  
2.2.1 Viruses  
The viruses used in this study are given in Table 4. The stock viruses previously 
grown on a Vero cell monolayer were amplified in Vero or C6/36 cells for this study. 
Viruses were harvested at the appropriate timing post – infection (p.i.) from infected 
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A gift from Emeritus 
Professor Edwin 
Westaway, Australia 
24 hours post 
infection (Vero 
or C6/36 cells) 
Flaviviridae Dengue Serotype 1 
(DV1) 
Kind gift from Dr. Ling 
Ai Ee, Singapore General 
Hospital 
7 days post 
infection (C6/36 
cells) 
Flaviviridae Dengue Serotype 2 
NGC 
(DV2) 
ATCC, USA 3 days post 
infection (C6/36 
cells) 
Flaviviridae Dengue Serotype-4 
(DV4) 
ATCC, USA 7 days post 
infection (C6/36)
 
2.2.2 Infection of Cell Monolayers  
Confluent cell monolayers in 75cm2 or 25cm2 flasks were used for infection. The cell 
culture medium was discarded and the monolayer washed with 5 millilitres of PBS 
(Appendix 1g). Virus suspension with a multiplicity of infection (MOI) of 10 was 
made up to 2 or 1 millilitres with virus diluent (Appendix 2a) for 75cm2 or 25cm2 
flasks, respectively and incubated over the monolayer at 37 °C for an hour with 
rocking every 15 minutes to ensure even infection. After one hour, unabsorbed viruses 
were washed off with five millilitres of PBS (Appendix 1g) and an appropriate volume 
of maintenance media (Appendix 2b to d) was added to the flask. The infected cells 
were then incubated at 37 °C or 28 °C, in separate incubators as those used to 
cultivate uninfected cells, until the appropriate harvest time (Table 4).  
 
Mock - infected controls used in this study were prepared as abovementioned except 
that a similar amount of virus diluent (Appendix 2a) was used instead of virus. 
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 2.2.3 Preparation of Virus Pools  
Virus pools were prepared using 75 cm2
 
flasks. Infection was carried out as described 
in Section 2.2.2. The virus was harvested at specific time points when cytopathic 
effects were pronounced (Table 4). At the end of the incubation period, the infected 
supernatant was harvested and spun down at 1000 x g for 10 minutes (Sigma 
Laborzentrifugen GmbH, Germany) to pellet any cellular debris. Aliquots of 500 
microlitres of the clarified supernatant was pipetted into 1 millilitre sterile cryovials 
(Nalge Nunc International, Roskilde, Denmark), capped and immediately snap frozen 
at - 80 °C with denatured ethanol. The frozen ampoules were stored in a  
- 80 °C freezer (Thermo Fisher Scientific, Massachusetts, USA). Plaque purified virus 
were not used in any of the experiments to replicate the mixed virus pool naturally 
found in human infections. 
 
2.2.4 Plaque Assay  
BHK cells were seeded onto 24 - well plates at a concentration of 2 × 105 cells per 
well and were incubated at 37 °C with 5 % carbon dioxide for 24 hours (Section 
2.1.4). Ten - fold serial dilutions of the virus sample was prepared in virus diluent 
down to 10-8 (Appendix 2a). Aliquots of 100 microlitres from each dilution were 
transferred in triplicates onto confluent cell monolayers in the wells. After an hour of 
incubation at 37 °C under 5 % carbon dioxide with the plate rocked every fifteen 
minutes to ensure even distribution of the virus inocula, the diluted virus inocula were 
removed, and the cell monolayers washed once with PBS (Appendix 1g). 
One millilitre of overlay medium (Appendix 2e) was pipetted into each well. The trays 
were incubated at 37 °C in a humidified carbon dioxide incubator. Plates were 
incubated two or five days for WNVS or DV, respectively. Formation of plaques was 
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visualized by staining the monolayer with 0.5 % crystal violet in a 25 % 
formaldehyde solution (Appendix 2f) for at least two hours at room temperature on an 
orbital shaker (Labnet Intl. Inc., Edison, USA). The excess formaldehyde fixative was 
removed for proper hazardous chemical disposal, the trays washed under a running 
tap to remove residual dye, and dried in a well ventilated 60 °C oven for two hours 
(Memmert GmbH, Schwabach, Germany). Plaques were counted and the titre 
calculated as PFU per ml supernatant (PFU/ml) or PFU per gram tissue (PFU/g).  
 
For the evaluation of organs from the suckling mice passaging experiments as 
described in Section 2.3.6, two wells from each 24 - well plate used for plaque assay 
was layered with pre – titred unpassaged WNVS previously grown on Vero cells. The 
purpose of this is to evaluate the plaque size of the passaged virus. All the wells were 
processed in the same way and after the plates were stained and dried, a photograph 
was taken. Regions of plaques as seen in Figure 4 were then converted to negative 
colours through the ‘Find Edges’ function on ImageJ software (v1.37, National 
Institute of Health, USA). The resulting image, as seen in Figure 5 was then measured 
for plaque sizes using the line tool. The diameters of 10 plaques were measured for 
both passaged virus and control unpassaged virus for each plate. The mean was 
determined and plotted graphically against the standard plaque size as determined by 
Vero grown WNVS. 
 
All statistical analysis was done using Minitab 14 (Minitab Inc., Pennsylvania, USA) 
by Student’s t – test, normality test, and standard error. Graphs were plotted with 
Microsoft Excel 2007 (Microsoft Inc., Washington, USA). 
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Figure 4: A photograph of two wells of plaque assay. 
 
 
Figure 5: The ‘Find Edges’ function converts the photograph into negative colours. 
The same wells were used to measure plaque diameters. 
 
2.3 ANIMAL WORK 
2.3.1 Experimental Mice 
All BALB/c mice were purchased from the Centre for Animal Resources (CARE), 
National University of Singapore (NUS) and kept at the Department of Microbiology 
Animal Holding Facility, NUS, under SPF conditions in microisolator cages 
(Alternative Design Inc., USA). BALB/c adult mice used were approximately five to 
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six weeks old while pups experimented on were between two and three days old. The 
double knockout for interferon α / β and γ receptor mice, AG129-/- (Alpha and 
Gamma interferon receptor knockout on a 129 mouse background) were obtained 
from Dr. Woulter Schul of Novartis Institute of Tropical Diseases (NITD), Singapore. 
AG129-/- mice were housed in a pathogen free environment using a flexible film 
isolator at the Animal Holding Unit (AHU), NUS. Experiments conducted adhered to 
the International Guiding Principles for Animal Research and were approved by the 
NUS Institutional Animal Care and Use Committee (IACUC).  
 
2.3.2 Mice Experiments on Dengue Virus 
2.3.2.1 AG129 Mice 
Groups of three 10 - week old mice were used to test the efficiency of DV2 infection 
in adult AG129-/- immunocompromised mice. The virus was diluted to PFU levels of 
105, 106, 107, or 108 and inoculated intravenously with a tuberculin syringe and a 25G 
needle (BD Bioscience, New Jersey, USA) and bled at days 1, 2, 3, 4, 5, and 10 post 
inoculation.  
 
Next, groups of 2 mice were inoculated with 107 PFU of DV2 virus and sacrificed at 
days 1, 2, 3, 4, 5, and 10 post infection via suffocation by purified carbon dioxide in a 
Perspex chamber (Soxal Pte. Ltd., Singapore). Necropsy of the brain, spleen, and liver 
was done after ensuring the mice were dead by footpad pressure. The organs were 
weighed, stored in cryovials (Nalge Nunc International, Roskilde, Denmark), and then 
snap frozen with ethanol at - 80 ˚C. Organs were stored frozen until used. A portion of 
tissue was kept for bio – imaging (Section 2.5). Tissue homogenates were processed 
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for plaque assay while sections were stained with haematoxylin & eosin as well as for 
virus antigen. 
 
2.3.2.2 BALB/c Mice 
To test the difference in infectivity between the immunocompromised mouse strain 
AG129 and immunocompetent BALB/c, adult BALB/c mice were inoculated with 
concentrated DV1 and DV2 through the tail vein with a 27G ½” needle (BD 
Bioscience, New Jersey, USA) while restrained by a Mice Tailveiner® (Braintree Sci. 
Inc., Massachusetts, USA). Supernatant from a 75 cm2 flask of DV1 and DV2 
infected C6/36 cells as described in Section 2.2.2 was first spun down at 1000 x g for 
10 minutes to pellet any cell debris. The clarified supernatant was then transferred to a 
100000 Dalton pore size Vivaspin (Sartorius – Stedim AG, Germany) and spun at 
2500 x g for 30 minutes to concentrate the ten millilitre supernatant to 0.5 millilitres. 
The resultant virus titre increased one log from 6 to 7 log PFU/ml, confirmed by 
plaque assay (Section 2.2.4). Each mouse was inoculated with 100 microlitres of 
concentrated virus and one mouse from each dengue serotype infection was sacrificed 
on day 1, 3, 5, and 18 post inoculation, respectively. Blood was collected via cardiac 
puncture (Section 2.3.4) while the brains, livers, and spleens were harvested as 
described in Section 2.3.2.1 and processed as detailed in Section 2.3.5. A small 
portion of tissue was kept for bio – imaging purposes (Section 2.5). 
 
To test the effect of injecting different dengue strains into the same mouse to mimic a 
heterologous infection in hope of eliciting a stronger host response against the 
secondary virus infection, a second experiment was completed. It used two BALB/c 
mice per group in two groups. The fist group was inoculated with DV1 through the 
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tail vein at day 0 of the experiment before being inoculated again with DV2 at day 14. 
The second group of mice received the reverse sequential virus serotype treatment. 
Mice were sacrificed at day 21 of the experiment and both blood and organs collected. 
 
2.3.3 West Nile Virus Infection in BALB/c Mice 
2.3.3.1 Adult Mice 
Five-weeks old BALB/c mice were inoculated with WNVS through the tail vein. 
Supernatant from a 75cm2 flask of WNVS infected C6/36 or Vero cell monolayer as 
described in Section 2.2.2 was spun down at 1000 x g for 10 minutes to pellet any cell 
debris. The clarified supernatant virus titre was approximately 9 log PFU/ml. Each 
mouse was inoculated with 100 microlitres of virus and 2 mice were sacrificed by 
carbon dioxide suffocation on days 1, 3, 5, and 18 post inoculation. Necropsy of the 
brain, spleen, and liver was done after ensuring the mice were dead. A portion of 
tissue was fixed for bio – imaging purposes (Section 2.5).  
 
2.3.3.2 Suckling Mice 
Suckling BALB/c pups one to two days old were inoculated intracranially with 5 
microlitres of the same WNVS stock as described in Section 2.3.3.1 using a 50 
microlitre gastight glass syringe (Hamilton Co., Nevada, USA) connected to a 30G 
needle (BD Bioscience, New Jersey, USA). Two mice were harvested every 6 hours 
from 18 hours post infection for a total experimentation period of 3 days. In addition, 
groups of 3 – 4 suckling mice were inoculated intracranially with 50000, 10000, 5000, 
1000, 500, and 100 virus particles made up to 5 microlitres in virus diluents 
(Appendix 2a). Mice were checked every 12 hours and the brains from dead mice 
harvested, homogenized, and quantified for infectious virus particles (Section 2.2.4). 
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2.3.4 Blood Collection from Adult Mice 
Blood samples were collected from adult mice using two methods; cardiac puncture 
and submandibular bleeding. Cardiac puncture was performed on deeply 
anaesthetised mice after carbon dioxide asphyxiation. A 1 millilitre tuberculin syringe 
was connected to a ½” 26G needle (BD Bioscience, New Jersey, USA) and injected 
into the thoracic cavity through the diaphragm underneath the sternum at the 
epigastric region of the mouse on its back. The needle was introduced at a 10 – 30 
degree angle from the horizontal axis of the sternum in order to enter the heart. Blood 
was slowly drawn out from the ventricle of the beating heart until the blood stopped 
flowing. Approximately 1 millilitre of whole blood could be obtained from each adult 
mouse. 
 
Submandibular bleeding was done using 4 or 5 millimetre Goldenrod animal lancets 
(Medipoint Inc., New York, USA) in a class 2A biohazard hood following 
instructions by the manufacturer as published (Golde et al., 2005). Restrained animals 
were first swabbed at the cheek area with absolute ethanol. The animals were held by 
the skin between the shoulder blades and the sharp point of the lancet quickly lunged 
into the back of the jaw of the mouse, slightly behind the hinge of the jawbones, 
towards the ear. Once pierced, a serum collection tube was immediately placed under 
the cheek to collect the blood drippings (BD Bioscience, New Jersey, USA). When 
200 microlitres of whole blood has been collected, the flow was stopped by applying 
direct pressure on the wound site with gauze held for a minute. 
 
In all cases, whole blood was spun down at 14000 x g for 10 minutes at 4 ˚C (Sigma 
Laborzentrifugen GmbH., Germany). The serum was aliquoted into cryovials and 
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snap frozen in absolute ethanol at - 80 ˚C before being used for plaque assay as 
outlined in Section 2.2.4. 
 
2.3.5 Homogenization of Tissue Samples 
Tissue samples collected from all mice necropsies were weighed and homogenized 
with ice – cold virus diluent (Appendix 2a). Buffer was added to the tissue samples in 
a volume to weight ratio of 2 : 1; microlitre : microgram. All samples were crushed 
using hand – held  1, 3, or 5 millilitre glass homogenisers with a rated cylinder – 
plunger clearance of 0.01 to 0.03 millimetres (Sartorius – Stedim AG, Germany). The 
tissues were crushed until no large particles could be seen in the homogenate, 
approximately ten to twenty strokes. Cell debris was spun down in a microfuge at 
10000 x g for 10 minutes at 4 ˚C. The supernatant was aliquoted and stored in 
cryovials at - 80 ˚C until used. 
 
2.3.6 Passaging Experiments  
2.3.6.1 Mouse Only Regime  
Stock West Nile virus was subjected to a passaging regime of 10 rounds in suckling 
BALB/c brains. Virus harvested from Section 2.2.3 was inoculated into suckling mice 
brains as described in Section 2.3.3.2. Mice were sacrificed after 54 hours and the 
brains, livers, and spleens were harvested and processed as described in Sections 
2.3.3.2 and 2.3.5. 
 
The organ homogenate supernatant was tested for number of infective viruses by 
plaque assay as depicted in Section 2.2.4. It was also used to infect a second batch of 
suckling mice; passage 2. The experiment was carried out as described above and this 
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process was repeated for 10 rounds for a total passage repeat of ten rounds. Virus 
supernatant from each stage of passage was kept at - 80 ˚C under lock (Thermo Fisher 
Scientific, Massachusetts, USA). This passaging regime is labelled as the ‘m’ series 
and was carried out in five biological repeats.  
 
2.3.6.2 Mouse – C6/36 Regime 
The mouse – C6/36 regime protocol followed closely the mouse only regime detailed 
in Section 2.3.6.1 except that after each mouse passage, 500 microlitres of brain 
homogenate supernatant was used to infect a monolayer of C6/36 cells. Confluent 
monolayers were incubated with 500 microlitres of brain homogenate supernatant 
made up to 2 millilitres with virus diluent (Appendix 2a) for an hour with rocking 
every 15 minutes. After one hour, unabsorbed viruses were washed off with 5 
millilitres of PBS (Appendix 1g) and 10 millilitres of maintenance medium (Appendix 
2b) were added to the flask. The infected C6/36 cells were then incubated at 28 °C for 
24 hours before the supernatant was harvested and stored as described in Section 
2.2.3. This process was repeated for 10 passage rounds with each passage consisting 
of a round of virus growth in suckling mice brain followed by virus growth on 
confluent C6/36 monolayer. This passaging regime is labelled as the ‘c’ series and 
was reiterated in five biological repeats.  
 
2.3.7 Isolation of Foetal Mice Brains for Primary Cell Culture 
Primary mouse neural cultures were prepared from mouse embryos by the modified 
protocol of Brewer (1997) and Diniz and group (2006). Pregnant BALB/c mice at 
approximately gestation day 15 to 16 were sacrificed by carbon dioxide asphyxiation. 
When the pregnant mouse stopped breathing, it was held by the neck and tilted 
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downwards. Through the middle of the abdomen of the mouse, the skin of the 
pregnant mouse was cut open through the abdomen to release the uterus and the 
embryos. The embryos were removed and each was cut at the neck to remove the 
head. The heads were collected in a 35 millimetre plastic petri dish (Corning Inc., 
New York, USA) containing cold virus diluent (Appendix 2a). The brains were 
obtained from the heads after peeling off the skin and the cranium. These were 
transferred into a clean petri dish with cold virus diluent. The thin layer of membrane 
covering the brain containing blood vessels was then carefully peeled off using two 
sharp #7 Jewellers Forceps (Dumont S.A., Switzerland). This was done under an 
Olympus SZ51 stereomicroscope (Olympus Corp., Japan). 
 
Once all visible membranes had been removed, the whole brain or mid - brain section 
was taken and washed in another petri dish of cold virus diluent (Appendix 2a) before 
being cut into small pieces approximately 0.2 centimetres in diameter and collected in 
a 1.5 millilitre microfuge tube. To this, 500 microlitres of papain (Worthington 
Biochemical Corp., New Jersey, USA) (Appendix 1i) was added and the tube kept on 
a floater in a 37 ˚C GFL water bath for 15 minutes (Gesellschaft für Labortechnik 
GmbH, Burgwedel, Germany). The tube was gently inverted a few times every five 
minutes. A 1000 microlitre micropipettor was then very gently used to dislodge the 
enzyme treated cells as much as possible. This was then left in the water bath for 
another 15 minutes and the micropipettor was used again to dislodge the cells. Once 
the cells were seen to be suspended with no large clumps, the tube was centrifuged at 
500 x g for 10 minutes at 4 ˚C. The pellet from whole brain single cell suspension was 
resuspended in 20 millilitres of DME growth medium with inactivated serum 
(Appendix 1d) for astrocytes and glial cells or Neurobasal media supplemented with 
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B27 (Invitrogen Corp., Carlsbad, USA) for cortical neurons derived from mid – brain 
sections of single cell suspension. After thoroughly mixing the cells, it was plated 
onto 25 cm2 tissue culture flasks pre-coated with poly – L – lysine (Appendix 1j) and 
incubated in a 37 ˚C humidified incubator. Cells were left for at least 2 weeks before 
any experiments were performed. Half the volume of media was removed and 
replaced with fresh media twice weekly. 
 
2.3.8 Post – Passaging Mouse Experiments 
2.3.8.1 Adult BALB/c Mice 
A total of five virus samples of passage ten viruses from both Sections 2.3.6.1 and 
2.3.6.2 were used to infect adult five week old BALB/c mice via the intravenous 
route. A hundred microlitres of virus was injected into the tail vein of 5 mice per virus 
sample, with a total of 50 mice used. Virus titres are reported in Section 4.3.1. Two 
mice were left for up to 4 weeks to check for mortality and morbidity. These 2 mice 
were also bled through the submandibular method as described in Section 2.3.4 every 
other day. The blood was spun down and the serum tested by plaque assay (Section 
2.2.4). The remainder 3 mice per group were sacrificed one at a time on days 1, 3, and 
5 post inoculation. The mice were bled by cardiac puncture (Section 2.3.4), and 
brains, livers, and spleens harvested and homogenised (Section 2.3.5). The resultant 
supernatant was used for plaque assay (Section 2.2.4). A small portion of tissue was 
kept for bio – imaging (Section 2.5). 
 
A second experiment was carried out to test the level of morbidity caused by the 
different passaged virus by observing if adult mice lost weight as a result of virus 
inoculation. The experiment was carried out by injecting 100 microlitres of the 10 
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different passage 10 viruses through the tail vein of the mice. The controls used were 
mice inoculated with unpassaged virus. Two mice per virus sample were used and the 
mice were weighed every 12 hours for 20 days with the point of injection represented 
as 0 hour.  
 
2.3.8.2 Suckling BALB/c Mice 
Suckling mice one to two days old were injected intracranially with passage 10 
viruses. Each strain of passaged virus was inoculated into 9 suckling mice. This group 
was divided into 3 subgroups and each subgroup received 50, 500, or 5000 virus 
particles of passaged virus diluted to 5 microlitres with virus diluent (Appendix 2a). 
The mice were injected using a presterilized 50 microlitre gastight syringe (Hamilton 
Co., Nevada, USA) connected to a 30G needle (BD Bioscience, New Jersey, USA). 
The suckling mice were constantly kept in a cage with the dam on soft corncob 
bedding (Harlan Teklad Laboratories, Madison, USA). Every 12 hours, the mice were 
inspected and mortality recorded. Brains from dead suckling mice were harvested and 
homogenised (Section 2.3.5) for plaque assay (Section 2.2.4). 
 
2.3.8.3 Primary Neural Cell Line 
Primary neural cells grown (as processed in Section 2.3.7) in 25 cm2 flasks were 
infected with passage 10 viruses at an MOI of 10 following the procedure outlined in 
Section 2.2.2. A total of 5 millilitres of maintenance media was added to the flask and 
every 12 hours for 6 days, 300 microlitres of infected media was removed for plaque 
assay and replaced with 300 microlitres of fresh media. The extracted media was spun 
down at 5000 x g for 5 minutes to pellet all cell debris and the supernatant stored at - 
80 ˚C until used for plaque assay (Section 2.2.4). 
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2.4 DIRECT POLYMERASE CHAIN REACTION SEQUENCING 
2.4.1 Extraction of Virus Ribonucleic Acid (RNA)  
Viral RNA extraction procedure was carried out using QIAmp® Viral RNA 
extraction kit (Qiagen NV, Venlo, Nederlands). A 140 microlitre aliquot of West Nile 
virus supernatant (approximately 3 x 109
 
PFU/ml) was added to 560 microlitres of 
Buffer AVL containing carrier RNA in a 1.5 millilitre RNase and DNase free 
microfuge tube (Axygen Scientific, Union City, USA). The mixture was incubated at 
25 ºC on a heat block for 10 minutes (USA Scientific Inc. Ocala, USA), followed by 
the addition of 560 microlitres of absolute ethanol (Merck KGaA, Darmstadt 
Germany). The solution was then transferred to the QIAmp spin column and spun at 
6000 x g for 1 minute (Sigma Laborzentrifugen GmbH., Germany). The filtrate was 
discarded. The spin column was spun again at 6000 x g for 1 minute after adding 500 
microlitres of Buffer AW1. This step was repeated with Buffer AW2. Viral RNA was 
eluted from the spin column by adding 30 microlitres of Buffer AVE and spun at 
6000 x g for 1 minute. Viral RNA was stored at - 80 ºC until used. 
  
2.4.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RT-PCR was performed to synthesise cDNA from harvested West Nile virus RNA 
extracted as described in Section 2.4.1 using the ImProm – IITM Reverse Transcription 
System (Promega Corp., Madison, USA). Specific primers were synthesised 
corresponding to specific locations on the virus genome as detailed in Table 5 (1st 
Base Pte. Ltd., Singapore). All primers for this project were synthesised by the same 
company. The primers were dissolved in DEPC treated water (Appendix 3a) to a stock 
concentration of 10 micromolars.  
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Table 5: List of RTPCR Primers Used and its Sequences 
Original RNA sequence (5’ – 3’) First 
Base 
Synthesised Primer (5’ – 3’) Name 
ACAGCTTCAACTGCTTAGG 962 CCTAAGCAGTTGAAGCTGT RT10 
GTGAAGTTGACATCAGGACA 1801 TGTCCTGATGTCAACTTCAC RT9 
CTGCCACCACTGAAAAAT 2783 ATTTTTCAGTGGTGGCAG RT8 
ATATGTCATTCTCGTTGG 3693 CCAACGAGAATGACATAT RT7 
AGGCGTTTACAGAATCATGA 4671 TCATGATTCTGTAAACGCCT RT6 
CCCCTTTCCAGAGTCTAA 5583 TTAGACTCTGGAAAGGGG RT5 
TGAAGTCATCACAAAGTTGG 6351 CCAACTTTGTGATGACTTCA RT4 
GCGGTGGTCGTCAATCCATC 7471 GATGGATTGACGACCACCGC RT3 
AACATGACAAGCCAGGTA 8383 TACCTGGCTTGTCATGTT RT2 
TGTATTAAATAGTTGTATG 10412 CATACAACTATTTAATACA RT1 
AGTGGAGGACACTGTTTTG 10380 CAAAACAGTGTCCTCCAC RT13 
 
Four microlitres of experimental RNA was mixed into 1 microlitre of gene – specific 
primer in an autoclaved, nuclease – free, thin – walled PCR tube and briefly spun 
down (Abgene Ltd., Epsom, UK). The tube was heated to 70 ˚C for 5 minutes in a 
thermal cycler (Bio Rad Labs., California, USA) and immediately chilled on ice for 
another 5 minutes. The tubes were then spun down for 10 seconds in a 
microcentrifuge to collect the condensate. The transcription mix premixed as 
described in Appendix 3b was then added to the tube on ice to make up a final 
reaction volume of 20 microlitres.  
 
The tube was capped tightly and placed in the thermal cycler to be equilibrated at 25 
˚C for 5 minutes, then 42 ˚C for 1 hour and lastly 70 ˚C for 15 minutes to inactivate 
the reverse transcriptase. The products were promptly kept at – 20 ˚C until used. 
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2.4.3 Polymerase Chain Reaction Amplification (PCR) 
PCR was used to amplify specific gene sequences using the respective primers 
flanking the 5’ and 3’ end. Amplification was performed using Platinum Pfx DNA 
Polymerase (Invitrogen Corp., Carlsbad, USA) which has a 3’ to 5’ exonuclease proof 
– reading activity to minimise the incorporation of mismatched nucleotides during 
amplification. Primers were designed and the sequences are as displayed in Table 6.  
 
Table 6: Primer Sequences for PCR Amplification 
Primer Pair Sequence  
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PCR Amplification mix was prepared as described in Appendix 3c. Twenty 
microlitres of prepared first strand cDNA from Section 2.4.2 was added to the 
Amplification Mix to make up a 50 microlitre reaction. The tube was capped and 
centrifuged briefly to collect the contents. The template was denatured for 2 minutes 
at 94 ˚C followed by 30 cycles of PCR amplification in an iCycler (Bio Rad Labs., 
California, USA) as follows: each cycle consisted of 94 ˚C for 15 seconds, 55 ˚C for 
30 seconds and 68 ˚C for 1 minute, which enabled repetitive DNA denaturation, 
primer hybridization and primer extension, respectively. An extra step of 72 ˚C for 5 
minutes allowed final extension to occur and ended with a holding step at 4 °C. Tubes 
were stored at – 20 ˚C until used.  
 
2.4.4 Agarose Gel Electrophoresis  
The PCR amplification products were visualized with agarose gel electrophoresis. A 
1.0 % agarose gel was cast as described in Appendix 4a. The fluid of agarose mixture 
was poured into a gel tray where air bubbles were removed using a pipette tip before 
the gel comb was inserted. The solidified gel was then submerged in the gel – 
electrophoresis tank (Bio Rad Labs., California, USA) filled with 1 x TBE buffer 
(Appendix 4b). Fifteen microlitres of DNA sample was mixed with 2 microlitres of 6 
x gel loading buffer (Bio Rad Labs., California, USA) before loading into a well. Ten 
microlitres of Bench Top 100bp DNA Ladder (Promega Corp., Madison, USA) was 
also loaded as a relative molecular size reference. The sample was then 
electrophorized at 120 volts for 45 minutes. The DNA bands were then visualized 
under UV light (UV transilluminator, Vilber Lourmat, UK) and a digital photograph 
of the gel was taken with a ChemiGenius station (Syngene, Synoptics Ltd., 
Cambridge, UK).  
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2.4.5 Deoxyribonucleic Acid Sequencing and Analysis 
Sequencing PCR was carried out on an ABI Prism 3100 Genetic Analyser using 
BigDye Terminator v.3.1 (Applied Biosystems, California, USA). Each reaction used 
4 microlitres of Big Dye Mix and 1 microlitre of primer from the list given in Table 7. 
Five microlitres of PCR product from Section 2.4.3 was added to the mix. The total 
volume of 10 microlitres of solution was added with 2 microlitres of 3 molar sodium 
acetate (Appendix 4c) and 50 microlitres of 95 % ethanol (Appendix 5c). The mixed 
solution was transferred into a new 1.5 ml microfuge tube and incubated on ice for 10 
to 15 minutes. The solution was then spun at 14000 x g for 20 minutes at four degrees 
Celcius. The resulting supernatant was discarded. Next, 250 microlitres of 70 % 
ethanol (Appendix 5c ) was added to the tube and it was again spun for 20 minutes at 
top speed. After the liquid was blotted off with a tissue paper, the remaining pellet 
was dried on a 55 ˚C heat block for approximately 30 minutes or until it was dry. The 
samples were then processed through the ABI Prism 3100 Genetic Analyser. 
 
Sequences obtained were Blasted against the complete West Nile Sarafend genome 
sequence found on the Genbank website under accession code AY688948. Regions of 
differences were noted. Genome editing and assembling were performed using 
Lasergene 7.2 (DNASTAR Inc., Wisconsin, USA). Sequencing was done only in the 
forward direction but for each fragment, portions of overlap existed for the whole 
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Table 7: List of Primer Sequences for Sequencing PCR 
Primer 
Pair Name 




1 CACAGTGCGAGCTGTTTC 62 388 
CGCCTGTGCTGGAGCTGTGA 450 512 
ACGTAGGATATCTCTG 584 399 
2 TGAGCAACAGGGACTTCC 983 421 
GACGACTGTCGAATCAC 1404 397 
TGAGCAACAGGGACTTCC 983 421 
GACGACTGTCGAATCAC 1404 547 
3 TATACCGGAAAAGACG 1951 251 
CAGAGGAGCTCAACGA 2202 581 
TATACCGGAAAAGACG 1951 251 
CAGAGGAGCTCAACGA 2202 420 
4 GGAAGGAGTCTGTGGCCTGC 2622 382 
TGTGACTCGAAAATCATCGG 3004 495 
ACCCTCGTGCAGTCGAGAGT 3499 194 
ACCCTCGTGCAGTCGAGAGT 3499 313 
AGGCAAGGTGGACCAACC 3812 418 
TACAGAAGTGATGACTGCA 4230 441 
5 AGGCAAGGTGGACCAACC 3812 418 
TACAGAAGTGATGACTGCA 4230 318 
CACCTTGGGCCATTCTCC 4548 203 
ATACACTATGGCACACCAC 4751 430 
6 TGTCCTTGATTTGCA 5181 402 
TGTCCTTGATTTGCA 5181 412 
GAGTCTAATGCTCCTATC 5593 428 
CGATGAGTACTGCTATGG 6021 330 
CGATGAGTACTGCTATGG 6021 410 
7 CTCTGAAGTCCTTCAAAG 6431 420 
AGACTGACAACCAGCTCG 6851 380 
CAGGTGACTCTGACTGTGAC 7231 240 
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8 CAGGTGACTCTGACTGTGAC 7231 423 
GAGAAGCCTGTCCTCAAG 7663 408 
GTCGACGTTTTCTATAGACC 8071 313 
GTCGACGTTTTCTATAGACC 8071 423 
9 CTCCTCAATTCTGACACTAG 8494 419 
CCTAGGAGCGATGTTTG 8913 483 
CGAGCTCACGTACCGAC 9396 354 
10 GTCAAAGGTCCGCAAAGACA 9750 351 
AGAATGGATGACGACTGA 10101 311 
GTCGACGTTTTCTATAGACC 8071 423 
CTCCTCAATTCTGACACTAG 8494 419 
CCTAGGAGCGATGTTTG 8913 483 
CGAGCTCACGTACCGAC 9396 354 
11 GTCAAAGGTCCGCAAAGACA 9750 351 
AGAATGGATGACGACTGA 10101 279 
  
 
2.5 BIO – IMAGING 
2.5.1 Fixation and Processing of Samples 
Harvested tissues were immediately cut into approximately 5 millimetre thick 
sections, and placed in jet cassettes and fixed in 4 % paraformaldehyde for at least 24 
hours at 4˚C (Appendix 5a). It was then transferred to 4 ˚C PBS (Appendix 1g) until 
further processing. The tissue processor Leica TP1050 (Leica, Microsystems GmbH, 
Wetzlar, Germany) with an overnight automated embedding program (Appendix 5b) 
was used to fix the sections. 
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A Leica EG1160 (Leica, Microsystems GmbH, Wetzlar, Germany) tissue embedding 
centre was employed to embed all the fixed samples into paraffin blocks using 
stainless steel moulds and embedding rings. Tissue sections were embedded in molten 
wax and hardened to a block at - 20 ˚C for 2 hours. Blocks were then removed from 
moulds, trimmed of residual wax and stored at room temperature. 
 
For primary cell lines, the cells were obtained as described in Section 2.3.7 and 
layered onto poly – L – lysine coated cover slips (Appendix 1j). After 2 weeks in a 37 
°C humidified incubator, the cells were washed twice with PBS (Appendix 1g) and 
fixed with 4 % paraformaldehyde (Appendix 5a) for 30 minutes at room temperature. 
 
2.5.2 Paraffin Sectioning 
Before cutting, paraffin blocks were cooled on ice for an hour. Semi – thin 4 
micrometre sections were obtained using a Leica RM2235 rotary microtome and 
disposable high – profile steel blades (Leica, Microsystems GmbH, Wetzlar, 
Germany). The wax ribbon was then floated on a 40 ˚C water bath (Medax Nagel, 
Germany). Positively charged silane coated Histobond slides (Paul Marienfeld 
GmbH, Germany) were used to pick up the floating sections and slides were left to 
drip dry by the side of the water bath before being thoroughly desiccated in a covered 
box overnight at 37˚C. The dried slides were then stored at room temperature awaiting 
further experiments. 
 
2.5.3 Dewaxing - Rehydration and Dehydration - Clearing Method 
Paraffin dewaxing was accomplished using xylene. Slides were soaked in 2 rounds of 
fresh xylene (Merck KGaA, Darmstadt Germany) for 3 minutes each. Rehydration 
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followed dewaxing and the slides were put through a decreasing alcohol concentration 
gradient (Appendix 5c) ending with deionised water (Barnstead, New Hampshire, 
USA). Slides were soaked in each solution for 2 minutes (Appendix 5d). 
  
Dehydration and clearing follows the reverse steps of rehydration and dewaxing. 
Slides were soaked for 2 minutes each starting from deionised water and ending with 
absolute alcohol following the list in Appendix 5d but in reverse order and then for 3 
minutes each in 2 rounds of xylene (Merck KGaA, Darmstadt Germany). 
 
2.5.4 Hematoxylin and Eosin Staining 
Paraffin – embedded and sectioned tissues on slides from Section 2.5.2 were heated 
on an Electrothermal slide drying bench (Barnstead, New Hampshire, USA) at 70 ˚C 
for 10 minutes before dewaxing as described in Section 2.5.3. Slides were then soaked 
in various reagents or chemicals as noted in Appendices 5e to g. A ready – made 
modified Harris Hematoxylin was used (Sigma-Aldrich, St. Louis, USA). The 
protocol is outlined in Appendix 5h. 
 
Slides were then dehydrated as described in Section 2.5.3; cover slips were mounted 
with Histofluid (Paul Marienfeld GmbH, Germany), and viewed under brightfield 
microscopy (Section 2.5.7). Sections were examined for histopathological signs. 
 
2.5.5 Immunohistochemistry (IHC)  
2.5.5.1 Detection of Viral Antigens 
Rehydrated sections (Section 2.5.3) were washed in running tap water for five 
minutes. Antigen was retrieved by microwaving for 10 minutes in sodium citrate 
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buffer, pH 6.0 (Appendix 6a), in a EMS 9000 microwave oven (Electron Microscopy 
Sciences, USA) at 99 C. The slides were then left to cool for 20 minutes at room 
temperature before being washed again in running tap water for 5 minutes.  
 
All steps below were carried out in a moist chamber. The slides were subjected to 
endogenous peroxidase blocking in 0.6 % H2O2 in methanol for 15 minutes (Appendix 
6b) before washing twice in TBS buffer (Appendix 6c) for 5 minutes. The sections 
were then incubated with 1 : 20 dilution of normal rabbit serum (Sigma-Aldrich, St. 
Louis, USA) for 20 minutes in order to block non – specific antibody binding. 
Excessive serum was drained and the slides incubated with anti – WNV monoclonal 
antibody (Microbix Biosystems Inc., Ontario, Canada), at a dilution of 1 : 500, for 2 
hours at room temperature. This was followed by washing twice in TBS for 5 
minutes. DV – infected samples were incubated with anti – DV envelope protein 
monoclonal antibody, 4G2, from the American Tissue Culture Collection, USA. The 
dextran – polymer Envision+ horseradish peroxidase conjugated anti – mouse 
antibody (Dako A/S, Denmark) was layered on the sections at 1 : 300 dilution at room 
temperature for an hour. The slides were then rinsed once in TBS for 5 minutes. 
Sections were developed with the kit provided 3, 3’-diaminobenzidine (DAB) 
chromogen, incubated for 5 to 10 minutes at room temperature with the timing 
dependent on the speed of signal development. The sections were rinsed twice at an 
interval of 5 minutes each in TBS buffer. Slides were washed in running tap water for 
5 minutes, counter – stained using Harris hematoxylin for 30 seconds, washed again 
in running tap water and dehydrated in graded ethanol and xylene as described in 
Section 2.5.3, and mounted with Histofluid mounting medium (Paul Marienfeld 
GmbH, Germany). 
Materials and methods 
52 | P a g e  
 
2.5.5.2 Detection of Various Neural Cell Types 
Primary cell lines, as plated onto cover slips and fixed in Section 2.5.1 were tested for 
purity of extraction as well as for specific cell type. The cover slips were tested for 
neurons with anti – Neun antibody, astrocytes with anti – GFAP antibody, and 
oligodendrocytes with anti – CNPase antibody (Chemicon, Millipore, USA). The 
fixed samples were first blocked with BSA blocking solution (Appendix 7a) for an 
hour before being incubated with the primary antibody diluted to 1 : 500 in PBS 
(Appendix 1g). The coverslips were then washed thrice in PBS for 5 minutes each and 
then secondary Alexa Fluor 488 rabbit anti – mouse antibody (Invitrogen Corp., 
Carlsbad, USA) diluted to 1 : 1000 in PBS was added and left to incubate for another 
hour. The secondary antibody was washed off with PBS thrice for 5 minutes each 
before the coverslips were counterstained with DAPI (Invitrogen Corp., Carlsbad, 
USA) for 10 minutes. The coverslips were then mounted onto low autofluorescence 
glass slides (Paul Marienfeld GmbH, Germany) with Prolong Gold mounting media 
(Invitrogen Corp., Carlsbad, USA). 
 
2.5.6 Immunogold – Silver Staining (IGSS) 
Paraffin – embedded tissue sections were cut to 4 micrometres thick and attached onto 
silane slides (Section 2.5.2) before dewaxing and rehydration (Section 2.5.3). The 
sections were then incubated for 15 minutes in aldehyde blocking solution (Appendix 
7b). All incubations were performed in a moist chamber at room temperature. Slides 
were washed in PBS (Appendix 1g) twice for 5 minutes each and then blocked with 
bovine serum albumin (Appendix 7a) for 30 minutes. The next washing step using 
Aurion BSA - C (Appendix 7c) lasted 5 minutes and was repeated twice. Primary 
antibody incubation was performed overnight at 4˚C with monoclonal anti – dengue 
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virus envelope protein antibody, 4G2, from the American Tissue Culture Collection, 
USA. The next BSA – C washing step lasted 3 rounds of ten minutes each followed 
by incubation with secondary antibody conjugated to ultra – small 1 nanometre gold 
particles (Aurion ImmunoGold, Netherlands) at room temperature for 2 hours. 
Sections were then postfixed in 2 % gultaraldehyde for 2 minutes (Appendix 7d). The 
BSA – C wash was again performed but for 4 rounds of 10 minutes each. The silver 
enhancement (Aurion ImmunoGold, Netherlands) took approximately 20 minutes. 
This was followed by 3 rounds of 5 minutes deionised water washes (Barnstead, New 
Hampshire, USA). Sections were then counterstained for 10 minutes in Harris 
hematoxylin (Sigma-Aldrich, St. Louis, USA), dehydrated according to Section 2.5.3, 
mounted on coverslips with Histofluid (Paul Marienfeld GmbH, Germany) and 
viewed under epi – polarizing light (Section 2.5.7). 
 
2.5.7  Microscopy 
For brightfield microscopy, an upright microscope CX40 (Olympus Corp., Japan) 
with achromat objectives attached with a Pixera Penguin 150CL (Pixera Corp., USA) 
CCD was used. The Penguin is a charged – coupled device (CCD) digital camera with 
1.5 million true pixels. Immunogold – silver enhancement was viewed using a Zeiss 
Axiophot II (Carl Zeiss Inc., Germany). The microscope was equipped with Plan – 
Neofluar objectives and an epi – polarization reflector block in the filter house 
consisting of an immunogold – silver filter, polarizer, polarizer emitter, exciter, and 
UV blocking filter (Carl Zeiss Inc., Germany). The same Pixera CCD camera was 
used on the Zeiss microscope.  
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For brightfield and immunogold – silver staining, white balance was performed with a 
suitable transmitted light level. The light intensity was then fixed at that level 
throughout the viewing and image acquisition session. For immunogold – silver 
viewing through the epi – illumination method, all compensation filters including 
quarter lambda and polarizing plates were removed beforehand. The iris and field stop 
was adjusted with every objective change to ensure optimal viewing and image 
capturing condition. The condenser was left open and transmitted light was only 
added on when the reflected light has been adjusted.  
 
Fluorescence was visualized with an inverted microscope IX81 (Olympus Corp., 
Japan) fitted with a mercury lamp and suitable filtersets (Omega Optical, USA). 
Images were acquired by Metamorph v6.2 (Molecular Devices, MDS Inc., USA) with 
a CoolSnap HQ monochrome camera (Photometrics, Roper Scientific, USA). 
 
2.6 ELECTRON MICROSCOPY 
An equal amount of PBS containing 4 % glutaraldehyde and 4 % paraformaldehyde 
(Appendix 8a) was added to the media containing mock or virus – infected primary 
cells from 25 cm2 flasks. Fixation was performed overnight at 4 oC. Fixed cells were 
scrapped with a cell scrapper (Nalge Nunc International, Roskilde, Denmark), 
pelleted at 1000 x g for 10 minutes and washed thrice for 5 minutes each with  PBS 
(Appendix 1g) before postfixation in 1 % osmium tetroxide (Appendix 8b) at room 
temperature for an hour. The samples from henceforth were placed on a tissue rotator 
for better infiltration. A few crystals of potassium ferricyanide (Merck KGaA, 
Darmstadt Germany) were added to the 1 % osmium tetroxide solution to further 
enhance the contrast of membranous structures. Subsequently, the cells were washed 
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thrice for 5 minutes each with E - Pure™ water (Barnstead, New Hampshire, USA) 
before dehydrated with increasing concentrations of ethanol; 25 %, 50 %, and 75 % 
ethanol for 10 minutes each, 95 % ethanol for 20 minutes, and thrice of absolute 
ethanol for 20 minutes each (Appendix 5c). The dehydrated cell pellets were then 
infiltrated with increasing concentrations of a polyhydroxy – aromatic acrylic resin, 
LR White (LRW), at 3:1, 1:1, and then 1:3 ratio of ethanol to LRW for 30 minutes 
each at room temperature, followed by 30 minutes of absolute LRW at room 
temperature. Subsequently, the pellet was left in fresh absolute LRW overnight at 
room temperature. The next day, absolute LRW was used to further infiltrate the 
specimen (four times, each for an hour). Embedding and polymerization was carried 
out at 60 ºC ovens for 48 hours in 00 size gelatin capsules. 
 
The embedded specimens were then trimmed on a EM TRIM specimen trimmer 
(Leica, Microsystems GmbH, Wetzlar, Germany) and sectioned into 50 – 70 nm – 
thick sections using an ultramicrotome (Ultracut E, Reichert-Jung, Germany). The 
ultrathin sections were picked up onto 200 mesh uncoated copper grids (TAAB Lab. 
Equipment Ltd., England) and stained with saturated aqueous uranyl acetate 
(Appendix 8d) for 5 minutes. Excess stain was washed off using deionized water. This 
was then followed by secondary staining with Reynold’s lead citrate solution 
(Appendix 8e). The sections were allowed to dry on a hot plate before viewing under a 
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3.0  RESULTS 
3.1  INFECTION OF MICE WITH DENGUE VIRUS 
3.1.1 Infection of Adult Mice with Dengue Virus 
Stock dengue virus was grown on C6/36 cells and titred. The yield of DV1 was 107, DV2 
were 106, and DV4 was 104 PFU/ml (Section 2.2.3 and 2.2.4). Adult BALB/c mice in 
groups of twos was first tested for levels of viremia and mortality when injected with 100 
microlitres of stock DV through the tail vein (Section 2.3.2.2). The two different DV 
were either used for inoculation individually or in combination, with the inoculation of 
consecutive virus 2 weeks after the first infection. There were no observed deaths in any 
of the groups. Mice sacrificed on days 1, 3, 5, and 18 after the first virus inoculation and 
on day 21 after the post second inoculation (Section 2.2.4) were found to be negative for 
virus in serum, liver, brain, and spleen. Therefore, the wild type DV from the laboratory 
stock was unable to show any mortality or morbidity in adult BALB/c mice. Moreover, 
histological sections from mice organs (Section 2.5.4) showed no obvious pathology. As 
there were no detectable virus levels, no immunohistology was done. 
 
3.1.2 Infection of Adult AG129 Mice with Dengue Virus 
3.1.2.1 Testing of Various Dengue Virus Doses 
As the immunocompetent BALB/c adult mice did not show any signs of mortality or 
morbidity from the DV inoculation, an experiment was done on immunocompromised 
mice with double knockout of alpha and beta, and gamma interferon receptors, AG129 
(Section 2.3.2.1). This was done to see if the virus was able to infect 
immunocompromised mice. First, the effect of different dengue virus doses on the level 
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of viremia was tested on adult mice inoculated intravenously with 105, 106, 107, or 108 
PFU/ml DV2.  Three mice were bled on days 1, 2, 3, 4, 5, and 10 post inoculation 
(Section 2.3.4). The 10th day bleed was performed to test for virulence at a late time 
point. Figure 6 shows the log10 PFU/ml titres in serum samples. From this it was evident 
that there was little difference between the 107 and 108 PFU/ml DV2 inoculated mice. As 
the 108 PFU/ml stock required an additional step of concentration using Vivaspin 
columns (Section 2.3.2.2), it was more economical to proceed with the neat 107 PFU/ml 
virus pool. In addition, the virus was able to persist in mice for at least 5 days unlike in 
the immunocompetent BALB/c mice. The data also corresponded to approximately the 
same timeframe during which human dengue patients exhibit viremia in a clinical setting 
(Sabin, 1952). The virus was not detected at day 10 post infection. It is not known if the 
cause for this was the inability of the virus to persistently infect the mice or the immune 
system although deficient, was able to clear the virus. However, this experiment proved 
that DV could still infect mice although only in the immunocompromised strain.  
 
 
Figure 6: Log10 virus yield from sera of AG129 mice inoculated with various doses of 
DV2 bleed on different days. The results show a dose dependant response and the 7 log 
virus is the best titre to work with as it does not require any virus concentration step 
while giving acceptable virus titres as well as the least variation in results in the 
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3.1.2.2 Short Term Virus Infection Study 
Adult AG129 mice in groups of two were next infected with 107 PFU/ml of DV2 virus 
intravenously through the tail vein and pairs of mice were sacrificed on each day from 
days 1 to 5 (Section 2.3.2.1). Figure 7 shows the level of viremia in the sera of mice. In 
addition, organs were harvested for plaque assay as well as histological analysis. Figure 8 
shows the virus levels in spleens and livers of mice infected with DV2 harvested on 
various days. The brains showed no virus presence and were thus not shown. 
Haematoxylin & eosin staining as well as immunohistochemistry was done to detect the 
pathological changes as well as to detect viral antigens in the organs (Section 2.5).  
 
 
Figure 7: Level of virus in sera of adult AG129 mice inoculated with DV2 over 5 days. 




Figure 8: Virus levels in spleens and livers of adult AG129 mice inoculated with DV2 
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The histological sections from spleens, livers, and brains of mice were stained by 
haematoxylin & eosin and observed under brightfield microscopy. Overt changes could 
be seen in tissue sections from mice sacrificed on day 3 post inoculation onwards. Figure 
9b shows inflammation in the red pulp of spleen in infected mice (white arrows) while 
the same area was clear of any infiltrating cells (green arrows) in the control sections 
(Figure 9a). The dense infiltrating cells almost obliterated the white pulp markings 
(orange arrows) making it indistinctive from the red pulp, which is characteristic of 
inflammation. The gross morphology of the spleens also showed overt splenomegaly as 
the size of spleens from infected mice were up to 150 % compared to uninfected ones as 
observed during organ harvesting. Cells infiltrating into the spleen causing the 






Figure 9: Red pulps of mock – inoculated (a) and DV2 – inoculated (b) AG129 mice 
spleens at day 3 post infection showing cell infiltration (white arrows) in the red pulp that 
totally masks the white pulps (yellow arrows). Cell infiltration is absent in the mock 
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The test for viral antigens using the standard immunohistological avidin – biotin complex 
did not yield any results although plaque assay showed virus titre of 103 PFU/g in spleens 
(Figure 8). As such, a more sensitive method was employed in order to detect virus 
antigens. The immunogold – silver staining (IGSS) method is a very sensitive method 
using secondary antibodies – conjugated to ultrasmall gold particles which can be 
magnified with silver deposits that has a natural affinity towards gold (Section 2.5.6).  
 
From the same tissue block of Figure 9, IGSS was done and the white pulp shown in 
Figure 10. It was very clearly seen that two cells have bright markings indicating the 
antigen localization (Figure 10a, yellow arrows). The staining follows a granular pattern 
commonly seen in immunofluorescence staining. A macro view (Figure 10b) shows the 
positive – labelled cells along the red pulp sinuses between two white pulps (white 
arrows). It was suggested that virus – infected cells in the bloodstream or lymph nodes 
were carried to the spleen where they gathered and were retained, resulting in 
inflammation. It has not been proven that the spleen cells per se were infected as 
examination of day 10 post – inoculated mice did not show positive labelling for antigens 
in the different organs. Plaque assay could be a more sensitive assay compared to 
immunohistochemistry because virus particles could be hidden after paraformaldehyde 
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Figure 10: A granular labelling of DV antigens with 4G2 mAb in infiltrating cells in the 
spleen of AG129 mice inoculated with DV2 at day 3 post inoculation. The infiltrating 
cells are localized specifically to the inflamed red pulp (yellow arrows). The white pulp 
area is demarcated by white arrows. Original magnification 630x (a) and 400x (b). 
 
 
The brains of mice sacrificed at day 3 post inoculation did not show any titre by plaque 
assay. Immunohistochemistry on paraffin sections gave nonspecific staining at blood 
vessel and meninges regions (Figure 11) when the Envision+ kit was used (Section 
2.5.5.1). IGSS returned no false positive results. 
 
   
Figure 11: Nonspecific labelling on blood vessels (a - arrow) and meninges (b - arrows) 
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In one of the mice tested, it was found that the brain section was positive for viral 
antigens (Figure 12 – red arrows) in cells surrounding a blood vessel that showed 
perivascular cuffing (black arrows), an inflammatory response where immune cells 
congregate around a blood vessel which has been activated by chemokines. The neural 
cells surrounding this blood vessel stained specifically in the cytoplasm and showed 
distinct granular markings. Other sections of the brain showed no such staining or 
inflammatory signs. It is possible that no living virus was present in the tissue but viral 
debris could have been picked up by the surrounding cells or seeped into the organ 
through the compromised blood vessel.  
 
 
Figure 12: Clear indication of a compromised blood vessel in the brain section; 
perivascular cuffing (black arrows) and specific labelling of virus antigens nearby (red 
arrows). The AG129 mouse is inoculated intravenously with DV2 and sacrificed on day 2 
post inoculation. Original magnification 400x. 
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The liver sections were closely evaluated for pathological changes and antigen staining 
but no significant observation was noted. This was unexpected as Figure 8 clearly shows 
the liver had an approximate virus load of 105 PFU/g on day 3 post infection. As the liver 
is a major blood reservoir, it could be that the virus load came from the blood trapped in 
the organ as perfusion of the organs was not done prior to organ harvesting. 
 
3.1.2.3 Long Term Virus Infection Study 
To study the long term effects of DV in AG129 mice, virus infection was repeated but 
with mice sacrificed on day 10 post infection (Section 2.3.2.1). By this time, no infectious 
particles were detected in either serum or organs (Figure 6). However, it was postulated 
that mice could continue to mount an immune response against the virus even after the 
virus was completely cleared as a result of the initial immunogenic priming. The 
evaluation of the brain and livers found no significant pathological changes but the spleen 
showed strong immunological response. In the spleens of two mice sacrificed at day 10 
post infection (Figure 13), germinal centres in the white pulp were strongly activated 
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Figure 13: Spleens from AG129 mice inoculated with DV sacrificed at day 10 post 
infection. Yellow arrows point to B cell germinal centres in the spleen. White arrows 
point to red pulp areas that are clearing up after being filled with inflammatory cells 
during the early infection phase in Figure 9. Original magnification 40x. 
 
 
Areas of T cell proliferation were also appearing indicating that the virus was able to 
stimulate both arms of the adaptive immune system (Figure 14 and 15). B – cell germinal 
centres in the white pulp and T – cell proliferation areas in the red pulp (yellow arrows) 
were easily identified. The spleen was still inflamed as seen by the perivascular cuffing 
(Figure 15, white arrows). However, verification using specific T and B cell markers has 
to be performed in order to confirm this postulation.  
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Figure 14: Areas of T cell proliferation (yellow arrows) in AG129 mice inoculated with 




Figure 15: Perivascular cuffing made up of basophilic cells (white arrows) and a 
germinal centre (yellow arrow) points to a strong immune response in inoculated AG129 
mice sacrificed on day 10 post inoculation. Original magnification 100x. 
 
 
Immunohistology of various organ sections for virus antigens were all negative except for 
one serendipitous case of a possible phagocytic cell in the brain cortex that displayed 
positive staining for viral antigen (Figure 16 – arrow). It was probable that this 
phagocyte was clearing up cell debris left by dead cells containing virus proteins.  
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Figure 16: A phagocyte removing cell debris containing virus proteins (arrow). The 
micrograph comes from a brain section of an AG129 mice inoculated with DV and 
sacrificed on day 10. Original magnification 400x. 
 
The immunocompetent BALB/c mice inoculated with DV did not show any form of 
mortality or morbidity. On the other hand, the immuno – deficient AG129 mice 
inoculated with DV mounted an immune response and had detectable levels of viremia 
for at least four days in various organs. However, in order to study the full spectrum of a 
disease and the host reaction to the immunogen, an immunocompetent model is needed. 
As such, experiments using West Nile virus Sarafend (WNVS) virus was next done to see 
if this virus could cause more overt signs and symptoms in the BALB/c model. West Nile 
virus was perceived to be a better model since the virus grows to 109 PFU/ml and higher 
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3.2 INFECTION OF MICE WITH WEST NILE VIRUS (SARAFEND) 
3.2.1 Infection of Adult Mice with West Nile Virus (Sarafend) 
Stock WNVS was grown on C6/36 or Vero cells and titred at 109 PFU/ml (Section 2.2.4). 
Adult BALB/c was first tested for levels of viremia and mortality when inoculated 
intravenously with 100 microlitres of stock WNVS (Section 2.3.3.1). The virus was 
injected through the tail vein with two mice per group and bled on days 1, 3, 5, and 18 
post inoculation through the submandibular vein (Section 2.3.4). The sera were tested by 
plaque assay for levels of infective virus particles (Section 2.2.4). Table 8 showed the 
results of the pilot study for WNVS grown in C6/36 cells while Table 9 showed the study 
using Vero cell – grown virus. Similarly, two mice were killed on days 1, 3, 5, and 18 
post inoculation; the organs harvested, homogenized and titred for infectious viruses. 
From Tables 8 to 9, only one mouse had residual virus load on day 1 post infection. The 
rest of the mice cleared all 109 PFU/ml of WNVS in less than 24 hours. Histological 
sections from all timepoints stained with haematoxylin & eosin showed no signs of 
disease or pathology. This clearly indicated that the WNVS stock similar to the DV 
(Section 3.1) was unable to infect the immunocompetent BALB/c mouse model or cause 
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Table 8: PFU/ml sera or PFU/g tissue of adult BALB/c mice inoculated with WNVS 
grown on C6/36 cells and bleed on different days to test for viremia. Titres are means 
from two different mice. 
Organ  Day 1  Day 3  Day 5 Day 18 
Serum 2 x 101  0 0 0 
Liver  0  0 0 0 
Brain  0  0 0 0 
Spleen  0  0 0 0 
 
Table 9: PFU/ml sera or PFU/g tissue of adult BALB/c mice inoculated with WNVS 
grown on Vero cells and bled on different days to test for viremia. Results derived from 
the mean of two mice. 
Organ  Day 1  Day 3  Day 5 Day 18 
Serum 0  0 0 0 
Liver  0  0 0 0 
Brain  0  0 0 0 
Spleen  0  0 0 0 
 
As the virus was not able to infect adult mice, it was decided to test on suckling mice. 
Sucklings are more susceptible to infection as the mice immune system is not yet fully 
developed. 
 
3.2.2 Infection of Suckling Mice with West Nile Virus (Sarafend) 
Ten million WNVS particles were injected into the brains of suckling mice and two mice 
were harvested every 6 hours from 18 hours post infection onwards. The brains were 
collected for plaque assay and the means shown in a typical growth curve as seen in 
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Figure 17. It was clear that the maximum virus titre was found at 54 hours post 
inoculation. This result would be later applied in Section 3.3.   
 
The high titre at 18 hours post inoculation could be from the initial inocula and the virus 
entered into the eclipse phase between 18 to 24 hours post inoculation to begin new cycle 
of replication. The exponential phase of the progeny virus production was observed from 
24 hours post infection onwards. The virus titre plateaued from 30 hours post infection 





Figure 17: WNVS growth curve in BALB/c suckling mice brain at different periods post 
infection. At 54 hours post infection the virus titre is found to be the highest. Each point 
represents the mean of 3 mice. Error bars represent standard errors. 
 
Suckling mice were also tested for survival times with different dosages of stock WNVS 
inoculated intracerebrally into the brain (Section 2.3.3.2). The mice were checked every 
12 hours and dead suckling mice were dissected and the brains harvested for 
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small differences could be seen between the survival times of suckling mice inoculated 
with different virus doses. Mice started dying on day three post inoculation onwards with 
a steady drop in the number of surviving mice until day seven to eight post infection. 
Outliers seen were mice infected with 10000 PFU/100 microlitres – infected mice as the 
day of most recorded deaths was pushed back to day 10 post infection compared with day 
4 post inoculation for the other groups. The brains were harvested for plaque assay and 
showed consistent virus titre levels of between 107 to 109 PFU/g tissue sample.  
 
 
Figure 18: Survival curve of BALB/c suckling mice intracerebrally inoculated with 
various WNVS loads. All curves except the 10000 PFU line show a strong drop from day 
3 onwards. 
 
The different killing trend for the 10,000PFU injected suckling mice could be attributed 
to error in experimental methods as the group was only made of 3 mice. However, 
collectively with the different doses tested, a total of 21 suckling mice were used and this 
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The results convincingly showed that wild type DV and WNVS from the laboratory were 
not able to consistently infect and cause any form of mortality or morbidity in adult 
immunocompetent mice. Suckling mice succumbed to the virus when inoculated 
intracerebrally with a range of dosages of infectious particles without any dose dependent 
pattern. Because the immunocompetent adult mice were injected through the intravenous 
route and not intracerebrally, it was able to clear the virus infection as compared to the 
suckling mice. The suckling mice also did not have a fully mature immune system. It was 
therefore not surprising that the virus infection showed such variation when injected into 
those two mice models using different inoculation routes. 
 
Since the virus had been passaged through cell culture for many years in the laboratory 
setting, it was postulated that the virus became adapted to infecting specific cell lines and 
could not establish infection in in vivo animal models. It was thus hypothesised that the 
virus could be re – adapted to infect adult mice should the virus be re – passaged 
repeatedly in mice. This became the objective of the subsequent study detailing the 
effects of passaging WNVS in an immunocompetent model. 
 
3.3 PASSAGING OF WEST NILE VIRUS (SARAFEND) THROUGH 
SUCKLING MICE AND C6/36 CELL CULTURE 
The WNVS was chosen for the passaging experiment instead of DV as there are four 
dengue serotypes. Selecting one serotype, strain, or isolate over the others would be 
difficult. Moreover, DV is known to show fewer and weaker signs and symptoms in both 
infected humans and animals. WNVS on the other hand is able to infect 
immunocompetent mice as reviewed in Table 2. As such, it was of interest to study if and 
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how the laboratory strain of cell culture attenuated WNVS could evolve into a mouse – 
infecting strain given suitable adaptive conditions. 
 
In nature, WNVS transmits between birds and blood sucking arthropods. To mimic 
nature while adapting the virus to infect mice, WNVS was passaged through suckling 
mice brains and C6/36 mosquito cell culture. Stock WNVS was subjected to ten rounds 
of continual passaging through either only suckling mice brains (‘m’ series, Section 
2.3.6.1) or both suckling mice brains and C6/36 cells (‘c’ series, Section 2.3.6.2). Mouse 
organs were harvested and weighed before being snap frozen at -80 °C. After 
homogenizing the samples at 50 % w/v (Section 2.3.5), it was spun down and the 
supernatant used for plaque assay (Section 2.2.4). Both passaging routines were 
duplicated 5 times resulting in a total of 10 passaged viruses (Section 2.3.6). The 
resulting viruses generated from each passage level were assayed for infectivity as well 
as plaque size (Section 2.2.4).  
 
To explain the terminology used, the two different passaging regimes used were known 
as ‘m’ and ‘c’ series. Virus passaged through suckling mice brains repeatedly for ten 
rounds was known as 10m, i.e. the tenth passage of the ‘m’ passaging regime. 
Conversely, the ‘c’ series delineates viruses passaged alternately through suckling mice 
brain and C6/36 mosquito cell line. So the tenth passage of this series was known as 10c. 
Because both series were repeated five times in tandem, there were ten passaged viruses, 
five from the suckling mouse brain regime: 10m1, 10m2, 10m3, 10m4, and 10m5; and 
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five from the suckling mouse brain – mosquito C6/36 cell culture regime: 10c1, 10c2, 
10c3, 10c4, and 10c5. 
 
From each round of passaging, the virus was titred by plaque assay (Section 2.2.4). In 
addition, each assay plate had two positive control wells using unpassaged Vero cell 
grown WNVS. These two wells were used as a benchmark for plaque size. The average 
of ten plaque diameters of the unpassaged WNVS was compared against the average of 
ten plaque diameters of the passaged virus on each plate. The results from all 10 different 
repeats for all 10 consecutive passages were then plotted on a graph and displayed as 
Figures 19 to 21 as a plaque ratio curve of the passaged virus against the unpassaged 
WNVS. The size of unpassaged WNVS plaque was set at an absolute value of 1. 
 
Figure 19 clearly showed an increase in relative plaque sizes for viruses passaged 
through suckling mice brain at two points; passage number two, and approximately 
passages five to eight. The synchronisation of increase of plaque size between the 
different repeats was clearly seen at passage two and less obvious at the larger increase 
between passages five to eight. It was suggested that with increasing passaging rounds, a 
wider range of plaque size viruses could be found, giving rise to haphazard cyclic ratio 
trends towards passage 10. The largest plaque size observed was 40 % larger than the 
unpassaged virus (Figure 19 – m2). On average there was a general trend of larger size 
plaques with increasing passage number. 
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Figure 19: Relative plaque sizes from the mouse - only ‘m’ passaged viruses over 10 
passages. Each point represents the mean from two mice. The ratio of 1 represents 
baseline value of no difference in plaque size between passaged and unpassaged viruses. 
Error bars on average curve represents standard errors. 
 
  
For the mouse – C6/36 ‘c’ passaging series, Figure 20 showed the virus plaque sizes 
from the alternate mouse passage while Figure 21 displayed the alternate C6/36 passaged 
virus plaque sizes. Compared to the mouse only ‘m’ passaging regime, the plaque sizes 
from the mouse – C6/36 passage showed a general decrease in size as compared to the 
unpassaged virus plaque size. From the average curve, the graph pattern was different 
compared to the bimodal trend in Figure 19 as the general size change shown by the 
average graph indicated a lowering in plaque size with increased passaging. There was 
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different repeats were less synchronised in cyclic size patterns as compared to the ‘m’ 
passaged virus in Figure 19. 
 
 
Figure 20: Relative size of virus plaques from the alternate mouse passage of the mouse - 
C6/36 ‘c’ passaged series. There is a drop in plaque size with increasing passaging. 
Each point represents the mean from two mice. The ratio of 1 represents baseline value 
of no difference in plaque size between passaged and unpassaged viruses. Error bars on 
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Figure 21: Relative size of virus plaques from the alternate C6/36 passage of the mouse - 
C6/36 passaged series. The average trend shows the plaque size dropping with 
increasing passaging. Each point represents the mean from two mice. The ratio of 1 
represents baseline value of no difference in plaque size between passaged and 
unpassaged viruses. Error bars on average curve represent standard errors. 
 
 
Standard deviations from ten plaque sizes were calculated and displayed as a graph 
(Figures 22 to 24). The standard deviation of plaque sizes was a representative figure of 
how varied the plaque sizes are. A larger standard deviation indicated a more diverse 
range of plaque sizes. The average standard deviation hovered between 1 and 3.5 units 
throughout the passaging. There was a peak in average standard deviation for both the 
‘m’ and ‘c’ series passages at different passage numbers.  Higher standard deviations 
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Figure 22: Standard deviation of plaque sizes of the different passage repeats for the 
mouse – only ‘m’ passaged viruses over 10 pasages. The average graph shows a peak in 
virus size variation at passage seven. The average errors are higher than the ‘c’ series. 




Figure 23: Standard deviation of plaque sizes of the different passage repeats from the 
alternate mouse passage of the mouse - C6/36 ‘c’ passaged series. The average line 
fluctuates greatly during passages five to eight. There is a peak in average plaque size 
variation at passage five with 3 of 5 repeats showing a peak on that passage. No 
statistically significant points are detected on the average graph. Error bars represent 
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Figure 24: Standard deviation of plaque sizes of the different passage repeats from the 
alternate C6/36 passage of the mouse - C6/36 ‘c’ passaged series. The average line is 
relatively linear and has the least variation compared to the other graphs (Figures 22 
and 23). The average graph shows a gentle cyclical increase in standard deviation with 
passaging. Error bars represent standard errors. 
 
 
Throughout the passaging process, virus titres remained relatively consistent; the plots 
(Figures 25 to 30) showed the log virus titres from various organs of the suckling mice 
for each virus passage from the mouse ‘m’ only passages. Virus titres in the brains were 
highest at an average of 108 PFU/g tissue (Figures 25 to 26) while the livers were on 
average one log lower at 107 PFU/g tissue (Figures 27 to 28) and in spleens a further log 
lower at 106 PFU/g tissue (Figures 29 to 30). No blood was collected from the suckling 
mice as there was insufficient volume to complete the experiments. The virus inoculated 
into the brains of suckling mice could migrate and proliferate in both livers and spleens 
of the inoculated mice showing that the blood – brain barrier was still underdeveloped in 
the sucklings. It was also noted that the suckling mice inoculated with the virus at late 
passage numbers (passage eight to ten) showed less severe symptoms of illness at 48 
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stop suckling, lost weight and were mostly inactive. The virus at late passages thus 
appeared to become attenuated. The viruses were still neurovirulent at passage 10 as 
significant virus titres were obtained from the brains of suckling mice. No error lines 
were shown for the line graphs as it is the average from only 2 mice. 
 
The different titre levels of virus in different organs were a reflection of virus tropism and 
infectability. Suffice to say WNVS retained its ability to infect and cause severe disease 
in suckling mice throughout the whole passaging period. Starting titres from all tested 
samples were comparable to titres at passage 10 indicating the virus was replication – 
competent throughout the ten passages.  
 
Bar graphs (Figures 26, 28, and 30) showed the more erratic mean virus titers found in 
the brains, livers, and spleens of sacrificed suckling mice from the mouse ‘m’ only 
passaging method as compared to the latter mouse – C6/36 ‘c’ passaging experiments 
(Figures 31 to 36). The graphs for livers and spleens (Figures 28 and 30) seemed to show 
a bimodal distribution with a drop around passage five. The standard error bars showed 
some variations in the virus titer but compared to the line graphs, one can conclude that 
the titers from each organ were quite conserved over different passages. This gave some 
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Figure 25: Log10 PFU/g tissue sample of virus in suckling mice brains from different 
passages of the mouse only passaging series ‘m’. Each point represents the mean from 
two mice. A null titre in Brain 4 passage 6 was due to ethanol seeping into the cryovial 




Figure 26: Average Log10 PFU/g tissue sample of virus in suckling mice brains from the 
5 repeats of different passages in the mouse only passaging series ‘m’. Although the 
absolute titre for one repeat dips significantly in passage 6 (Figure 25) the average 
graph does not show any statistically significant variation between the titres of passage 6 
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Figure 27: Log10 PFU/g tissue sample of virus in suckling mice livers from different 





Figure 28: Average Log10 PFU/g tissue sample of virus in suckling mice livers from the 5 
repeats of different passages in the mouse ‘m’ only passaging series. A bimodal 
distribution can be seen with peaks at passage 2 and 7. Asterisks indicate significant 
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Figure 29: Log10 PFU/g tissue sample of virus in suckling mice spleens from different 




Figure 30: Average Log10 PFU/g tissue sample of virus in suckling mice spleens from the 
5 repeats of different passages in the mouse ‘m’ only passaging series. There is a 
bimodal distribution with average virus peaks at passage 3 and 7. Asterisks indicate 




Virus levels from the mouse – C6/36 ‘c’ passaging regime yielded titres not unlike the 
mouse ‘m’ only passaging method. Figures 31 to 36 showed the log virus titres in brains, 
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one log. No trend could be spotted from the graphs as the virus yield remained relatively 
constant throughout the passaging rounds. Statistical analyse comparing each passage 
virus titre against other passage numbers detected no significant titre change (P < 0.05). 
 
 
Figure 31: Log10 PFU/g tissue sample of virus in suckling mice brains from different 




Figure 32: Average Log10 PFU/g tissue sample of virus in suckling mice brains from the 
5 repeats of different passages in the mouse – C6/36 ‘c’ passaging series. The average 
graph shows little variation in virus titres. No statistically significant variation in titres 
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Figure 33: Log10 PFU/g tissue sample of virus in suckling mice livers from different 





Figure 34: Average Log10 PFU/g tissue sample of virus in suckling mice livers from the 5 
repeats of different passages in the mouse – C6/36 ‘c’ passaging series. There is a 
unimodal distribution with a peak at passage 7. No statistically significant variation in 
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Figure 35: Log10 PFU/g tissue sample of virus in suckling mice spleens from different 




Figure 36: Average Log10 PFU/g tissue sample of virus in suckling mice spleens from the 
5 repeats of different passages in the mouse – C6/36 ‘c’ passaging series. A bimodal 
distribution is present with virus peaks at passages 2 and 8. No statistically significant 




As for the C6/36 alternate passages from the mouse – C6/36 series, the virus titre 
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in virus titres at passage number five when four out of five repeats experienced a sharp 
decline with an average decrease of about 1.25 log10 PFU/ml or a 17 fold reduction taking 
the average 5th passage titre as comparison. This could be biologically significant as it 
was observed in four out of the five repeats. However, this decrease was only 
momentary. At passage six the virus titre reverted to that of passage four with an increase 
of 1.0 log10 PFU/ml or an 11.5 fold increase on average. Statistical analyses comparing 
passage five virus titres against all other passage numbers showed significant change in 
virus titre (p < 0.05). A bimodal distribution was seen in this group with a drop of about 
one log virus titre at passage number 5 (Figure 38). 
 
The passage 4, 5, and 6 viruses were used to re – infect C6/36 cells to reproduce the drop 
in virus titre seen. However, the drop seen in passage 5 could not be reproduced. 
Evaluation of supernatants from the re – passaged stocks was performed for viral RNA 
levels by real – time PCR, viral protein levels by Western blotting, and infectious virus 
levels by plaque assay. None of the methods showed a drop in virus levels at the fifth 
passage upon re – infection in C6/36 cells. This was repeated twice, with similar results. 
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Figure 37: Log10 PFU/ml of virus from C6/36 cells from different passages in the mouse 
– C6/36 ‘c’ passaging series. Each sample represents one flask of cells, no repeats are 





Figure 38: Average Log10 PFU/ml of virus from C6/36 cells from the 5 repeats during the 
different passages in the mouse – C6/36 ‘c’ passaging series. A bimodal distribution is 
seen with titre peaks at passage 3 and 8. All the passage titres are statistically different 
from the passage 5 titre (p<0.05) except passage 1 as indicated with asterisks. Error 
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4.0  RESULTS 
4.1 EVALUATION OF POST PASSAGING VIRUS STRAINS  
The ten rounds of ten different passaged virus strains were evaluated through different 
means described below to determine for any phenotypic changes between the unpassaged 
and passaged viruses. The virus was tested for infectivity in both adult and suckling 
BALB/c mice. The mice were evaluated for virus loads in different organs by plaque 
assay as well as time of death. Furthermore, adult mice inoculated with the virus were 
weighed every 12 hours for 20 days to observe if the virus caused any inhibition in 
animal growth. The organs from the infected mice were also processed for 
histopathology. From the observed results, a further experiment was carried out to map 
the growth kinetics of the unpassaged and passaged virus on primary mouse neural 
cultures. First the various viruses were grown in an astrocyte/oligodendrocyte mixed 
culture and subsequently in neuronal primary cell culture. All the experiments suggested 
that passaged WNVS were more pathogenic and neuroinvasive compared to unpassaged 
WNVS. 
 
4.2 INFECTION OF SUCKLING BALB/C MICE TO EXAMINE THE 
VIRULENCE OF PASSAGED WEST NILE VIRUS (SARAFEND) 
Testing the ten passaged viruses on suckling mice was done by injecting 50, 500, or 5000 
virus particles in 5 microlitres intracranially into suckling mice and observing for 
mortality (Section 2.3.8.2). Groups of 9 suckling mice were used for each of the 10 
passaged viruses. Figures 39 to 40 showed the results from this experiment. The time of 
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death after infection for each group was counter intuitive as it did not follow any dose 
dependent trend. The initial hypothesis was a higher dose of virus would lead to shorter 
survival times. Only the group 10c1 had a trend following this hypothesis and there was 
thus insufficient evidence to support it. 
 
 
Figure 39: Mortality levels of suckling mice inoculated with passaged viruses from the 
‘c’ regime. The x – axis shows the amount of virus particles injected (50, 500, or 5000 
virus particles in 5 microlitres) while the y – axis shows the hour of mortality post 
inoculation. Each point refers to one mouse. Only 10c1 follows the initial hypothesis that 
a higher virus dose would cause an earlier time of death. All other viruses do not show 
any clear distribution pattern. The three groups of mice are not statistically different 
from each other (p<0.05). Each point is representative of one mouse. Each virus has two 
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Figure 40: Mortality levels of suckling mice inoculated with passaged viruses from the 
‘m’ regime. The x – axis shows the amount of virus injected (50, 500, or 5000 virus 
particles in 5 microlitres) while the y – axis shows the hour of mortality post inoculation. 
Each point refers to one mouse. None of the viruses show any dose – dependent killing 
potential. Each virus has two mice per group. Averages represent mean survival times of 
each virus titre group. 
 
Comparing Figures 39 to 40 to the survival curve of unpassaged virus (Figure 18), 
unpassaged virus generally caused the death of mice at around 96 hours post inoculation. 
However, from Figures 39 and 40, suckling mice inoculated with passaged virus started 
dying as early as 12 hours but the median was at 36 hours post inoculation. There was a 
substantial time difference between the two sets. For the unpassaged virus group, the last 
suckling mouse died at 192 hours post inoculation (Figure 18) but for the passaged virus 
group, the last mouse died at 168 hours. Removing this mouse that died at 168 hours as 
an outlier, the difference in time between the death of mice from the passaged (144 
hours) and unpassaged (192 hours) virus strain infection was more than 48 hours. In other 
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However, between groups of suckling mice inoculated with different titres of virus from 
the same passaging regime, there was no discernable difference. Figures 39 and 40 
showed no trend or significant difference in mean survival times of suckling mice for the 
various virus doses infections; 50, 500, and 5000 virus particles. For suckling mice 
infected with unpassaged viruses in Figure 18, again no observable difference could be 
noted between the mean survival times of suckling mice inoculated with various virus 
doses; 100, 500, 1000, 5000, 10000, and 50000 virus particles. This was contrary to the 
hypothesis that virus infective dose played a role in virus replicative ability and thus also 
survival times. 
 
4.3 INFECTION OF ADULT BALB/C MICE WITH PASSAGED WEST NILE 
VIRUS (SARAFEND)  
4.3.1 Levels of Viremia in Various Organs Post Inoculation 
From this point, further investigations were done to examine the infectivity of passaged 
virus in adult mice (Section 2.3.8.1). From previous observations, unpassaged laboratory 
strain of WNVS grown in Vero cells did not cause any mortality or morbidity. Virus 
could not be detected in the liver, spleen, brain, or serum of the mice 24 hours after 
inoculation (Tables 8 to 9). For WNVS propagated in C6/36 cells, intravenous 
inoculation resulted in the presence of virus in serum after 24 hours at 101 PFU/ml. 
However, this dropped to zero on day 2 (Section 3.2.1). 
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Adult mice were injected intravenously with 100 µl of passaged virus at 108 PFU/ml 
(Section 2.3.8.1). It was noted that passaging had a profound effect on the levels of 
infectious virus particles in sera over time. Using passaged viruses as the inocula, the 
organs from the infected mice also showed presence of viruses on day 1 and 3 post 
inoculation, as shown in Figures 41 to 44. Tests on mice at day 5 post inoculation found 
that virus presence was not sustainable as all samples from sera, brain, liver, and spleen 
homogenates were negative for viruses. The passaged virus 10c3 was most virulent for 
the ‘c’ series as it yielded the highest virus titres in livers and spleens at day 1 post 
inoculation and in sera on day 3 post inoculation. 10m4 virus was the most virulent for 
the ‘m’ series with all organs from mice inoculated with this virus showing highest virus 
titres on day 1 post inoculation compared to other ‘m’ viruses. 
 
The highest virus levels were detected in sera and spleens. The same two organs were the 
sites of most sustainable virus infection. Livers were seen to be easily infected at day 1 
post inoculation but in both the ‘c’ and ‘m’ series, the virus titres quickly dropped to zero 
on day 3. Not surprisingly, spleens were the most infectable organ with 16 out of 20 
suckling mice inoculated with passaged viruses showing presence of virus on day 1 post 
inoculation. The spleen is a key organ in host immunological response against pathogens, 
an important site for antigen presentation, and crucial for B cell maturation. It is thus 
expected that the virus will congregate in this organ, either brought by professional 
antigen presenting cells, the bloodstream, or by natural tropism of the virus for this organ. 
This high and sustainable virus titre in Figures 41 to 44 was also co – relatable to 
pathology in Section 4.3.3. 
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Of interest in Figure 42 were the high titres of virus in brains of suckling mice inoculated 
with ‘c’ series passaged viruses and sacrificed at day 3 post inoculation. When compared 
to the null titres in the brains of adult mice inoculated with ‘m’ series virus in Figure 44, 
the higher neurotropism of the ‘c’ series passaged virus became obvious. The ‘c’ series 
passaged virus was able to initially establish itself in the brain of adult mice after passing 
through the blood brain barrier on day 1 post inoculation, and for viruses 10c3, 10c4, and 
10c5, replicated to higher titres on day 3 post inoculation as compared to day 1 (Figures 
41 and 42). The same phenomenon was not seen in the ‘m’ series (Figures 43 and 44) 
leading to the conclusion that WNVS passaged through suckling mouse brain and C6/36 
cells repeatedly became more adapted to infecting immunocompetent adult mice 
compared to WNVS passaged only through suckling mice brains. This proved that the 
insect cell line alternate passage was of importance for virus adaptation. Moreover, when 
comparing the virus titres in organs from both ‘c’ and ‘m’ virus series on day 3 post 
inoculation, ‘c’ resulted in more organs showing higher virus titres in more mice 
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Figure 41: Virus titres from adult mice inoculated with the mouse – C6/36 passaged virus 
‘c’ sacrificed on day 1 post inoculation. 1:Brain, 2:Liver, 3:Spleen, 4:Serum. The 108 
PFU/ml virus inoculated through the tail vein is detected in the brains as well as spleens, 
a site involved in immunological response. This shows that the passaged virus is 
neuroinvasive, being able to cross the blood – brain barrier to infect the brains from the 
blood stream. Average points indicate serum as the most infectable followed by spleens, 
livers, and lastly brains. 10c3 virus shows the highest titres in serum and livers while 
10c1 is highest for brains and 10c2 virus in spleens. Each virus has two mice per group. 




Figure 42: Virus titre levels from adult mice inoculated with the mouse – C6/36 passaged 
virus ‘c’ sacrificed on day 3 post inoculation. 1:Brain, 2:Liver, 3:Spleen, 4:Serum. The 
virus quickly clears from the livers but persists in other organs at lower PFU/ml. The 
virus titres are notably high in brain and spleen. 10c3 virus shows the highest titres in 
serum while 10c2 is highest in spleen and 10c4 virus in the brains. Each virus has two 
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Figure 43: Virus titres from adult mice inoculated with mouse brain passaged virus ‘m’ 
sacrificed on day 1 post inoculation. 1:Brain, 2:Liver, 3:Spleen, 4:Serum. Overall, there 
are fewer animals showing viremia in fewer organs and at lower levels as compared to 
the mouse - C6/36 passaged virus (Figure 41). The spleens are the most infectable organ 
with 8 out of the 11 mice showing some level of viremia. The brains are the least 
infectable with only 2 out of 11 animals showing low levels of virus load. 10m4 virus is 
the most virulent passaged virus as it gives the highest titres. Each virus has two mice per 




Figure 44: Virus titres from adult mice inoculated with mouse brain passaged virus ‘m’ 
sacrificed on day 3 post inoculation. 1:Brain, 2:Liver, 3:Spleen, 4:Serum. All animals 
have null virus levels except three mice each with one organ showing viremia. One 
mouse has a positive virus titre in the spleen while two others are positive in the sera. 
The brains and livers are totally devoid of virus. Each virus has two mice per group. 
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4.3.2 Effects of Passaged Virus Inoculation on Adult Mice Weight 
Besides inoculating the virus into adult mice to test for virus loads in different organs, 
mortality and morbidity as a result of virus infection was also studied (Section 2.3.8.1). 
The animals were observed daily for signs of illness, including ruffled fur, paralysis, and 
other general indications of illness. There was no observed mortality in any of the mouse 
groups injected with passaged virus for all 10 respective passaged viruses kept for 20 
days. This group of animals were also weighed every 12 hours for the whole period to 
detect for any overt change in health as sick mice will not feed well and this leads to 
weight loss.  
 
Figure 45 shows the raw data of mean weights of mice taken from 0 hours before virus 
inoculation to day 20 post inoculation. Each group consisted of two mice. There was no 
observable difference in weights after the inoculation of various passaged virus compared 
to the control mice inoculated with PBS. Mice used for the 10c1, 10c2, and 10c5 groups 
were obviously underweight at the start of the experiment. The animals were bought from 
a supplier and specific instructions for five week old mice were given. However, it was to 
be expected that there would be some variations in the mice weights. Figure 46 
represented the least square regression lines from the curves obtained in Figure 45. The 
slopes from the three underweight mice gained the most as compared to the other mice. 
All the animals inoculated with passaged virus gained more weight over the 20 day 
period compared to the PBS inoculated mice (Figure 47). There was no indication of any 
illness in any of the mice tested. 
Results 
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Mice inoculated with viruses, both passaged and unpassaged, gained more weight as 
compared to mice inoculated with PBS (Figures 45 to 47). Comparing the levels of 
weight gained to virus titres in inoculated mice (Figures 41 to 44) and pathological signs 
in inoculated mice (Table 10), no correlation was found between virus titres, 
survivability, and histopathology. However mice that displayed the highest virus organ 
titres in organs (10m4 and 10c3 viruses) represented mice with the least weight gained 
(Figure 47). Comparing the graphs in Figure 45, only mice inoculated with passaged 
viruses 10m2, 10m5, and 10c2 registered a drop in weight of any proportion within the 
first 72 hours after inoculation compared with its original weight at time zero. The same 
mice had the highest weight gain when mice weights at day 0 and day 20 were compared 
(Figure 47). It can be concluded that the passaged virus at this point although showing 
virus presence and histopathology in various organs of inoculated adult mice, had yet to 
be able to cause any noticeable effect on the inoculated animal’s general health including 
encephalitis or any other overt signs of illness. 
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Figure 45: Mice weights over 20 days as a test for morbidity. Adult 5 week old mice are 
weighed at day 0 before being inoculated with 108 PFU/ml of passaged virus. Mice are 
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Figure 46: Least square regression lines of mice weights over 20 days. Outliers in terms 
of starting weight can be identified as 10c5, 10c2, and 10c1 virus – infected mice. These 
underweight mice have higher growth rates and quickly caught up with the other animals 
over the 20 days observation period. Virtually all experimental animals have higher 
weight gain rates as compared to the control animal as seen by the steeper gradient of 
the passaged viruses compared to the control group. Gradients from all curves are tested 
for normality and no outliers are observed. 
 
 
Figure 47: Mice nett weight gained after 20 days and the weight gained when normalised 
to the control mouse growth. All experimental mice gain more weight compared to 
control mice over the same time period with the lightest mice gaining the most weight 
(10c2, 10c1 virus infection). The ‘c’ series mice on average gain more weight than the 
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4.3.3 Histological Effects in Mice Inoculated with Passaged Virus 
Histological sections of brains, livers, and spleens of adult mice sacrificed on day 1 and 3 
post inoculation (Section 4.3) were prepared and stained with haematoxylin and eosin 
(Section 2.5.4). Tissue sections were observed for signs of pathology. It was seen that the 
tissue sections showed inflammation in the spleen with infiltration of immune cells into 
the red pulp, foci of necrosis and inflammation in livers, as well as pyknotic cells and 
encephalitis in brains.  
 
The most obvious change was in mice spleens. The red pulps became filled with 
infiltrating cells and were inflammed from day 1 regardless of the passage regime (‘c’ or 
‘m’), a common response to infection. By day 3 post inoculation, all except for 10m2 and 
10m5 virus - infected mice showed signs of splenomegaly, a result of immune 
hyperplasia (Figure 48).  The ‘c’ virus passages seemed to be able to elicit a stronger 
immune response as seen in spleens. In livers, small areas showed grouped plasma cells 
or lymphocytes, most likely Kupffer cells, as these are the resident macrophages found in 
the liver. Kupffer cells were found around blood vessles and could be defined as 
perivascular cuffing. Again, this was more common in the ‘c’ passaged virus infection as 
compared to the ‘m’ passaged virus infection with three out of five ‘c’ virus infections 
having some form of pathology at day 3 post inoculation compared to only 2 viruses from 
‘m’. Besides this, no other overt sign of infection or inflammation could be detected in 
the liver (Figure 49). In the brains (Figure 50), only one instance of meningoencephalitis 
was detected in mice from day 1 and 3 post inoculation in mice inoculated with 10m1 
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passaged virus. No other mouse brain showed pathology except for an occasional 
pyknotic cell. The results were summarised in Table 10. 
 
 
Figure 48: A representative spleen from a day 1 post infected - mouse showing relatively 
clear red pulps (arrow, a) from 10m2 virus infection. The same is seen for mock - 
infected animals (arrow, b). By day 3 post infection, most animals start to show varying 
levels of inflammation (arrows, c and d) in the spleens. (c) a slide from 10m3 virus - 











Figure 49: Kupffer cells and other inflammatory cells in the livers of various mice 
injected with passaged virus. (a) shows a slide from 10m1 virus infection at day 3 with 
yellow arrows pointing to signs of perivascular cuffing around a portal tract, (b) 10c3 
virus inoculation at day 1 also exhibits perivascular cuffing (yellow arrows), (c) 10c1 
virus infection at day 3 with arrows showing focuses of dense inflammatory cells in a 
roselle pattern with apoptotic cells in the middle of the focus area, and (d) 10c3 virus 
infection at day 1 with arrows pointing to an area of focal inflammation. Evidence of an 
inflammatory response is usually associated with pyknotic cells (a and b, black arrows). 
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Figure 50: Meningoencephalitis in the pair of mice injected with 10m1 passaged virus. 
(a) shows a section from mice sacrificed on day 1 post inoculation with thickened 
membranous structures (arrows). (b) to (d) shows the same experiment on day 3 post 
inoculation. The leptomeningitis is more severe and contains red blood cells (yellow 
arrows). Also, there is perivascular cuffing around a blood vessel near the brain surface. 
There is a large recruitment of inflammatory cells to the thickened membranous 
structures and blood vessels (c – black arrows) indicating severe infiltration of brain 
parenchyma. All other brain slides from the same mouse do not show any other forms of 
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Brain Liver Spleen 
Inoculum Day 1 Day 3 Day 1 Day 3 Day 1 Day 3 
10c1 No pathology No pathology 
Perivascular cuffing,
Pyknotic cells, Focal 
necrosis 
Perivascular cuffing,
Pyknotic cells, Focal 
necrosis 
Inflammation Inflammation 
10c2 No pathology Pyknotic cells No pathology No pathology No pathology Inflammation 
10c3 No pathology No pathology 
Perivascular cuffing,
Pyknotic cells, Focal 
necrosis 
Perivascular cuffing,




10c4 No pathology Pyknotic cells No pathology Perivascular cuffing,Pyknotic cells No pathology Inflammation 








Pyknotic cells, Focal 
necosis 
No pathology Inflammation 
10m2 No pathology No pathology No pathology Pyknotic cells Light inflammation No pathology 
10m3 No pathology No pathology No pathology No pathology No pathology Inflammation 
10m4 No pathology No pathology No pathology No pathology No pathology No pathology 
10m5 No pathology Pyknotic cells No pathology Pyknotic cells No pathology Inflammation 
Table 10: Summary of histopathological findings from haematoxylin and eosin stained tissue sections of brains, livers, and spleens 
from mice inoculated with passaged virus ‘c’ and ‘m’ series sacrificed at day 1 and 3 post inoculation. The ‘c’ virus series is seen 
to cause more pathological effects in the mice although only virus 10m1 is able to cause noticeable meningoencephalitis. 
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4.4  INFECTION OF PRIMARY CELLS 
Results thus far showed that passaged viruses inoculated into both adult and suckling 
mice displayed higher virus levels for longer periods. This is especially true for the brains 
of adult mice as seen in Figures 41 to 44. As such, it is of interest to investigate the 
growth kinetics of passaged and unpassaged viruses specifically in the brain tissue. As it 
is impossible to closely monitor virus titre in live mice, primary neural cells were chosen 
as the closest in vitro model to mimic the whole brain mouse in vivo model (Section 
2.3.8.3). 
 
4.4.1 Isolation of Primary Cells 
Primary neural cells were isolated from embryonic BALB/c E16 (Section 2.3.7) and cells 
grown in either Neurobasal media or DMEM. The cells in Neurobasal media were largely 
neuronal cells (neurons) whereas cells in DMEM with FBS were a mix of neural cells 
containing astrocytes and oligodendrocytes. Anti - NeuN, CNPase, and GFAP antibodies 
were used to test for exact neural cell composition of the mixed culture. Figure 51 
showed the identification of the neural culture as a mixed oligodendrocyte – astrocyte 
culture by immunofluorescence. There were thus two batches of primary neural cells 
tested, a neuronal culture of pure neurons and a mixed neural culture containing a mix of 
astrocytes and oligodendrocytes. 
  
Results 







Figure 51: Positive labelling of 
primary neural cells with 
primary antibodies against 
GFAP labelling for astrocytes 
(a) and CNPase labelling for 
oligodendrocytes (b) conjugated 
to Alexa Flour 488. Antibodies 
against NeuN (c) for neurons do 
not show any specific labelling. 
This shows that the primary 
culture is an astrocyte – 
oligodendrocyte mixed culture. 
All photographs are taken with 
the same exposure time and light 
intensity. Original magnification 
1000x. 
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4.4.2 Levels of Virus Production on Infected Primary Astrocytes/Oligodendrocytes 
Primary cells were infected with PBS (mock), passaged, and unpassaged viruses as 
described in Section 2.3.8.3. The supernatant was collected at various time points and 
tested by plaque assay for infective virus particles (Section 2.2.4). Most of the infections 
started producing viruses at 12 hours post inoculation with titres ranging from 105 to 108 
PFU/ml. The viruses from the ‘m’ series passaging started off notably on a lower virus 
titre ranging from 100 to 106 PFU/ml (Figure 53) whereas the ‘c’ series passaging started 
between 106 and 108 (Figure 52). All the viruses except for 10m2 had a slow drop in 
virus titre over the 132 hour-period. 
 
Figure 52: Growth curves of unpassaged (Vero cell and C6/36 cell – grown) and ‘c’ 
passaged virus series on mouse primary neural culture. The ‘c’ series passages has a 
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Figure 53: Growth curves of unpassaged (Vero cell and C6/36 cell – grown) and ‘m’ 
passaged virus series on mouse primary neural culture. 10m2 virus has an atypical 
growth pattern. The ‘m’ series passages has a starting virus yield of 100 to 106 PFU/ml at 
12 hours post inoculation while the ‘c’ series passages has a starting PFU/ml of 106 to 
108 (Figure 52).  
 
4.4.3 Persistent Virus Infection in Primary Neural Culture with 10m2 Virus 
From Figure 53, it was obvious that there was an abnormality in the 10m2 passaged 
viruses. The initial photomicrographs for the early time points for 10m2 virus infection 
showed no difference compared to mock - infected control flasks. It was thus left to grow 
beyond 132 hours post inoculation. Titred every week after that, it was seen that the virus 
titre was consistently at 104 PFU/ml, as seen in Figure 54. A persistent infection was 
established with this infected culture. After 8 weeks (1428 hours), the total supernatant 
was removed and the cell monolayer washed twice with PBS. Fresh media was then 
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found to be 3.6 x 104 PFU/ml. This proved that it was new virus progeny that was being 
released into the media and not original viruses that remained in the culture. Fifty percent 
of the media was changed every 3 days from week 8 onwards (1344 hours). 
 
 
Figure 54: Growth curve for 10m2 virus infection on primary neural cell culture over a 
total period of 2100 hours (12.5 weeks). The virus titre remains low until 120 hours (day 
5) post inoculation when it rises steadily to a peak of 105 PFU/ml. The titre drops from 
2100 hours (week 12.5) to below 103 PFU/ml (Figure 55).  
 
 
Primary cells persistently – infected with 10m2 virus were found to be confluent after 12 
weeks (2016 hours) and at this point, the virus titre dropped to 102 PFU/ml. The flask was 
then subcultured 1 : 2 following protocols outlined in Section 2.1.3. The virus titre was 
continually titred every week from both flasks and the results detailed in Figure 55. The 
virus titres started dropping from week 10.5 (1764 hours) post inoculation (Figure 54) 
and at week 16 (2688 hours) post - inoculation, the experiment was terminated (Figure 
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Figure 55: Titres of 10m2 virus from subcultured persistently - infected primary neural 
cells. The experiment ends on week 16 post - inoculation and cells are processed for 
electron microscopy. 
 
4.4.4 Gross Phenotypic Changes During Infection of Primary Astrocytes/ 
Oligodendrocytes 
Photomicrographs of the primary astrocyte/oligodendrocyte culture were taken at various 
time points to give a visual representation of the infection. Comparing the different 
slides, it was observed that the initial infection by WNVS grown in Vero cells or C6/36 
cells showed differences in gross morphology of the infected cells. The three images 
(Figure 56) displayed representative micrographs of primary neural cells infected at MOI 
of 10 with Vero cell grown WNVS at 48 hours (2 days), 132 hours (5.5 days), and 3 
weeks post inoculation. The following three micrographs from Figure 57 showed 
photomicrographs at similar timepoints of cells infected with WNVS grown from C6/36 
cells. The final set (Figure 58) showed control cells mock - infected at the same 
timepoints. The Vero cell - grown virus was able to infect and disrupt the monolayer but 
did not fully kill all the cells. On the contrary, the C6/36 cells grown virus caused 
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Figure 56: Micrographs of neural cells infected with WNVS previously grown in Vero 
cell culture at 48 hours (a), 5.5 days (b), and 3 weeks (c) post - inoculation. After an 
initial high level of cell death, the remaining cells recover in three weeks and the cell 
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Figure 57: Micrographs of neural cells infected with WNVS previously grown in C6/36 
cell culture at 48 hours (a), 5.5 days (b), and 3 weeks (c) post - inoculation. The infected 
- monolayer shows progressive cytopathic effects ending with total cell death of the cell 
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Figure 58: Micrographs of neural cells mock - infected at 48 hours (a), 5.5 days (b), and 
3 weeks (c) post - inoculation. The monolayer remains confluent throughout the study. 
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All ten passaged viruses caused cytopathic effects in infected cells in the first few days 
with cell rounding and lifting. By the end of day 7, cell attrition stopped and from that 
point until week 3, the remaining cells on the flask surface were observed to re – colonise 
the flask. Figure 59 and 60 showed micrographs representative of the ‘c’ series passaged 
virus, 10c1 and 10c5, whereas Figure 61 and 62 represent the ‘m’ series passaged virus 
10m2 and 10m4. The observable difference between these two viruses was the levels of 
relative cell death. The ‘c’ series passaged viruses caused more neural cell death as 
compared to the ‘m’ series passaged viruses. 
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Figure 59: Micrographs of neural cells 
infected with WNVS 10c1 at 0.5(a), 
2(b), 3(c), 4.5(d), 7.5(e), 10(f), and 
18(g) days post - infection. The cells 
are more susceptible to the ‘c’ series 
passaged virus strains compared to the 
‘m’ series passaged viruses. The 
remaining cells recover over time. 







116 | P a g e  
  
 
Figure 60: Micrographs of neural cells 
infected with WNVS 10c5 at 0.5(a), 
2(b), 3(c), 4.5(d), 7.5(e), 10(f), and 
18(g) days post - infection. The cells 
are more susceptible to the ‘c’ series 
passaged virus strains compared to the 
‘m’ series passaged viruses. The 
remaining cells recover over time.  
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Figure 61: Micrographs of neural cells 
infected with WNVS 10m2 at 0.5(a), 
2(b), 3(c), 4.5(d), 7.5(e), 10(f), and 
18(g) days post - infection. The 
remaining cells recover faster than 
those infected with 10c5 infection. Cells 
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Figure 62: Micrographs of neural cells 
infected with WNVS 10m4 at 0.5(a), 
2(b), 3(c), 4.5(d), 7.5(e), 10(f), and 
18(g) days post - infection. The 
remaining cells recover faster than 
those infected with 10c5 virus and 
exhibit very little cytopathic effects. 
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4.4.5 Electron Microscopy Evaluation of the Persistently - Infected Primary 
Astrocytes/Oligodendrocytes 
Primary neural cells persistently - infected with 10m2 passaged virus (Section 4.4.3) was 
fixed and processed for electron microscopy (Section 2.6). Ultrathin sections were 
viewed under a transmission electron microscope and images were captured at various 
magnifications. Most cells seen were thin, rod - shaped with distinct nucleus, and dark 
myelin bodies in the cytoplasm (Figure 63). These cells were identified as light 
oligodendrocytes with long processes responsible for the myelination of CNS axons. 
These cells are known to be capable of cell division and are active in myelin sheath 
growth and maturation (Young and Heath, 2006). From the previous section, it was seen 
that cells in flasks showing low cytopathic effect could re – colonise the flask (Figure 59 
to 62). Because astrocytes are incapable of myelenation or cell division, the cells seen 
through the electron microscope could only be oligodendrocytes. This led to the 
deduction that astrocytes were preferentially infected by WNVS. Most cells under the 
electron microscope looked unhealthy with compromised membranes and oversized 
vacuoles (Figure 64). These were easily differentiated from healthy cells which had 
dense vacuoles and organised cytoplasm (Figure 63). The identification of remaining 
cells as oligodendrocytes also excluded the possibility of primary cell culture 
contamination with epithelial cells.  
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Figure 63: A typical oligodendrocyte with prominent nucleoli (yellow arrow), myelin 
sheaths (red arrows), and Golgi stacks (green arrow). Original magnification 15000x. 
 
 
Figure 64: A compromised oligodendrocyte cell with enlarged vesicles (yellow arrows) 
and disrupted membrane (red arrows). In addition, there is a large increase in the 
number of myelin sheaths. The areas of myelin sheath growth do not show normal 
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4.4.6 Levels of Virus Production in Infected Primary Neurons 
The same passaged and unpassaged viruses in Section 4.4.2 were used for infecting a 
monolayer of primary mouse neurons isolated from E16 mice at an MOI of 10. From 
Figures 65 and 66 below, it could be seen that the level of peak and overall virus 
production from the unpassaged (Figure 65) and passaged (Figure 66) viruses were 
different. The maximum virus titres from cultures infected with passaged viruses were 
generally higher than the unpassaged viruses. This showed that the passaging affected the 
virus neurovirulence by increasing the maximum virus titre during infection as well as 
causing peak virus infection to occur at an earlier time – point. 
 
Figure 65: Growth curves of unpassaged viruses on mouse primary neural brain culture. 
Virus titre peaks at 36 hours post inoculation for the C6/36 cell – grown WNVS while the 
Vero cell – grown WNVS peaks later at 60 hours post inoculation. For both virus 
inoculations, there is an exponential rise in the virus titre from 12 to 36 hours post 
inoculation. The virus titres start to decrease after 60 to 72 hours. The numbers in 
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Figure 66: Growth curves of the ten passaged viruses on primary neuronal mouse brain 
culture. Virus titres generally peak early at 24 hours post inoculation and then slowly 
drift downward over the days. The curves for passaged and unpassaged virus are 
different. All of the passaged viruses except 10m3, 10c1, and 10c3 achieve peak virus 
titre that is higher than the peak virus titre of unpassaged viruses as seen when 
comparing the numbers in brackets which represent peak virus titres (Log10 PFU/ml). No 
difference in virus titre between ‘c’ and ‘m’ series at any time point can be detected 
unlike in Section 4.4.2 where the ‘c’ series passaged viruses gives higher PFU/ml levels 
as compared to the ‘m’ series passaged viruses at 12 hours post inoculation.  
 
4.4.7 Gross Phenotypic Changes During Infection of Primary Neurons 
The phase contrast micrographs taken at 24 hour intervals showed the rapid dying of cells 
with the onset of cytopathic effect. Most of the cell population lifted off the flask by the 
third day post inoculation (Figures 67 and 68). Neurons infected with unpassaged Vero 
and C6/36 cell grown WNVS were found to show cytopathic effects earlier compared to 
passaged viruses which at the end of 4.5 days post infection still had some adherent 
neurons on the tissue culture dish surface. The remaining cells were small and appeared 
unhealthy. The passaged virus produced a higher and longer plateau of virus titre 
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corresponded to the photomicrographs of infected cells in which passaged virus 







Figure 67: Micrographs from 
unpassaged C6/36 cell culture 
grown WNVS infection on 
primary neuronal cells at 
different hours post infection a 
(24 hours), b (48 hours), and c 
(72 hours). At 72 hours, only 
cell debris can be seen in the 
culture dish. Original 
magnification 10x. 
Results 




Figure 68: Micrographs of 
primary neuronal cells infected 
with passaged virus from the 
stock 10m2 virus at various time 
points of a (24 hours), b (48 
hours), c (72 hours), and d (96 
hours). At 96 hours post 
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5.0 RESULTS 
5.1 DIRECT SEQUENCING OF UNPASSAGED VIRUS 
The genome from stock WNVS grown on C6/36 cells (Section 2.2) used in this study was 
sequenced (Section 2.4). The resulting nucleotide as well as translated amino acid 
sequence were blasted against the complete WNVS genome sequence (AY688948) 
deposited in Genbank by Li and colleagues (2005) to detect any variation in unpassaged 
virus. Only one mutation was found in the NS2a protein at amino acid residue 2 where 
asparagine mutated to threonine. No other conserved or non – conserved mutations were 
observed throughout the entire RNA genome. This shows that the virus genome had not 
changed much despite approximately three years of passaging since the publication of Li 
and colleagues (2005). 
 
5.2 DIRECT SEQUENCING OF PASSAGED VIRUSES 
The five ‘c’ and five ‘m’ passage 10 viruses were sequenced directly as outlined in 
Section 2.4. Genetic domains encoding proteins C, E, NS2a, NS2b, NS4a, and NS4b were 
sequenced. Regions encoding C and E proteins were chosen to represent the structural 
proteins while NS2a, NS2b, NS4a, and NS4b represented the non – structural proteins. 
The prM, NS1, NS3, and NS5 genes were not selected as these genes code for vital 
proteins crucial for virus replication and growth. Mutations in this region will affect virus 
viability and growth significantly. As no drastic changes in virus titres were seen at the 
end of the 10 virus passaging rounds, it was assumed, although untested, that these 
regions had changed little. The virus genomes were not first cloned into an amplification 
vector as Pfu DNA polymerase was used which has 3’ to 5’ exonuclease proofreading 
Results 
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capabilities. Complete sets of target sequences were obtained from the ten passaged 
viruses. 
 
5.2.1 Sequences of West Nile Virus (Sarafend) C Protein 
The RNA isolates from the ten various passaged viruses was reverse transcribed, 
amplified, sequenced, and translated into protein sequences (Section 2.4). Table 11 
showed the various viruses’ mutations in the C protein regions of the passaged virus 
genomes. All passaged viruses had mutations in the C protein regions. The passage 10c5 
and 10m1 showed a mutation at the first amino acid that changed the start codon. As this 
mutation was found to be the consensus sequence through sequencing, it is a tolerable, 
non lethal mutation. 
 
The other mutations were found at residues 24, 26, and 29 of C protein (Table 11). 
Residue 24 and 26 are at the start of the first α – helix while residue 29 is in the middle of 
it (Figure 69). It is known that these residues are part of the hydrophobic interior of the C 
protein 3 – helix core (Dokland et al., 2004; Ma et al., 2004). All three mutations from 
glycine to valine at residue 24, serine to alanine at residue 26 and glycine to valine at 
residue 29 caused an increase in nonpolarity and also increased the overall 
hydrophobicity as the hydropathy index increased significantly from -0.4 to 4.2 for G to 
V, and -0.8 to 1.8 for S to A mutations. The crystal structure also suggested that α – helix 
1 is flexible and plays a functional role in assembly and RNA binding. The helix 
movement would expose the hydrophobic site to allow for interaction with host 
membrane during assembly (Kofler et al., 2002). By maintaining the secondary structure 
stability, these residues played an important role in virus production. 
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Table 11: Mutations at the C protein region of passaged viruses. Hotspots are identified 
as amino acid residues 24 and 26 with 8 of the 10 passages having either one of these 











10c1 76 T to G 26 S to A 
10c2 71 to 72 GA to TG 24 G to V 
 355 to 356 GC to TT 118 A to F 
10c3 71 to 72 GA to TG 24 G to V 
 369 T to A 123 A to V 
10c4 71 to 72 GA to TG 24 G to V 
10c5 2 T to G 1 M to R 
 86 G to T 24 G to V 
10m1 2 T to G 1 M to R 
 86 G to T 29 G to V 
10m2 71 to 72 GA to TG 24 G to V 
10m3 76 T to G 26 S to A 
10m4 76 T to G 26 S to A 




Figure 69: Multiple sequence alignment of flavivirus C proteins. Residues of high 
similarity are in red and conserved residues are highlighted. The four rods represent 
helices. Conserved hydrophobic regions are in grey. Hotspot mutation at residue 24 and 
26 are at the start of helix 1. Den: dengue, Kun: Kunjin, WNV: West Nile, MVE: Murray 
Valley encephalitis, JEV: Japanese encephalitis, SLE: St. Louis encephalitis, YFV: yellow 
fever, TBE: tick borne encephalitis, LIV: louping ill, LAN: Langat, POW: Powassan (Ma 
et al., 2004).  
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Interestingly, when mutation points on Table 11 were studied; either a mutation was seen 
at the residue 26 – 29 region or at the residue 24 position but never together. The 
significance of this is unknown but it may be a possible event of convergent evolution 
where each mutation increased virus pathogenicity and are just two different 
mechanisms. Also, the amino acid residues mutated to were similar indicating that non-
conservative mutations to other amino acid residues may have deleterious or less 
beneficial effects. The plots by Protean software (DNASTAR Inc., USA) showed various 
changes in antigenicity, hydrophilicity, surface probability, and change in possible 

















Figure 70: Protean automated predictions of C protein secondary structures from 
representative unpassaged (a) and passaged viruses 10c1 (b), 10c5 (c), and 10m2 (d). 
These passaged viruses contain mutations at amino acid residues 26 (b), 1 and 29 (c), 
and 24 (d). The mutation at amino acid residue 26 sees a change in alpha regions 
predicted as well as a drop in the antigenicity (red arrows) compared to the unpassaged 
virus plot, while changes in residue 29 causes a decrease in antigenic index and an 
increase in hydrophobicity (green arrows). Mutations at amino acid residue 1 shows an 
increase in surface probability and hydrophilicity (black arrows) while residue 24 causes 
a sharp decrease in antigenicity (blue arrows). All the other mutations do not display any 
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5.2.2 Sequences of West Nile Virus (Sarafend) E Protein  
A single mutation was found in the E protein region of 10c1 among all the passaged 
viruses (Table 12). The mutation at amino acid residue 150 was mapped to a conserved 
glycosylated loop in domain I (Figure 71) solved crystallographically by two groups 
(Kanai et al., 2006; Rey et al., 1995). This mutation caused a large increase in 
hydrophobicity but the relevance of this mutation was unknown as it is part of the 
position 145 – 162 loop exposed on the viral surface (Kanai et al., 2006). Surface 
exposed residues would be in direct contact with the aqueous phase and could be 
negatively affected by such a mutation.  
 
Table 12: The only amino acid mutation found in the E protein from all 10 various 
passages of passaged virus. The residue mutating from alanine to valine is found in 
domain I and retains the nonpolar charge but the mutation causes an increase in 
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Figure 71: Multiple sequence alignment of 4 representative flavivirus E proteins. Bars 
above the sequences show areas of secondary structure. Residue 150 (black arrow) is in 
between beta sheets E0 and F0. TBE, JE, and YF has a polar, neutral, and hydrophilic 
residue in this position. Dengue however has a nonpolar hydrophobic residue, which is 
similar to the original Sarafend residue. The mutated amino acid (valine) is more 
hydrophobic compared to alanine. TBE: tick borne encephalitis, JE: Japanese 
encephalitis, YF: yellow fever virus (Rey et al., 2006). 
 
 
5.2.3 Sequences of West Nile Virus (Sarafend) Non Structural 2a (NS2a) Protein 
The passaged virus 10c2 showed 8 different nucleotide point mutations in the NS2a 
protein (Table 13). All the mutations were clustered to the first 6 amino acids indicating 
that this could be a potential multivariable site during the process of host adaptation.  
 
Mutation at amino acid residue 2 of NS2a protein was found in 7 of the viruses 
sequenced. Of these, 4 viruses showed asparagine to isoleucine mutation while the 
remaining three mutated to threonine. This asparagine to threonine mutation was however 
also noted in the unpassaged virus implying that this mutation was the consequence of 
prolonged passaging in tissue culture and not mouse passaging.  
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Table 13: Amino acid changes in the NS2a coding region arising from mutations at the 
nucleotide level as compared to the WNVS virus sequence deposited in Genbank. Points 
of interest include a mutation from stock unpassaged virus at amino acid 2. All passaged 
viruses except 10c1 and 10c3 has mutations in this region. The 10c2 passaged virus 
shows the most difference with 8 nucleotide mutations resulting in 4 amino acid changes. 
All the mutations are mapped to the first 6 amino acids of NS2a signaling the importance 











Unpassaged 5 A to T 2 N to I 
10c2 6 C to T Conserved  
 7 G to T 3 A to S 
 9 C to A 3 A to S 
 11 to 12 AC to TT 4 D to V 
 13 to 14 AT to GG 5 M to G 
 16 A to C 6 I to L 
10c4 5 A to T 2 N to I 
10c5 5 A to T 2 N to I 
10m1 5 A to C 2 N to T 
10m2 5 A to C 2 N to T 
 13 A to G 5 M to V 
10m3 5 A to C 2 N to T 
 330 A to G Conserved  
10m4 5 A to T 2 N to I 
 16 A to G 6 I to V 
10m5 5 A to T 2 N to I 
 
 
Evaluation of translated protein sequence of NS2a from passaged virus 10c2 and 10m2 as 
representative viruses against the unpassaged virus by Protean software (DNASTAR Inc., 
USA) revealed postulated changes in α – regions, β – regions, and antigenicity (Figure 
72). The mutations observed completely abolished areas of predicted alpha helix 
secondary structures and increased antigenicity levels.  
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Figure 72: Protean outputs predicting various secondary structures at the first 14 amino 
acids of NS2a of unpassaged virus (a), passaged virus 10c2 (b), and 10m2 (c). Passaged 
virus 10c2 contains mutations at amino acid residues 3 to 6 while 10m2 has mutations at 
residues 2 and 5. Of notable difference in passaged virus secondary structure predictions 
for the first 5 amino acids are the disappearance of alpha regions (orange arrows), the 
prediction of beta regions (blue arrows) and increase in antigenicity (red arrows). 
Comparing the unpassaged virus with 10c2 virus, the whole putative region of alpha 
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5.2.4 Sequences of West Nile Virus (Sarafend) Non Structural 2b, 4a, and 4b 
(NS2b, NS4a, and NS4b) Proteins 
No mutation, silent or unconserved was found in any of the proteins abovementioned, 









135 | P a g e  
 
6.0 DISCUSSION 
The initial objective of this study was to employ BALB/c, an immunocompetent mouse 
as a model for flavivirus infection. However, early studies using DV2 NGC and WNVS 
virus on adult immunocompetent mice resulted in no detectable infections (Sections 3.1.1 
and 3.2.1). Previous studies had shown that DV was able to only infect 
immunocompromised mouse models (Johnson and Roehrig, 1999; Lee et al., 2006). West 
Nile virus (Sarafend) on the other hand was observed to infect B6 mice and caused 100 % 
mortality at high PFU levels (Wang et al., 2003). This group however consistently 
passaged WNVS through suckling mice instead of cell culture. The disparity of results 
for WNVS infection between published literature and in this study could be due to the 
fact that the WNVS used here had been passaged repeatedly over the decades in cell 
culture causing it to be attenuated in terms of pathogenicity.  
 
6.1 Tests with Dengue Virus 
Tests on immunocompromised AG129 mice with DV2 NGC found the mice infectable 
with positive virus titres in serum, spleen, and liver (Figures 6 to 8). However, unlike 
previous publications (Chen et al., 2004; Lin et al., 1998; Shresta et al., 2004a; Shresta et 
al., 2004b), this virus did not cause any mortality or paralysis in AG129 mice. These 
studies also found that most mice developed severe paralysis. As dengue infection is not 
known to cause paralysis in humans, this reported observation may not a relevant 
phenotype for a dengue model.  
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In Figures 13 to 14, germinal centres were noted developing in both white and red pulp. 
This indicates that DV could stimulate the propagation of both B and T cells, respectively 
during early infection (Figures 9 to 15). T cell activation has only been observed after 
secondary DV infection in both human clinical samples and animal models but not at 
early time points after primary infection with DV (Yauch and Shresta, 2008). Even 
though dengue viruses used in this study were continually passaged in cell culture the 
virus remained antigenic. In spleens, virus antigens were found specifically in the 
cytoplasm of infiltrating cells (Figure 10) that gathered in the red pulp causing 
inflammation and splenomegaly (Figure 9). These would most likely be antigen 
presenting cells in the form of dendritic cells or macrophages gathered from circulating 
blood or lymph nodes as the same cell types were found susceptible to dengue virus 
infection in both mice and human (Blackley et al., 2007; Clyde et al., 2006; Kyle et al., 
2007). The work on dengue virus has been included to give a more complete overview of 
work done on different flaviviruses. It goes to show that the pathology and mechanisms 
are different as compared to West Nile virus and needs to be taken into account when 
comparing data from the two different viruses.   
 
6.2 Passaging of West Nile Virus (Sarafend) 
Passaging viruses can lead to either attenuation or increase in virulence. Studies have 
shown that passaging flavivirus through cell culture could lead to attenuation in various 
in vivo systems (Barrett et al., 1990; Ciota et al., 2007a; Dunster et al., 1990; Goto et al., 
2003; Miller and Mitchell, 1986). A single mutation in DV genome could significantly 
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increase or reduce disease in mice (Bordignon et al., 2007; Jia et al., 2007; Lee et al., 
2006; Liu et al., 2006). Similarly, in Japanese encephalitis, a single amino acid change in 
the envelope protein led to drastic change in virulence (Chiou and Chen, 2007). Even 
without any mutations after passaging, it was found that DV passaged through tissue 
culture was more rapidly cleared from the circulation or mice (Lee et al., 2006). Because 
of the complexity surrounding four serotypes of DV and the different substrains 
available, in this study, it was more manageable to work with WNVS which the 
laboratory had been using and whose sequence was already determined. Additionally, 
WNVS can be grown to higher titres compared to DV. This would greatly ease 
subsequent experimentation.  
 
Literature has shown that passaging WNV serially commonly causes cyclic movements 
of virus titre (Bordignon et al., 2007; Jerzak et al., 2007; Jerzak et al., 2008). The cause 
of titre drop is uncertain as the authors could only state that virus adaptation to the host 
could be a reason why titres fluctuated between passages. The virus’ ability to recover to 
normal titres after a drastic drop as in passage five (Figure 37) could be attributed to the 
reported existence of multiple genotypic variants or quasispecies found in all WNV 
populations (Ciota et al., 2007b; Jerzak et al., 2005) and has been proven in foot and 
mouth disease viruses (Martinez et al., 1991).  
 
This theory states that natural selection favours not simply the fastest growing replicator, 
but rather a virus with broad spectrum of mutants that are produced by erroneous copying 
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of the fittest sequence (Moya et al., 2004). The fastest replicating RNA viral genomes 
could be out competed by those with lower replication rates if the latter is capable of 
generating mutations from closely related variations. These papers also noted sudden 
severe drops in virus titres during passaging at various rounds similar to the drop seen at 
passage 5 of the ‘c’ series (Figure 37). Arthropod – borne RNA viruses are known to 
alternate hosts in nature through a vertebrate and an invertebrate host. A virus population 
having genetically distinct subgroups could survive better when transmitted through 
different environments (Aaskov et al., 2006). Additionally, even though the mutant 
spectrum may contain premature stop codons, it is still able to stimulate the host immune 
system that leads to clinical signs and the associated host response (Jerzak et al., 2007). 
Complementation allows these seemingly unfit subgroups to persist in the virus 
population. 
 
6.3 Plaque Size Change During Passaging 
Virus plaque size change is postulated to be a reflection of variability in virus genome 
and virulence. Small plaque WNV (Kunjin) virus was reported to produce low titres and 
high levels of interferons while small plaque WNV (New York) virus was attenuated 
both in vitro and in vivo (Jia et al., 2007; Liu et al., 2006). Small plaque size thus seemed 
to correspond to lower virus replication efficiency. Plaque sizes of all passaged viruses 
were measured and plotted (Figures 19 to 21). The standard deviations of the plaque 
sizes from these graphs were also drawn (Figures 22 to 24). 
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Plaque size generally became larger in the ‘m’ passaged virus series and smaller in the ‘c’ 
series through passaging up to passage 5 (Section 3.3) but reverted to unpassaged virus 
size at passage 10 (Figures 19 to 21). Passaging the virus through different methods has 
adapted it differently and also caused a cyclic movement in plaque size. The passaged 
viruses were found to be more infective than unpassaged viruses and the smaller plaque 
size ‘c’ series were more pathogenic than the larger size ‘m’ series (Section 4.3). Ciota 
and colleagues (2008) passaged WNV virus through 20 rounds of mosquito cell culture. 
Average plaque sizes were measured at passage 10 and 20. Passage 20 viruses were 
larger in size while the average plaque sizes at passage 10 did not differ from unpassaged 
virus (Ciota et al., 2008); this was mirrored in Figures 19 to 21 where the fluctuation of 
virus particle sizes returned to baseline level for ‘c’ and ‘m’ at passage 10. This showed 
that plaque size change is cyclical during passaging. 
 
Standard deviations of plaque sizes were calculated as a surrogate marker for diversity of 
virus population. It showed a cyclical pattern throughout the 10 passages for all the 
passaged viruses (Figures 22 to 24) suggesting that the virus genetic population was 
constantly adapting. The standard deviation of plaque sizes from C6/36 grown viruses 
became larger with passaging, indicated by the increasing standard deviation value with 
passaging (Figure 24). This is in line with the study of Ciota and colleagues (2007b) that 
suggested passaging WNV through a mosquito cell line caused a linear increase in 
genetic heterogenicity of the virus. Virus size diversity was found to fluctuate easily with 
passaging and could recover to baseline size in two to three passages (Jia et al., 2007). It 
was also seen that pools of viruses with high size diversity or large mutant spectrum 
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caused lower mouse mortality (Jerzak et al., 2007). From Figures 22 to 24, one notes the 
overall higher standard deviations for ‘m’ series passaged viruses correlating with its 
lower virus fitness seen throughout the results (Sections 4.3 and 4.4.2). There could have 
been some experimental errors in the results of Figures 25 to 36 on various passages. 
However, the omission of particular passages from the figures would raise more 
questions and doubts, and hence the full dataset was shown. 
 
6.4 Tests on Passaged Virus Virulence 
Comparing unpassaged to passage 10 viruses, suckling mice inoculated with passage 10 
viruses were found to die at earlier time points while inoculated adult mice showed virus 
positively in brains, livers, serum, and spleens up to day three post inoculation (Sections 
4.2 and 4.3). Passaged viruses inoculated onto primary cells also gave higher and earlier 
peak virus titres compared to unpassaged viruses (Section 4.2.6). This effect of passaging 
was previously noted in DV passaged through AG129 mouse brains and C6/36 for ten 
rounds (Kyle et al., 2007). The resultant virus caused peak virus titres in adult mice 
brains at day 2 instead of the unpassaged virus at day 4. The passaged DV could also kill 
single knockout A129 mice which has interferon α/β receptor knockout on which the 
unpassaged dengue could only cause paralysis. Comparing suckling mice inoculated with 
‘c’ series and ‘m’ series viruses, the ‘c’ virus inoculated suckling mice died at an earlier 
time point as compared to the ‘m’ series highlighting that passaging using different 
passaging routines affected the level of virus adaptation (Section 4.2).  
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When comparing the survival times of suckling mice inoculated intracerebrally with 
various doses of passaged (Figures 39 to 40) or unpassaged (Figure 18) WNVS, no clear 
distinction of dose response over 2.5 logs difference in virus inoculum was noted. The 
mean survival times of suckling mice inoculated with WNVS were indistinguishable 
between various doses. This was also seen in published data for both Murray Valley 
encephalitis virus and WNVS virus where no clear dose response curve was seen in 
suckling mice inoculated with a virus range difference of 4 logs (Licon Luna et al., 2002; 
Wang et al., 2003). This was also observed in studies with WNV (New York) where a 
difference of 3 logs of virus resulted in the same mean survival time and viremia in adult 
mice (Arroyo et al., 2001; Beasley et al., 2005; Borisevich et al., 2006; Shirato et al., 
2004). None of the authors suggested an explanation for this phenomenon.  
 
Only two of the 20 inoculated BALB/c mice showed signs of neuroinvasiveness in the 
form of meningitis although multiple mice had positive virus titres in the brains. This 
mimics reported human cases where less than 1 % of infected individuals developed 
severe neuroinvasive disease (Kramer et al., 2007; Mostashari et al., 2001). The passaged 
virus was found to be both neuroinvasive and neurovirulent as shown when the virus was 
able to cross the blood brain barrier of adult mice (Monath et al., 1983) and established 
viremia up to day three post inoculation (Figure 42). As the virus was found in the brains 
of adult mice at day one post inoculation, WNV was able to breach the blood brain 
barrier without the need for first infecting and replicating at a peripheral organ. This was 
shown to be possible in mice inoculated with WNV through the footpad (Hunsperger and 
Roehrig, 2006).  
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Comparing virus titres in adult mice brains inoculated with 10c4 and 10c5 passaged 
viruses at day 1 and 3 post inoculation, the titres increased dramatically from day 1 to day 
3 indicating the virus’ ability to replicate in the CNS. Moreover, in Figure 42, the virus 
titres from brain homogenates of mice inoculated with 10c4 and 10c5 passaged virus was 
positive although no virus was detected in the serum. The passaged virus was thus 
neurovirulent. This was again proven as passaged virus could productively infect 
neuronal cell cultures producing high virus titres for a week (Section 4.4.7). However, 
inflammation was noted in mice cerebella (Figure 50) which is typically not infected in 
human and nonhuman primate cases where neuroinvasion usually occurs in the substantia 
nigra, brainstem, basal ganglia, and cerebellum (Fratkin et al., 2004; Maximova et al., 
2008; Sejvar et al., 2003). The passaged virus was thus able to cross the blood brain 
barrier and infect mouse brain cells but in an atypical locale.  
  
6.5 Infecting Primary Cells with Passaged Viruses 
WNV is known to infect neurons and other CNS cells (Ceccaldi et al., 2004; Shrestha et 
al., 2003; Steele et al., 2000) although different neural cell cultures differ in infectability 
according to its culture type (Ceccaldi et al., 2004). This group found pure neuronal cell 
cultures very permissive to infection with up to 90 % of neurons infected at 48 hours post 
inoculation whereas primary mixed cultures of astrocytes/neuronal with a high 
percentage of astrocytes were resistant to WNV with only 10 % of astrocytes infected.  
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This study used two different primary cell cultures, a pure neuronal cell culture and a 
second mixed culture of astrocytes and oligodendrocytes. The results confirmed that 
neuronal cells were indeed more permissive to infection by WNVS as compared to the 
astrocyte/oligodendrocyte mixed culture (Sections 4.4.2 and 4.4.6). The neuronal cells 
showed a higher level of cytopathic effect at an earlier time point compared to the mixed 
culture. The time and peak titre virus production were also comparable to results obtained 
using WNV New York strain (Diniz et al., 2006; Shrestha et al., 2003). The 
photomicrographs from Figure 67 shows only cell debris at 72 hours post inoculation 
with unpassaged virus. The same has been reported by Shrestha and colleagues (2003). In 
effect, WNVS has retained its neurovirulent trait in neuronal cells despite multiple cell 
passages. The ‘c’ and ‘m’ passaging regimes has caused the virus to increase in 
neurotropism, able to penetrate the blood brain barrier at an early time point and to 
produce higher titres for longer periods in neuronal primary cells. 
 
Electron microscopy of remaining primary cells identified only oligodendroctyes but no 
astrocytes inferring that astrocytes were preferentially infected and killed by WNVS 
(Section 4.4.5). The inoculation of 10m2 on primary astrocyte/oligodendrocyte also 
proved that neural cells could be persistently infected for prolonged periods (Figure 54). 
West Nile virus has been isolated from the brains of monkeys, mice, and hamsters after 
5.5 months, 35 days, and 53 days post inoculation respectively (Pogodina et al., 1983; 
Shrestha and Diamond, 2004; Xiao et al., 2001). Human primary astrocytes has also been 
found infectable by WNV but the level of infection was ~100 – fold lower than human 
primary neuronal cells (van Marle et al., 2007). This suggested that astrocytes have a role 
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to play in the long term maintenance of WNV in the CNS and that WNV could persist in 
the CNS for prolonged periods without killing the host. Primary human oligodendrocyte 
cultures have also been shown to be less permissive for WNV replication compared to 
neurons and astrocytes (Cheeran et al., 2005). This was in line with electron micrographs 
that showed oligodendrocytes remaining at the end of WNVS infection on an 
astrocyte/oligodendrocyte mixed culture (Section 4.4.5). Moreover, Jordan and group 
(2000) showed human primary oligodendrocytes to be uninfectable by WNV. 
 
However, in terms of virus levels and sustainability, it was seen that the mixed cultures 
gave higher titres compared to the neuronal cells (Figures 52, 53, and 66). Peak virus 
levels lasted for longer periods in the mixed culture with the 10m2 virus – infected mixed 
culture showing positive virus titres up to week 16 post inoculation (Figure 55) but titres 
in inoculated neuronal cells persisted only up to day 7 (Figure 66). Similar observation 
was reported previously using WNV New York inoculated onto primary neural ICR 
mouse cells (Diniz et al., 2006). That report showed virus titres lasting 5 days for 
neuronal cells and 16 weeks for astrocyte cultures. Levels of virus production on infected 
primary astrocytes and oligodendrocytes showed the ‘c’ series viruses having a notably 
higher starting virus titre compared to the ‘m’ series (Figure 52) confirming once again, 
that the ‘c’ passaged viruses were better adapted to infect various hosts and cells 
compared to the ‘m’ series.  
 
Other articles have cited the CNS as a secondary site for WNV infection as virus was 
found only in the brain and spinal cord of inoculated B6 mice at day 9 post inoculation 
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(Garcia-Tapia et al., 2007). At 4 days post inoculation, only skin, spleen, and kidneys 
were found as possible virus propagation sites. Different mice may show different 
primary organs of virus replication. The same report found inflammatory lesions in the 
cerebral cortex which corresponded to histopathology in Figure 50. Another report using 
WNVS found the virus in the CNS by 24 hours post inoculation at titres ranging from 103 
to 108 PFU/g (Wang et al., 2003). As such, it was obvious that different mouse species as 
well as viruses will show varying signs at different time points and cannot be generalised. 
 
6.6 Changes in Virus Sequence 
Attenuation or increased virulence can occur in viruses due to genetic modification at any 
part of the virus genome. The structural proteins are important for receptor binding, 
membrane fusion, and host immune system evasion. Any change in amino acid residue 
could lead to differences in virus receptor binding and tropism, conformational change, 
and protein stability. The non – structural proteins are important cofactors and contribute 
to enzymatic activities for the proper folding and maturation of the virus. Hotspots of 
mutation were noticed in the passaged virus sequences for C and NS2a proteins. There 
were more mutations in the ‘c’ series passaged viruses as compared to the ‘m’ series 
(Tables 11 to 13). This was also seen by Jerzak and group (2008) when viruses were 
passaged in both alternating and single host.  
 
The mutations for C proteins were mostly concentrated at amino acid residue 24 (glycine 
to valine), 26 (serine to alanine), and 29 (glycine to valine). Either one of these mutations 
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(but not together) were found in 8 of the 10 passaged viruses. The amino acid changes at 
these sites of mutation were from and to the same amino acid species (Table 11) 
indicating that the selection stress was directed, resulting in similar amino acid mutations 
and the changes were not random.  
 
The single mutation at amino acid residue 150 on E protein from alanine to valine (Table 
12) represented a change on the surface of the protein. Surface exposed residues could 
influence receptor selectivity, vector preference and tissue tropism amongst other things. 
The residue does not have a known specific activity and was probably part of the linker 
protein between beta sheets (Figure 70). No previous publications on this residue could 
be found. 
 
A mutation was seen in the unpassaged strain NS2a gene compared with the Genbank 
reference sequence, indicating that the virus was still mutating while being passaged 
through cell culture. In a Cuban dengue outbreak, the NS2a gene was found to bear the 
most mutations from retrospective analysis of DV4 strains from 20 years of sampling 
(Bennett et al., 2003). This showed that NS2a gene was highly adaptive to change and its 
mutation could play a role in the evolution and survival of flaviviruses over prolonged 
periods. When comparing the mutations to pathology and viremia of adult and suckling 
mice inoculated with the passaged viruses, no obvious trend could be noted as there were 
relatively few mutations and almost all were concentrated at a few hotspots at the region 
of the first 6 amino acids of NS2a protein. However, no published work has indicated the 
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importance of this early region of NS2a protein as the cleavage site for NS1 – NS2a 
proteins was postulated to require the last 8 amino acids of NS1 and downstream 
sequences in the middle of NS2a (Chambers et al., 1990; Falgout & Markoff, 1995). The 
mutations seen were very similar across the various repeats and no difference was noted 
between mutation rates or locus of the ‘m’ and ‘c’ series.  
 
The other genes in the virus genome that were not sequenced are prM, NS1, NS3, and 
NS5. These genes carry important and very highly conserved, stable proteins or enzymes 
that are vital for proper virus infection and replication. Any mutation therein would affect 
the virus drastically in terms of viability.  
 
The sequencing of C, E, NS2, and NS4 genes represents 4104 base pairs sequenced per 
virus genome out of the 10300 virus base pairs. From a total of 10 passaging rounds and 
10 total repeats, 19 unique sites of nucleotide point mutation were detected from the 
sequencing results, conserved or unconserved. The rate of mutation per nucleotide 
passaged was thus 4.6 x 10-5 which is higher than virus mutation rates after passaging in a 
single host repeatedly which was reported to be approximately 1.7 x 10-5 (Jerzak et al., 
2008). This would suggest that theoretically, the passaging regime in this study exerted a 
high selective pressure on the virus causing increased rates of mutations.  
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The lack of mutations in the E, NS2b, NS4a, and NS4b sequences of passaged viruses 
could be due to two scenarios. Firstly there could be epigenetic changes that caused the 
increase in virulence seen. However, this phenomenon has not been described before in 
WNV and only once observed in DV (Lee et al., 2006). The other possibility was that 
mutations in various passaged virus had taken place but the consensus sequence of the 
genes showed no mutations. As the consensus nucleotide sequence is a representative of 
the population average from the myriad of diverse viral genomes within a population 
(Aaskov et al., 2006), signals from small subpopulations of mutated viruses would be 
masked by the more dominant unmutated population during sequencing. Only if 
individual plaque purified virus were isolated could these be sequenced (Ciota et al., 
2007b). This group passaged identical infectious clone – derived WNV through mosquito 
C6/36 and DF-1 cells for 40 and 20 rounds, respectively. The consensus sequence for 
both viruses came out similar to the unpassaged virus but when individual virus clones of 
the passaged virus were sequenced, the C6/36 cell culture passaged virus showed 18 
nucleotide point mutations while the DF-1 cell culture passaged virus had 7 point 
mutations. Thus, the consensus sequence can be misleading as it does not represent the 
true repertoire of genetic diversity of a virus population (Aaskov et al., 2006; Novella et 
al., 2004). However, we do not have specialist equipment or resources to plaque purify 
the viruses and individually sequence them. 
 
Still, multiple infections of the same cell are commonplace and with the high virus titre 
(108 PFU/ml) inoculated into mice, the long – term population size was large enough to 
complement defective or mutated viruses. It is also known that the transmission of 
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multiple lineages is advantageous as it ensures the presence of viruses differentially 
adapted to mouse or mosquito cells, decoying host immune responses, or allowing the 
production of more viral proteins (Aaskov et al., 2006).  
 
WNV has been shown to adapt differently to in vivo and in vitro hosts (Ciota et al., 
2007a). Passaging WNV in mosquito cell culture in vitro repeatedly was not sufficient to 
adapt the virus to infecting whole mosquitoes in vivo. This was attributed to the 
difference in complexity between whole organisms as compared to the simplistic 
monoclonal cell culture. Viral fitness within a whole mosquito would entail the virus’ 
ability to infect and replicate in various mosquito cell types and to migrate from the 
midgut to the salivary glands (Kramer et al., 1981). Extrapolating this, passaging WNV 
over time in a mammalian cell culture would lower the chance it could still productively 
infect the whole animal in vivo. This shows that the work herein was not perfect as 
mosquito cell culture was used instead of whole live mosquitoes but underscores the 
importance of passaging the virus in vivo in order to adapt WNVS to infect 
immunocompetent mice and to maintain its invasive properties in the long run. 
 
6.7 Conclusions 
The development of mouse models for flaviviruses remains a challenge today. The ideal 
model should be relevant in terms of route of infection and immunocompetence. The 
virus should induce similar signs of disease found in both humans and mice, manifesting 
a range of different symptoms from febrile disease, meningitis, encephalitis, to death. 
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West Nile Sarafend of lineage II is regarded to be less evolved as compared to lineage I 
flaviviruses, non – neuroinvasive, and highly attenuated in mice (Beasley et al., 2005).  
This study has shown it possible to adapt a lineage II strain to become more infectious by 
alternate serial passaging through two different hosts mimicking a natural infectious 
cycle. This would allow for experiments to be carried out in BSL 2 facilities instead of 
the required BSL 3 facilities for WNV pathogenesis studies.  
By this process of adaptation, plaque size and virus titres were observed to fluctuate in a 
cyclical pattern. The passaged viruses, when inoculated into immunocompetent mice 
were able to kill sucklings sooner and infect the brains, livers, and spleens of adults with 
positive virus titres up to day 3 post inoculation. Histological sections showed that the 
spleens were enlarged with massive leukocyte infiltration. The livers displayed pkynotic 
cells and large accumulations of inflammatory cells, while brains showed signs of 
meningoencephalitis. None of these signs were seen in mice inoculated with unpassaged 
viruses. The infection of passaged and unpassaged viruses onto primary neuronal and 
astrocyte/oligodendrocyte culture found astrocytes and neurons preferentially infected. 
Passaged viruses produced higher virus titres in neuronal cells compared to unpassaged 
viruses. Sequencing results indicated hot spots in the NS2a amino acid position 2 and 
structural protein C amino acid positions 24, 26, and 29.  
 
Comparing the mouse only passage ‘m’ against the mouse – C6/36 passage ‘c’ viruses, 
the ‘c’ series passaged viruses killed suckling mice earlier, had more positive titres in 
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adult mice organs, and gave higher titres when inoculated onto primary astrocyte 
cultures. It is possible that should this passaging continue the virus may become even 
more adapted and cause more severe disease and pathophysiological changes in adult 
mice. On the other hand, continued passaging may also result in virus attenuation. 
 
More experiments could be done to further the knowledge of this study. To determine if 
the virus passaging in C6/36 cells is vital for the mutations seen, a repeated passaging of 
round – 10 viruses in Vero or BHK should cause the reversion of seen residue mutations 
to its original residues at passage 0. The mutation analysis was not completed as it 
omitted the sequence of genes encoding prM, NS1, and NS3. Completing it would give a 
clearer picture of the total mutations and if the total mutation frequencies between C and 
M strains are comparable. It would also be good to test the passaged strain of virus on 
immunocompetent mice such as AG129 as such would display more signs and symptoms 
when infected with virus compared to Balb/C. This study was also limited in the number 
of mouse organs tested. The kidney, spleen, and lymph node have all been implicated in 
virus replication and spread. It would be advantageous to see the virus titre and 
pathological trend in these organs throughout the passaging routine. Another interesting 
aspect of the virus passaging that would be interesting to follow would be the 
immunological response in mice. This includes the upregulation of innate and adaptive 
immune response. Levels of cytokines, circulating lymphocytes, and number of 
infiltrating T and B cells in various organs could be studied by Elisa, flow cytometry, and 
histology to observe the immunological stimulatory effect of passaged versus unpassaged 
viruses.  
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Viruses are known to be easily adaptable with high mutation rates during replication. 
Knowledge on what changes happen when West Nile virus is passaged through different 
hosts is important in epidemiological studies as well as to understand the effects of long 
term routine passaging in the laboratory. This allows the manipulation of this virus to 
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APPENDIX 1  
Solutions for Cell Culture  
The following are formulations for the preparation of media used in the growing of 
various cell lines used throughout the project. All contents except foetal bovine serum 
and antibiotic - antimycotic were warmed to 25 ˚C and added to a glass beaker 
already containing 90 % of the final required volume of water. A magnetic stirrer was 
used to agitate the contents until all solids were fully dissolved.  
 
a) Growth Medium, M199 for Vero Cells (~pH 7.3).  
Items  Amount  Source  
Medium M199  1 bottle (commercial) Sigma-Aldrich, St. Louis, USA 
NaHCO3 2.2 g  Merck KGaA, Germany  
Foetal bovine serum  100 ml  PAA Laboratories GmbH, Austria
Deionised water 900 ml  Barnstead, New Hampshire, USA 
 
b) Growth Medium, RPMI for BHK Cell (~pH 7.3). 
Items  Amount Source  
RPMI-1640 10.63g  M0393, Sigma-Aldrich, St. Louis, USA  
NaHCO3 2.0 g  Merck KGaA, Germany  
Foetal bovine serum  100 ml  PAA Laboratories GmbH, Austria 
Deionised water 900 ml  Barnstead, New Hampshire, USA 
 
c) Growth Medium, L15 for C6/36 Cells (~pH 7.3). 
Items  Amount  Source  
L15  1 bottle (commercial) L4386, Sigma-Aldrich, St. Louis, USA
Foetal bovine serum  100 ml  PAA Laboratories GmbH, Austria 
Deionised water 900 ml  Barnstead, New Hampshire, USA 
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d) Growth Medium, Dulbecco’s Modified Eagle’s Medium (DME), for 
primary astrocytes and glial cells (~pH 7.3). 
Items  Amount  Source  
DME Medium 1 bottle 
(commercial)  
D1152, Sigma-Aldrich, St. Louis, USA  
Foetal bovine serum  100 ml  PAA Laboratories GmbH, Austria 
NaHCO3 3.7 g Merck KGaA, Germany 
Deionised water 890 ml  Barnstead, New Hampshire, USA 
Antibiotic - 
Antimycotic 
10 ml  Gibco, Invitrogen Corp., Carlsbad, USA 
The pH of the media were then adjusted to approximately pH 7.3 with a handheld pH 
meter (Beckman Coulter Inc., Fullerton, USA). The solution was then sterilised by 
filtration in a sterile environment through a 0.2 µm PES membrane bottle top filter 
unit (Nalge Nunc International, Roskilde, Denmark). From each bottle, a 20 ml 
aliquot of filtered media was used for screening of microbial contamination by 
incubation at 37 ˚C for three days before the addition of serum and antibiotic - 
antimycotic. Foetal bovine serum for the L15 and DME growth media was heat 
inactivated at 56 ˚C for 30 minutes in a pre – warmed water bath before being added 
into the sterile media. The serum supplemented media were kept at 4 °C. The cell 
culture media were warmed up in water bath to 37 ˚C before use.  
 
e) 1 M Hydrochloric Acid 
Hydrochloric acid (37 % - Merck KGaA, Germany) was diluted by 1 : 10 in deionised 
water (Barnstead, New Hampshire, USA) to create a 1 M solution of hydrochloric 
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f) 1 M Sodium Hydroxide  
Sodium hydroxide pellets (BDH Ltd., Poole, England) was weighed out to 50 g and 
mixed into 1 litre of deionised water (Barnstead, New Hampshire, USA) to create a 1 




g) Phosphate Buffered Saline (PBS)  
Items  Amount   Source  
NaCl  8.0 g Lab Scan Limited, Ireland 
KCl  0.2 g Merck KGaA, Germany 
Na2HPO4 1.15 g Merck KGaA, Germany 
KH2PO4 0.2 g Merck KGaA, Germany 
Deionised water 900 ml  Barnstead, New Hampshire, USA 
The above materials were dissolved in 1 litre of deionised water. The pH was adjusted 
to 7.2 using either 1 M HCl or 1 M NaOH. The solution was aliquoted and sterilised 
for 15 minutes at 121° C, 15 lbs. pressure (Hirayama Corp., Saitama, Japan). Storage 
was at 25 ˚C. 
 
h) Trypsin  
Trypsin solution for the dissociation of cells from culture flask was made by diluting 
10 ml of sterile porcine pancreas derived trypsin 10 x solution (Sigma-Aldrich Corp., 
St. Louis, USA) in 90 ml PBS (Appendix 1e). This 1 x stock of trypsin was stored at 4 
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i) Papain Solution 
Items  Amount   Source  
DNAse 0.5 mg Worthington Biochemical Corp., USA 
EBSS 0.5 ml E2888, Sigma-Aldrich, St. Louis, USA 
Papain 200 units Worthington Biochemical Corp., USA 
The above reagents were mixed together and kept at room temperature. 
 
j) Poly – L – lysine for coating flasks 
Poly – L – lysine was prepared from powder (P6282, Sigma-Aldrich, St. Louis, USA) 
into a stock solution of 10 mg in 5 ml of distilled water (Barnstead, New Hampshire, 
USA). The stock was then diluted 1 : 100 in distilled water to obtain a working 
concentration and sterilized by a 0.2 µm syringe filter (Sartorius – Stedim AG, 
Germany). This solution was used to plate the flask or coverslips overnight at room 
temperature. The next day, the solution was removed and the surface washed twice 
with distilled water. The flasks and coverslips were then left in a laminar flow to dry 
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APPENDIX 2  
Materials for Virus Infection, Growth of Virus and Plaque Assay  
a) Virus Diluent, Hanks’ Balanced Salts (pH 7.2 - 7.4)  
Items  Amount  Source  
Hanks’ Balanced Salts  1 bottle (commercial) H6163, Sigma-Aldrich, St. Louis, USA 
Deionised water 1000 ml  Barnstead, New Hampshire, USA 
The powdered Hanks’ Balanced Salt was added to a glass beaker containing 90 % of 
the final required volume of water. A magnetic stirrer was used to agitate the contents 
until all solids were fully dissolved. The solution was made up to 1000 ml and then 
tittered using a pH meter (Beckman Coulter Inc., Fullerton, USA) to approximately 
pH 7.3. The solution was then sterilised by filtration through 0.2 µm PES membrane 
bottle top filter unit (Nalge Nunc International, Rochester, USA). Storage was at 4 °C. 
Virus diluent was warmed to 37 ˚C before use. 
 
b) Maintenance Media, L15, for C6/36 Cell Culture 
Items  Amount  Source  
L15  1 bottle (commercial) L4386, Sigma-Aldrich, St. Louis, USA
Foetal bovine serum  20 ml  PAA Laboratories GmbH, Austria 
Deionised water 980 ml  Barnstead, New Hampshire, USA 
Maintenance media for C6/36 cells were prepared in the same way as the growth 
media for the same cell line in Appendix 1c, except for the volume difference of foetal 
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c) Maintenance Media, M199, for Vero Cell Culture 
Items  Amount  Source  
Medium M199  1 bottle (commercial) Sigma-Aldrich, St. Louis, USA 
NaHCO3 2.2 g  Merck KGaA, Germany  
Foetal bovine serum  20 ml  PAA Laboratories GmbH, Austria
Deionised water 980 ml  Barnstead, New Hampshire, USA 
Maintenance media for Vero cells were prepared in the same way as the growth media 
for the same cell line in Appendix 1a, except for the volume difference of foetal 
bovine serum and deionised water. 
 
d) Maintenance Media, DME Medium, for primary Neural Cells 
Items  Amount  Source  
DME Medium 1 bottle 
(commercial)  
D1152, Sigma-Aldrich, St. Louis, USA  
Foetal bovine serum  20 ml  PAA Laboratories GmbH, Austria 
NaHCO3 3.7 g Merck KGaA, Germany 
Deionised water 970 ml  Barnstead, New Hampshire, USA 
Antibiotic - Antimycotic 10 ml Gibco, Invitrogen Corp., Carlsbad, USA 
Maintenance media for primary neuronal cells were prepared in the same way as the 
growth media for the same cell line in Appendix 1d, except for the volume difference 
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e) Overlay Medium (pH 7.2 - 7.4)  
Items  Amount Source  
RPMI-1640 10.63 g  M0393, Sigma-Aldrich, St. Louis, USA 
NaHCO3 2.0 g  Merck KGaA, Germany 
Foetal bovine serum 20 ml  PAA Laboratories GmbH, Austria 
Deionised water 680 ml  Barnstead, New Hampshire, USA 
Carboxymethylcellulose (CMC) 4.0 g Merck KGaA, Germany 
Four grams of CMC was mixed well into 200 ml of deionised water. The mixture was 
then sterilised by autoclaving at 15 minutes, 121 °C, 15 lbs. pressure, and then left to 
cool. Double strength RPMI was made by adding the RPMI – 1640 powder to 480 ml 
of deionised water. Sodium bicarbonate was added and the media was adjusted to pH 
7.3. It was then filtered through a 0.2 µm PES membrane bottle top filter unit (Nalge 
Nunc International, Rochester, USA). Two hundred µl of the double strength media 
was added to cooled CMC solution and mixed well. Storage was at 4 °C. Overlay 
medium was warmed to 37 ˚C before use. 
 
f) 0.5 % Crystal Violet / 25 % Formaldehyde Solution  
Items  Amount Source  
Crystal violet powder 5.0 g  Sigma-Aldrich, St. Louis, USA 
37 % Formaldehyde solution 300 ml  Merck KGaA, Germany 
PBS  200 ml  See Appendix 1g 
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APPENDIX 3 
Materials for Reverse Transcription and Polymerase Chain Reaction  
a) DEPC – Treated Water 
One litre of 0.1 % DEPC treated water was prepared by adding 1 ml of DEPC 
(Sigma-Aldrich, St. Louis, USA) to 100 ml of deionised water (Barnstead, New 
Hampshire, USA) and mixed well to bring the DEPC into solution. It was left to stir 
on a magnetic stirrer / hotplate overnight at 37 °C (Bibby Sterilin, Barloworld 
Scientific Ltd., London, UK). The solution was then autoclaved to remove any trace 
of DEPC for fifteen minutes at 121 °C, 15 lbs. pressure (Hirayama Corp., Saitama, 
Japan). 
 
b)  Transcription Mix 
Items Volume in µl 
Nuclease – Free Water 5.5 
ImProm – II 5X Buffer 4.0 
Magnesium Chloride 2.0 
dNTP Mix 1.0 
Recombinant RNasein Ribonuclease Inhibitor 0.5 
ImProm – II Reverse Transcriptase 1.0 
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c)  PCR Amplification Mix 
Items Volume in µl 
10 x Pfx Amplification Buffer 5.0 
10 mM dNTP mixture 1.5 
50 mM MgSO4 1.0 
Primer Mix (10 µM each) 1.5 
Platinum Pfx DNA Polymerase 0.8 
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APPENDIX 4 
Materials for Agarose Gel Electrophoresis 
a) 1.0 % Agarose Gel  
Items  Amount Source  
Ultra – Pure Agarose  1.0 g  Invitrogen Corp., Carlsbad, USA 
1 x TBE  100 ml  Bio Rad Labs, California, USA 
Ethidium Bromide (10 mg/ml) 6 μl  Bio Rad Labs, California, USA 
The above mixture was topped up to 250 ml (excluding ethidium bromide) with 
deionised water and the mixture was boiled for three minutes in a microwave oven. 
The solution was allowed to cool to 45 °C before the addition of ethidium bromide. 
The solution was mixed well before pouring into the agarose gel apparatus in the 
fume cupboard.  
 
b) Tris – Borate – EDTA Buffer (TBE)  
The stock solution of 10 x TBE buffer (Bio Rad Labs, California, USA) was diluted 
by adding 10 ml of the 10 x TBE buffer to 90 ml of deionized water to obtain the 1 x 
TBE buffer.  
 
c) Three Molar Potassium Acetate 
Potassium Acetate (Sigma-Aldrich, St. Louis, USA) was weighed out and 2.95 g were 
added to 10 ml of deionised water (Barnstead, New Hampshire, USA). The solution 
was stirred and when all solids were dissolved, it was adjusted to pH 5.6 with glacial 
acetic acid (Merck KGaA, Germany). The solution was stored at 25 ˚C.  
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APPENDIX 5  
Materials for Bio - Imaging  
a) 4 % Paraformaldehyde in PBS  
Items  Amount Source  
Paraformaldehyde  4.0 g  Merck KGaA, Germany
PBS  100 ml  Appendix 1g 
Paraformaldehyde powder was first dissolved in 800 ml of PBS by heating to 60 ºC 
on a hotplate (Bibby Sterilin, Barloworld Scientific Ltd., London, UK). A few drops 
of 1 M NaOH solution (Appendix 1f) were added to clear the solution. The solution 
was cooled and topped up to 100 ml with PBS (Appendix 1g). 
 
b) Overnight Automated Embedding Program 
No. Medium Duration Temperature Source 
1 70 % ethanol 30 minutes 25 ˚C Merck KGaA, Germany 
2 80 % ethanol 30 minutes 25 ˚C Merck KGaA, Germany 
3 95 % ethanol 45 minutes 25 ˚C Merck KGaA, Germany 
4 95 % ethanol 45 minutes 25 ˚C Merck KGaA, Germany 
5 Absolute ethanol 90 minutes 25 ˚C Merck KGaA, Germany 
6 Absolute ethanol 90 minutes 25 ˚C Merck KGaA, Germany 
7 Xylene 30 minutes 25 ˚C Merck KGaA, Germany 
8 Xylene 30 minutes 25 ˚C Merck KGaA, Germany 
9 Xylene 30 minutes 25 ˚C Merck KGaA, Germany 
10 Paraffin wax 120 minutes 60 ˚C Fisher Sci., USA 
11 Paraffin wax 120 minutes 60 ˚C Fisher Sci., USA 
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c) Ethanol Concentration Preparation for Dewaxing 
Absolute ethanol was purchased from Merck KGaA, Germany while deionised water 
was filtered through a Barnstead E-pure system (Barnstead, New Hampshire, USA). 
Item Pure Ethanol volume (ml) Deionised Water volume (ml) 
95 % Ethanol 95 5 
70 % Ethanol 70 30 
50 % Ethanol 50 50 
25 % Ethanol 25 75 
 




3 95 % alcohol 
4 95 % alcohol 
5 70 % alcohol 
6 Tap water 
 
e) Acid Alcohol (1 %) 
The two liquids were mixed together and stored at 4˚C. 
Item Amount (ml) Source 
Ethanol (70 %) 99  Appendix 5c 
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f) Alkaline Solution 
The two liquids were mixed thoroughly and stored at room temperature. 
Item Amount (ml) Source 
Ammonia hydroxide 1 Fisher Scientific, USA 
Deionised Water 250  Barnstead, New Hampshire, USA 
 
g) Eosin 
Item Amount  Source 
Eosin powder (82 %) 5.0 g  Sigma-Aldrich, St. Louis, USA 
Deionised Water 1000 ml  Barnstead, New Hampshire, USA 
Eosin was mixed in 990 ml of water. Using 1 M hydrochloric acid or 1 M sodium 
hydroxide (Appendices 1e and 1f), the pH was adjusted to 7.4. The solution was 
topped up to 1 litre and kept at room temperature. 
 
h) Hematoxylin and Eosin Staining Protocol  
No. Reagent Time Source 
1 Harris’ hematoxylin 10 minutes Sigma-Aldrich, St. Louis, USA 
2 Running tap water 2 minutes - 
3 Acid alcohol (1 %) 2 dips Appendix 5e 
4 Running tap water 1 minute - 
5 Alkaline solution 3 dips Appendix 5f 
6 Running tap waster 3 minutes - 
7 Alcohol (70 %) 5 dips Appendix 5c 
8 Eosin 5 minutes Appendix 5g 
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APPENDIX 6 
Materials for Immunohistochemistry 
a) Sodium Citrate Buffer for Antigen Retrieval 
Item Amount  Source 
Tri – Sodium Citrate dihydrate 2.94 g Sigma-Aldrich, St. Louis, USA 
Deionised Water 1000 ml  Barnstead, New Hampshire, USA 
Tween – 20 0.5 ml ICN Biomedicals, USA 
The sodium powder was mixed into 1 litre of water and titred to approximately pH 
6.0. Then, 0.5 ml of Tween – 20 was added and mixed. The solution was stored at 4 
˚C until used. 
 
b) 0.6 % H2O2 in Methanol  
The two liquids were mixed thoroughly and stored at 4 ˚C. 
Item Amount (ml)  Source 
H2O2 30 % 2 Merck KGaA, Germany 
Methanol  98 Merck KGaA, Germany 
 
c) Tris-Buffered Saline (TBS) 
Item Amount Source 
Sodium Chloride 8.0 g Lab Scan Limited, Ireland 
Tris 0.61 g USB Corp., Ohio, USA 
Hydrochloric Acid  3.8 ml Appendix 1e 
Deionised Water  1000 ml Barnstead, New Hampshire, USA 
The chemicals were dissolved in 990 ml of water. Using 1 M hydrochloric acid 
(Appendix 1e), the pH was adjusted to 7.6. Deionised water was then used to top up 
the solution to 1 litre and kept at 4˚C. 
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APPENDIX 7 
Materials for Immunogold – Silver Staining (IGSS) 
a) Bovine Serum Albumin (BSA) Blocking Solution 
Item Amount Source 
Bovine Serum Albumin 5.0 g Gibco, Invitrogen 
Corp., Carlsbad, USA 
Phosphate Buffered Saline 100 ml Appendix 1g 
BSA was dissolved in 95 ml PBS. Using 1 M hydrochloric acid or 1 M sodium 
hydroxide (Appendices 1e and 1f), the pH was adjusted to 7.4. The solution was then 
topped up to 100 ml and kept-at - 20 ˚C. 
 
b) Aldehyde Blocking Solution 
Item Amount Source 
Glycine 0.94 g Merck KGaA, Germany 
Phosphate Buffered Saline 250 ml Appendix 1g 
Glycine was dissolved in 245 ml PBS. Using 1 M hydrochloric acid or 1 M sodium 
hydroxide (Appendices 1e and 1f), the pH was adjusted to 7.4. The solution was then 
topped up to 250 ml and kept at - 20 ˚C. 
 
c) Aurion BSA – C Wash Solution 
Item Amount Source 
BSA – C  1 ml Aurion immunoGold, Netherlands 
Phosphate Buffered Saline 100 ml Appendix 1g 
BSA – C was mixed with 95 ml of PBS. Using 1 M hydrochloric acid or 1 M sodium 
hydroxide (Appendices 1e and 1f), the pH was adjusted to 7.4. The solution was then 
topped up to 100 ml and kept at - 20 ˚C. 
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d) 2 % Gultaraldehyde Fixative Solution 
Item Amount Source 
Glutaraldehyde 2.0 g Sigma-Aldrich, St. Louis, USA 
Phosphate Buffered Saline 100 ml Appendix 1g 
Reagents were mixed and stored at 4 ˚C. 
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APPENDIX 8 
Materials for Electron Microscopy (EM) 
a)  4 % Glutaraldehyde and 4 % Paraformaldehyde  
Item Amount Source 
25 % Glutaraldehyde 16 ml Agar Scientific, USA 
25 % Paraformaldehyde 16 ml Agar Scientific, USA 
Phosphate Buffered Saline 68 ml Appendix 1g 
Items were mixed in a glass bottle in the fume hood before storage at 4 oC. 
 
b) 1 % Osmium Tetroxide in 1 x PBS  
Item Amount Source 
Osmium tetroxide 1.0 g TAAB Lab. Equipment Ltd., England 
Phosphate Buffered Saline 100 ml Appendix 1g 
The ampoule was opened in a brown glass bottle with the buffer inside. Mixture was 
swirled to ensure that the osmium tetroxide was dissolved totally. The solution was 
stored at -20 °C. 
 
c) LR White 
Item Amount Source 
LR White 500 ml Ted Pella Inc., California, USA 
Benzyol peroxide 28.7 g Ted Pella Inc., California, USA 
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d) Saturated Aqueous Uranyl Acetate 
Item Amount Source 
Ryter kellenburger buffer 5 ml Appendix 11f 
0.1 M CaCl2 5 ml Merck KGaA, Germany 
0.1 M HCl 6.5 ml Merck KGaA, Germany 
Uranyl acetate 1.3 g Merck KGaA, Germany 
The above items were added to 13 ml of deionised water and stored at room 
temperature in a bottle covered with aluminum foil. The saturated solution was 
centrifuged at 2000 x g before use. 
 
e) Reynold’s Lead Citrate solution 
Item Amount Source 
Lead citrate 1.3 g BDH Ltd., Poole, England 
Sodium citrate 1.8 g Merck KGaA, Germany 
The items were added to 30 ml of deionised water and stirred continuously for about 
45 minutes to ensure the complete conversion of lead nitrate (impurity) to lead citrate. 
Subsequently, 8 ml of 1 M NaOH (Appendix 1f) was added and the solution topped up 
to 50 ml with deionised water. The solution was stored at 4 oC. 
